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Summary 
Understanding of human pathology has been greatly advanced by the use of ‘model 
organisms’, such as yeast and Drosophila. While these models have led to great 
advances in the treatment of human disease, they are limited by variations in 
physiology, metabolism, and genetic background. 
The development of humanised mice, in which the gene or genes of interest have 
been excised from the genome and replaced with the functional human counterpart, 
may have the potential to bridge the gap between preclinical mouse models and 
human disease.   
The work carried out in this thesis utilises a number of transgenic-animal models 
where the metabolic pathways involved in the metabolism of drugs have either been 
deleted or humanised in order to delineate the impact that such systems have on 
drug metabolism, distribution, and efficacy.  These pathways include the cytochrome 
P450-dependent monooxygenase system and the constitutive androstane and 
pregnane X nuclear receptors.  
The aims of this work were to assess whether these humanised mouse models better 
represented human drug metabolism and pharmacokinetics compared to wild-type 
animals. Using a novel anti-cancer agent pazopanib as a test substrate, the work 
detailed in this thesis assesses differences in the pharmacokinetic profile of 
pazopanib in various humanised and knock out animal models, as well as differences 
in toxicological responses. Furthermore, this project looks at variations in the efficacy 
of pazopanib in syngeneic tumours in humanised and wild-type mice. 
 
III 
 
 
The techniques used in this work include liver microsome preparations and drug 
stability assays in vitro, pharmacokinetic profiling of drugs, and syngeneic tumour 
growth studies in vivo. Drug stability studies in vitro identified a species difference in 
pazopanib metabolism between wild-type mouse and human liver microsomes. 
Furthermore, this difference was attenuated in humanised CYP3A4/3A7 mouse liver 
microsomes when compared with human liver microsomes, suggesting that 
humanised mice represent a better model for human pazopanib metabolism in vitro. 
This species difference in metabolism was reflected in in vivo pharmacokinetic studies 
with humanised CYP3A4/3A7/hCAR/hPXR mice exhibiting significantly decreased 
maximum plasma concentration, clearance and half-life of pazopanib compared to 
wild-type mice. Finally, this work addresses the efficacy of pazopanib in a mouse 
derived B16 melanoma tumour growth study in vivo. Pazopanib retarded the growth 
of melanoma tumours in both wild-type and humanised CYP3A4/3A7/hCAR/hPXR 
mice. Overall survival was reduced in animals which has been induced using Aroclor-
1254, which suggests that induction of the cytochrome P450 system does induce the 
turnover of pazopanib thereby reducing bioavailability and efficacy in vivo.  
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Introduction
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1.1 Current Chemotherapeutic Strategies 
Modern chemotherapeutic strategies have evolved from advances in our 
understanding of the molecular mechanisms involved in the progression of cancer. 
Advancements in molecular profiling, radiologic and imaging technology have 
allowed insights into the growth patterns, metabolism and heterogeneity of many 
tumours, while the use of genetic techniques have provided tools with which 
predictions can be made regarding the likelihood of disease recurrence and drug 
sensitivity in individual patients (Walko and McLeod 2008).  
The traditional approach to treating cancers was with broad spectrum cytotoxic 
compounds such as ifosfamide and cyclophosphamide. While these drugs are 
effective at halting tumour cell growth, and killing cancerous cells, their major flaw 
is their lack of selectivity for cancerous tissue. This results in a narrow therapeutic 
index, with significant damage to healthy cells, and an often severe side effect 
profile (Brock 1996).  The ultimate goal in anticancer drug development is to 
improve the efficacy and selectivity of cancer treatment by exploiting the 
differences between cancer cells and normal cells (Balis 2002). 
1.2 Limitations of Current Strategies 
In 2003, an article published by DiMasi and Grabowski gave an in depth account of 
the costs incurred in developing new drugs. The figure quoted was approximately 
$900 million over a 12 to 15 year investment period. Factors contributing to these 
escalating costs included failures by pharmaceutical companies to terminate 
research on drugs which fail approval tests in good time, lengthy development 
processes and underutilization of emerging development technologies (DiMasi, 
Hansen et al. 2003). Existing, ‘traditional’ chemotherapeutics have been widely 
2 
 
 
criticised for limited efficacy, development of resistance, and vast inter-patient 
outcomes. It is therefore of paramount importance to assess whether or not these 
drugs could be better utilised by understanding optimum dosing strategies in 
particular cancers and patients.  This not only would reduce the cost of licensing 
new drugs, many of which are abandoned due to funding shortages and stringent 
FDA guidelines for clinical trials, but would potentially improve patient prognosis.  
1.3 Drug Metabolism 
Under most circumstances, drugs and xenobiotics which enter the body are 
metabolized in order for that drug to be excreted either in the bile or urine. 
Generally, drugs are broken down into metabolites of increasing polarity in order 
for this to be achieved. Polar groups may be created by oxidation, reduction or 
hydrolysis reactions, or, alkyl groups may be removed to reveal polar groups within 
the compound itself. These metabolites may then be conjugated to glutathione, 
methyl, sulphate, acetyl, glucose or amino acid groups in further reactions. These 
metabolites may exist in different ratios and with differing volumes of distribution. 
They may also be excreted at different rates (Gillette 1971). Understanding these 
reactions and pathways is of crucial importance as the metabolism of a drug may 
have significant effects on its pharmacokinetic and pharmacodynamic activity, with 
possible consequences for efficacy. Drug metabolism is divided into ‘phase 1’ and 
‘phase 2’ metabolism. 
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1.3.1 Phase 1 Drug Metabolism 
Phase 1 metabolism is a functionalization process in which functional, polar groups 
are revealed or inserted into a compound. This serves to increase the water 
solubility of the compound and facilitate its excretion by renal and biliary routes, as 
well as creating substrate groups for Phase 2 metabolism. Phase 1 metabolism 
involves several enzymatic systems including cytochrome P450 enzymes (P450s), 
and flavin-containing monooxygenases (FMO) (Gonzalez 2005).  
1.3.2 Cytochrome P450 Enzymes 
The cytochromes P450 are a superfamily of haem-containing enzymes which are 
constitutively expressed in the liver, small intestine, lung and kidney, as well as 
being expressed at lower levels in a variety of other tissues. They are inducible, and 
are implicated in both xenobiotic metabolism and in the synthesis of endogenous 
substrates including bile acids, lipids and steroids. They catalyse mixed-function 
oxidase (MFO) reactions, in which they drive the insertion of a molecular oxygen 
atom into a vast range of substrates, often creating active metabolites that may go 
on to act as substrate of Phase 2 metabolism. They exhibit an absorbance peak at 
450 nM when they are reduced and bound to carbon monoxide, hence their title 
‘P450’ (Omura and Sato 1962). The cytochromes P450 are membrane-bound 
enzymes which are primarily located in the endoplasmic reticulum (ER), where they 
catalyse reactions which are necessary for cholesterol and sterol biosynthesis. 
Certain CYPs are also compartmentalised in other subcellular regions, including the 
plasma membrane, inner mitochondrial membranes and lysosomes (Neve and 
Ingelman-Sundberg 2008). Cytochrome P450 mediated oxidation reactions can be 
described by the following illustration: 
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Where RH is the substrate of the reaction, and ROH, the oxidised product.  
1.3.2.1 Cytochrome P450 Structure and Function 
The cytochromes P450 constitute a large, complex superfamily of proteins, which 
share a highly variable sequence homology. In eukaryotic cells, P450s are 
membrane bound, in either the mitochondria or the endoplasmic reticulum (ER). 
Both mitochondrial and ER-bound enzymes require electron donation in order to 
function. Mitochondrial P450s, also known as “class 1” P450s receive NADPH-
derived (mitochondrial) electrons from a two-protein redox chain, (FAD reductase
→ iron-sulphur protein→ P450), whereas microsomal, or, “class 2” P450s receive 
NADPH-derived electrons directly from a flavin mononucleotide (FMN) /flavin 
adenine nucleotide (FAD)-containing reductase (Hasemann, Kurumbail et al. 1995). 
1.3.2.2 NADPH-Cytochrome P450 Reductase 
Cytochrome P450 reductase (POR), is an integral membrane protein which is able 
to donate electrons to cytochrome P450, as well as other electron acceptors 
including microsomal haem-oxygenase and cytochrome b5. POR is an unusual 
enzyme in the sense that it contains both a FMN and a FAD prosthetic group.  POR 
contains four structural domains from the N- to C- termini; the FMN-binding 
domain, the connecting domain, the FAD- and the NADPH-binding domains. The 
two electron-accepting domains of POR makes it an ideal “transducer” of reducing 
entities, as NADPH  is a two-electron donor, while cytochrome P450 is a two-
electron acceptor, however, these two electrons are accepted sequentially (Wang, 
Roberts et al. 1997). 
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Figure 1.1 Diagram of NADPH- Cytochrome P450 Reductase 
                  
            (Scott and Miller 2008).  
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1.3.2.3 Cytochrome P450 Catalytic Cycle  
 
  
(i) The resting ferric (Fe3+) form of P450 binds to substrate (RH)   
(ii) The substrate-enzyme complex is reduced by a single electron (e−) to 
the ferrous (Fe2+) state  
(iii) Molecular oxygen (O2) binds to the reduced complex.  
(iv) A second electron is received from the redox partner NADPH/NADH. 
(v) H2O is released through a reaction between the molecular oxygen and 
protons from the surrounding medium, leaving an activated oxygen 
atom. 
(vi) The activated oxygen atom interacts with the substrate molecule. 
(vii) The substrate becomes hydroxylated and is released from the cycle. 
(viii) The cycle may then continue upon further substrate binding.  
(McLean, Clift et al. 2006) 
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1.3.2.4 Metabolism, Resistance and the Cytochrome P450 System 
The metabolism of a particular drug may have a direct impact on its duration of 
efficacy. This is an important consideration in which the P450s are implicated.  
Xenobiotics may act to induce or supress the expression and activity of certain P450 
isoforms. If there is an inhibition of P450s by a given drug, metabolism of any 
compound which is a substrate to the inhibited P450 will be slowed and higher 
levels will remain in the body for a greater length of time. This may lead to the 
requirement to lower the drug dose to avoid toxicity. The opposite is true of drugs 
causing an induction of P450s. The induction of a CYP enzyme isoform responsible 
for the metabolism of a drug may reduce its expected therapeutic capacity due to 
diminished plasma concentrations. A higher dose of the parent drug may therefore 
be required for effective therapy, with further dosage reviewing as and when the 
inducer effects are withdrawn  (Saxena, Tripathi et al. 2008). It is also important to 
consider the potential effect of co-administered drugs, given to alleviate co-
morbidities and side-effects of chemotherapy, such as analgesics and anti-emetics. 
Self-medications and herbal preparations, while often seen by patients as 
innocuous, may fall into the same category.  Many of these drugs are metabolised 
by way of the P450 system and therefore have the potential to change the 
pharmacokinetics of an anti-cancer drug. This may render the drug ineffective, or 
cause it to be present at toxic or lethal doses (Marechal, Yu et al. 2006). 
CYP3A4 is one of the most highly inducible P450s and consequently the concomitant 
administration of CYP3A4 inducers such as dexamethasone limits the oral 
availability of drugs which are substrates for this enzyme, thus lowering the dose in 
vivo and potentially leading to a loss of efficacy.  
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Several well described examples of clinical drug-drug interactions leading to loss of 
efficacy involve the anti-fungal agent rifampicin. One such study by Backman et al. 
showed that the AUC of the CYP3A4 substrate midazolam was decreased to 2-4 % 
of control by a 5-day pre-treatment with rifampicin 600 mg daily in healthy human 
subjects. This was attributed to the potent CYP3A4 induction in the liver and 
intestine caused by rifampicin (Backman, Kivisto et al. 1998) 
1.4 Phase 2 Drug Metabolism 
While metabolite products of phase 1 metabolism may be directly excreted from 
the body, many undergo further biotransformation by phase 2 enzymes. Phase 2 
drug metabolising enzymes are responsible for the conjugation of phase 1 
xenobiotic products with endogenous molecules. These conjugations generally 
result in further polarisation of molecules which increases the ease with which they 
may be excreted. These conjugations occur primarily through methylation, 
esterification, acetylation, glucuronidation, sulfation, and glutathione and amino 
acid conjugation. Phase 2 enzymes include quinone reductases (QR), 
methyltransferases, epoxide hydrolases (EPH), N-acetyltransferases (NAT), 
glutathione S-transferases (GST), UDP-glucuronosyltransferases (UGT), and 
sulfotransferases (SULT) (Hinson and Forkert 1995). Similarly to phase 1 drug 
metabolising enzymes, phase 2 enzymes are almost ubiquitously expressed, 
however they are significantly enriched in the liver, intestines, kidney and lung 
(Chen, Tang et al. 2012). 
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1.5 Phase 3 Drug Metabolism 
 
Phase 3 drug metabolism is the most recently described phase of drug metabolism 
and refers to the active transport of drugs across cell membranes by drug 
transporters (Omiecinski, Vanden Heuvel et al. 2011). Research into phase 3 drug 
metabolism and transport dates back to 1976 when Juliano and Ling discovered a 
membrane bound glycoprotein on the surface of Chinese hamster ovary cells which 
modulated drug permeability. They named this complex “permeability glycoprotein” 
(P-glycoprotein), which was the first member of what now are collectively referred 
to as the ATP-binding cassette (ABC) family of drug transporters (Juliano and Ling 
1976). In addition to the ABC transporters, other important xenobiotic transporters 
include the organic anion transporters and organic cation transporters and the 
organic anion-transporting polypeptides of the of the solute carrier families, SLC22A 
and SLCOs (Hagenbuch 2010). Drug transport can contribute to the development of 
drug resistant phenotypes through the transport of drugs out of cells and away from 
their site of action.  
 
1.6 The Role of Nuclear Receptors: CAR and PXR 
Regulation of the detoxification response by the body to xenobiotics is regulated at 
a transcriptional level by nuclear receptors (NR) in humans and animals. The nuclear 
receptor family of ligand-activated transcription factors includes the steroid, 
retinoid, and thyroid hormone receptors as well as many orphan receptors, whose 
physiological ligands remain unknown.  
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The expression of cytochrome P450 enzymes is regulated on a transcriptional level 
by the nuclear receptors- pregnane X receptor (PXR), the vitamin D3 receptor (VDR) 
the constitutive androstane receptor (CAR), and the aryl hydrocarbon (AH) 
receptor. 
PXR was first described in 1998 (Kliewer, Moore et al. 1998) and shown to respond 
to a variety of compounds such as xenobiotics, natural and synthetic steroid 
hormones, and dietary phytoestrogens (Blumberg, Sabbagh et al. 1998). Its binding 
domain is largely hydrophobic, with a binding volume of 1150 Å3. It is flexible and 
able to accommodate a vast array of substrates (Watkins, Wisely et al. 2001).  
Since its discovery, PXR has been found to be activated by a range of structurally 
related compounds such as rifampicin, phenobarbital, hyperforin, paclitaxel and 
tamoxifen (Harmsen, Meijerman et al. 2009). When unbound, PXR is located in the 
cytoplasm. When bound to and activated by a ligand, the PXR-ligand complex 
translocates to the nucleus where it forms a heterodimer with retinoid-X-receptor 
(RXR). PXR then interacts with DNA response elements located on its target genes, 
and in doing so, PXR is able to up-regulate its target genes though transcriptional 
induction (Ihunnah, Jiang et al. 2011). The most well-known of these target genes is 
CYP3A4, however CYP2C9, CYP2B6, CYP2C19, CYP3A5, and UGT1A1, among others, 
are also implicated (Krausova, Stejskalova et al. 2011). This raises the concern of 
auto-induction, where a given anti-cancer agent may in fact induce its own 
metabolism. This has been seen in the use of the alkylating pro-drug 
cyclophosphamide, which is metabolised to 4-hydroxycyclophosphamide and 
aldophosphamide by several enzymes including, CYP3A4, CYP2A6, CYP2B6, CYP2C8, 
CYP2C9 and CYP2C19 (Scripture, Sparreboom et al. 2005). Cyclophosphamide has 
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been shown to induce mRNA levels of CYP2C8, CYP2C9 and CYP3A4 and in doing so, 
accelerates the rate of its own clearance resulting in a need for increasing doses of 
cyclophosphamide to maintain its therapeutic effect (Hassan, Svensson et al. 1999).  
CAR shares approximately 40 % homology in the ligand binding domain with PXR, 
and is most abundantly expressed in the liver (Moore, Parks et al. 2000). Similarly 
to PXR, CAR acts as a xenosensor for drugs and exogenous compounds, however, it 
is also involved in the regulation of bile acid and cholesterol homeostasis (Rezen, 
Tamasi et al. 2009). CAR, like PXR, is sequestered in the cytoplasm when unbound. 
Upon binding to a ligand, CAR translocates to the nucleus where it forms a 
heterodimer with RXR and binds to phenobarbital-responsive elements of CYP2B 
genes, leading to an up-regulation in their expression (Xie, Barwick et al. 2000).  
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a) 
 
b) 
 
Figure 1.2. Schematic of PXR and CAR Translocation and Transcription 
When unbound, a) PXR and b) CAR are sequestered in the cytoplasm. Upon ligand 
binding, the receptor-ligand complex translocates to the nucleus where they form 
a heterodimer with RXR, leading to the transcription and expression of target 
genes. 
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1.6.1 PXR and Drug Resistance 
PXR is also implicated in the development of multi-drug resistance (MDR). In a study 
by Harmsen et al. human colon adenocarcinoma-derived LS180 cells treated with a 
range of anticancer drugs including vincristine, vinblastine and cyclophosphamide 
showed increased P-glycoprotein (Pgp) induction when co-transfected with a PXR 
expression plasmid. Pgp is a member of the ATP Binding-Cassette (ABC) transporter 
family of proteins, which facilitate the transport of drugs out of cells. Pgp induction 
is regarded as one of the major mechanisms of the development of resistance to 
anti-cancer drugs (Szakacs, Paterson et al. 2006). When PXR was knocked down and 
cells treated with the anticancer drugs, no Pgp induction was seen. These data 
strongly suggest a role for PXR in Pgp-related drug resistance (Harmsen, Meijerman 
et al. 2009). 
Interest in pharmacogenetics, the heritable variations in metabolic pathways 
amongst a population, is growing rapidly as knowledge of the area develops. There 
is an increasing focus on patient targeted therapy, with a view to improving the 
outcome of treatments that may be effective in one patient and have little to no 
effect on another. Ultimately, selecting patients for certain treatments based upon 
the presence or absence of a molecular predictor, or a patient’s own genetic 
background would improve the efficacy of treatment, and reduce costs of 
treatments significantly (Carden, Sarker et al. 2010). There have been several recent 
studies in which PXR activation has been associated with resistance to 
chemotherapy. One such study by Raynal et al. described a positive relationship 
between PXR expression and activity levels in human colon cancer cells, and 
resistance to irinotecan therapy. They noted that PXR expression was highly varied 
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between tumour samples, and suggest that genotyping individual tumours for PXR 
could improve patient survival by identifying suitable candidates for specific 
therapies. Furthermore they suggest that PXR down-regulation may be a novel 
approach to circumvent PXR-mediated chemotherapy resistance (Raynal, Pascussi 
et al. 2010). 
1.7 Drug Transporters  
Many drugs are sufficiently lipophilic to diffuse across cell membranes; however, 
many are anions or cations and their transport across cell membranes depends on 
the function of a variety of drug transporters. In recent years, drug transporters 
have become more widely recognised as significant determining factors with 
regards to drug metabolism and pharmacokinetics. (DeGorter, Xia et al. 2012). Most 
drug transporters belong to one of two major superfamilies of transporters; ATP-
binding cassette (ABC) and solute-linked carrier (SLC). Drug transporters are, in 
many ways, comparable to P450s in the sense that they are differentially expressed 
in various tissues, are subject to polymorphisms, and are implicated in 
pharmacokinetics and drug-drug interactions (Zhang, Strong et al. 2006).  
 
1.8 Difficulties Associated with Current Chemotherapeutic Regimens 
It is not uncommon for initially successful chemotherapy to suddenly lose its 
efficacy during a course of treatment, as the tumour develops resistance to the 
drug.  There are many mechanisms by which tumour cells may develop resistance, 
as many cells from a given patient have different genetic make-up. This is 
dependent on both the tissue of origin of the cancerous cells as well as the 
expression patterns of oncogenes, activity of tumour suppressors and random 
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genetic variations attributed to the ‘mutating phenotype’ of many cancers. 
Subsequently, all cancers may express a variety of drug-resistant genes and 
transporters. As a result, even the most selective and effective anti-cancer drug may 
allow accelerated growth of other, resistant cell types and a shift in the phenotype 
and genetic make-up of the cancer (Gottesman 2002). This is illustrative of a need 
for a new approach to cancer therapy in place of, or alongside drugs which target 
neoplastic cells. There is emerging awareness of the interactions between the 
tumour, host, and ‘microenvironment’ of the cancer, as well as mounting interest 
in potential therapies which focus on the non-cancerous stromal cells of the tumour 
microenvironment, with which the tumour interacts in order to aid its survival (West 
and van de Rijn 2007). In a study by Orimo et al. Carcinoma-associated fibroblasts 
(CAFs) were isolated from six human invasive mammary carcinomas which were 
obtained from mastectomies. Separate fibroblasts were also extracted from 
normal, non-cancerous tissue obtained from reductive mammoplasty as a 
comparative control. These fibroblasts were combined with MCF-7 Ras human 
breast cancer cells and administered subcutaneously to nude mice as a human 
xenograft. Their results show that CAFs are significantly more competent at 
enhancing tumour growth compared with normal fibroblasts (Orimo, Gupta et al. 
2005). Tumour heterogeneity is a driving factor for the development of many 
cancers. A tumour may arise from one or more tumour initiating cells (TICs), all of 
which may express a different set of mutated oncogenes, affording them the ability 
to evolve drug-resistance pathways and grow even when challenged with several 
treatment strategies. As a result of heterogeneity, tumours may develop 
morphologically distinct zones containing populations of both mutated and normal 
cells. This may be affected by the development of the tumour micro-vasculature, as 
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these cell populations often have different nutritional requirements (Calderwood 
2013). 
1.9 History of Pharmacogenetics 
The oestrogen receptor was first identified in the 1960’s on the basis of its ability to 
bind radiolabeled oestrogen. Within the following decade the oestrogen receptor 
had become a predictive biomarker of the hormone-responsiveness of breast 
tumours (Osborne 1998). 
Approximately 70 % of all breast cancers express oestrogen or progesterone 
receptors and are classified as ‘Oestrogen Positive’. Tamoxifen is a selective 
antagonist for the oestrogen receptor and has been used for almost thirty years as 
a breast cancer chemotherapeutic, making it one of the very first molecularly 
targeted drugs to be approved by the FDA in the 1970s (Higgins and Stearns 2010). 
The success of tamoxifen paved the way for many more molecularly targeted drugs 
that have revolutionised the way in which chemotherapy regimens are designed. In 
1989, Hudziak and colleagues described a monoclonal antibody which they had 
generated to target the ERBB2 protein encoded for by the HER-2/neu proto-
oncogene. This was based on a previous finding by Slamon and colleagues that this 
gene is overexpressed by up to 30% in certain breast and ovarian cancers (Slamon, 
Godolphin et al. 1989). Hudziak showed that in vitro, ‘4D5’, as the monoclonal 
antibody was coined, was able to target ERBB2 expressing cells selectively to cause 
a decrease in proliferation as well as a down regulation of ERBB2 itself (Hudziak, 
Lewis et al. 1989). Presently, a modified version of 4D5, trastuzumab is now a front 
line therapy in HER-2 positive breast cancer. Trastuzumab may be given as a 
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monotherapy, to act via antibody dependent cytotoxicity to inhibit ERBB2 signalling, 
or in combination with broader cytotoxic drugs (Gelmon 2008). 
 These advances are promising; however, there are still many questions surrounding 
the use of genetic testing. These issues range from the financial implications of 
genotyping patients during a course of treatment, the time that such a process 
would require as well as the rather more ethical dilemma of the impact that a 
negative genetic result may have on a patient’s morale who is subsequently denied 
a particular treatment (Hapgood 2003). Despite these concerns, it is clear that more 
work in this area is needed to identify successful drugs, such as tamoxifen and 
trastuzumab, for a broader spectrum of cancers. Given the sheer number of genes 
involved in cancer development, there is no shortage of potential targets; however 
there has been limited progress in the development of clinical, ‘personalised’ drugs 
since trastuzumab. The situation changed in 2007 when AstraZeneca revived 
interest in pharmacogenetics by launching clinical trials of olaparib, for breast and 
ovarian cancer (Tutt, Robson et al. 2010). 
Despite the promise that these drugs show, and the distinct pathways and 
mutations they target, the question still remains, what percentage of patients will 
respond?  As mentioned earlier, variations in an individual’s capacity to metabolise 
a drug may, in some cases, render it completely ineffective in some patients, 
regardless of their particular variations. Therefore it is important to look beyond the 
drug and to assess the metabolic capacity of the patient. Ideally, single nucleotide 
polymorphism (SNP)-based phase 1 optimisation ought to be carried out; however, 
due to fiscal and ethical constraints, this is not a routine procedure (Yap, Sandhu et 
al. 2010). 
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1.10 Considerations in Personalised Therapy 
There is profound inter-patient variability in the outcome of cancer treatment.  This 
must be related either to the physiology and genetics of the tumour itself or to the 
genetics and phenotypic characteristics of the patient.  In the latter case, an 
important determinant of therapeutic outcome is the absorption, metabolism and 
disposition of the anti-tumour agents themselves.  In some patients rapid 
elimination of the drugs used can lead to lack of efficacy, in others prolonged 
exposure to the anti-tumour agent can result in life-threatening drug side effects. 
The metabolism of a particular drug is heavily dependent on the drug metabolising 
enzymes (DME) present in a particular patient. DMEs are subject to significant 
variation and may be profoundly affected by chronic co-medications administered 
alongside a chemotherapeutic agent. For example, dexamethasone is as 
corticosteroid, commonly prescribed to a majority of cancer patients for the 
alleviation of pain, nausea and chronic fatigue that can be caused by anti-cancer 
agents (Yennurajalingam, Frisbee-Hume et al. 2013). Dexamethasone is a PXR 
ligand, and therefore an inducer of CYP3A4 in man (Pascussi, Drocourt et al. 2001). 
Anti-cancer drugs which are also metabolised by CYP3A4 may be metabolised more 
rapidly in patients also receiving dexamethasone compared to patients not 
receiving dexamethasone.   
In humans, the DMEs with the highest impact on drug disposition are the 
cytochrome P450 enzymes. These enzymes are responsible for phase 1 metabolism 
of xenobiotics and toxins and often functionalise a drug to allow further metabolism 
by phase 2 enzymes. Certain pro-drugs, such as cyclophosphamide are also 
converted to their active form by the action of P450 enzymes (Pass, Carrie et al. 
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2005). Of these enzymes, certain isoforms have been found to be highly 
polymorphic, generating distinct phenotypes in humans. Of these, CYP2C9, 
CYP2C19 and CYP2D6 (Gough, Miles et al. 1990) are highly polymorphic and 
together they account for approximately 40% of hepatic phase 1 metabolism. 
CYP2D6 is perhaps the most widely studied isoform as its polymorphisms result in 
distinct and clinically relevant phenotypes known as poor, intermediate, efficient or 
ultra-rapid metabolisers of CYP2D6 drugs which include common medications such 
as various tricyclic antidepressants and beta blockers. This polymorphism has direct 
effects on approximately 50 % of all pharmacotherapeutics in current use, with 
normal doses causing adverse reactions, or no response at all (Rodriguez-Antona 
and Ingelman-Sundberg 2006). 
It is clear that in order to develop more efficacious cancer therapies, novel drugs 
must be identified which possess some degree of selectivity for tumour cells, but 
also that have a favourable pharmacokinetic profile. Drugs must be selected based 
on specific pathways dysregulated in any particular tumour. Several novel drugs 
have recently been described such as those discussed previously, that have been 
passed into clinical trials on the basis of their favourable qualities, namely - low 
toxicity, selectivity and efficacy. The general aim of this research is to establish the 
metabolism of these compounds in order to define their suitability for a particular 
patient. Furthermore, established anti-cancer drugs must be revisited with regards 
to polypharmacy and co-medication. It is highly possible that greater efficacy could 
be achieved with these drugs through a better understanding of the interactions of 
co-administered medications on their metabolism. 
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There is increasing awareness of the effects of polypharmacy on patient outcomes. 
This is a poorly-defined term that incorporates drug-drug interactions, improper 
medication administration, and excessive or conflicting drug administration 
(Bushardt, Massey et al. 2008). Polypharmacy has been linked to higher incidences 
of drug-related problems and poorer outcomes. This is a major implication in the 
outcome of chemotherapy, as many drugs impact on, or depend on the same 
metabolic enzymes, including the CYP450 system, for their efficacy and clearance 
(Marechal, Yu et al. 2006). 
1.11 Drug Toxicity and Idiosyncratic Reactions 
Idiosyncratic drug reactions are adverse reactions to a drug which are specific to an 
individual. Idiosyncratic reactions are toxic reactions that a patient may experience, 
which does not routinely occur in the general population of patients receiving a 
therapeutic dose of the drug in question. In this respect, idiosyncrasy is not related 
to ‘drug overdose’, where the dose of drug received is greater than the intended 
therapeutic dose, which may result in adverse reactions. An adverse reaction may 
be referred to as an idiosyncratic reaction, providing that the adverse response is 
not a consequence of the observed action or function of the drug. For example, 
arrhythmia caused by prolonged exposure to verapamil would not be considered an 
idiosyncrasy, as verapamil is a calcium channel blocker when used in a therapeutic 
setting, and arrhythmia may result purely from the blockade of the cardiac calcium 
channel. In other words, adverse reactions which are predictable are not considered 
to be idiosyncratic. The term idiosyncratic is often used in the same context as ‘type 
B reactions’, hypersensitivity, and allergy (Uetrecht 2007). As idiosyncratic reactions 
cannot be explicated based upon the pharmacology of the drug, they are largely 
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unexplained. While there has been a great deal of research into drug toxicity in 
terms of dosing strategies, and metabolism of parent compounds to toxic 
metabolites,  the basic mechanisms of idiosyncratic reactions remain largely 
unknown (Knowles, Uetrecht et al. 2000). One well described example of a rare 
idiosyncrasy with drug treatment is hepatotoxicity in patients treated with the non-
steroidal anti-inflammatory drug (NSAID), diclofenac. Diclofenac is a widely 
prescribed drug worldwide for the treatment of rheumatic conditions and pain 
management. Like other NSAIDs, diclofenac acts via inhibition of cyclo-oxygenase 
(COX) 1 and -2, and in doing so inhibits the synthesis of leukotrienes, prostacyclin 
and prostaglandins. No dose-response relationship between diclofenac dose or 
duration and hepatotoxicity exists, neither is it possible to reproduce diclofenac-
induced hepatotoxicity in animal models, which confounds attempts to define the 
mechanism by which it occurs in patients. This has led to a number of patient-
specific biomarkers of susceptibility to diclofenac-induced injury to be investigated, 
including polymorphisms in CYP450s, class 1 and class 2 major histocompatibility 
molecules, and mitochondrial dysfunction however, these have not been shown to 
be involved in clinical studies (Boelsterli 2003).    
 
1.12 Drug-Induced Liver Injury 
The liver is central to the metabolism of virtually all foreign compounds which enter 
the body, making the liver a common site of drug-induced toxicity seen in patients.  
Drug-induced liver injury may be ‘dose-dependent’, such as acute liver toxicity in 
acetaminophen overdose (Craig, Bates et al. 2011), or chronic and progressive such 
as cirrhosis and fibrosis resulting from prolonged ethanol consumption (Bardou-
Jacquet, Legros et al. 2013), In some cases, hepatotoxicity may be transient, 
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beginning shortly after commencement of drug therapy, and subsiding with 
continued treatment. Such transient hepatotoxicity occurs in approximately 10 – 20 
% of patients receiving isoniazid, with little consequence (Nolan, Goldberg et al. 
1999). The nature of hepatic injury can be categorized into a number of disease 
states, including cytotoxic injury, cholestatic injury, phospholipidosis, fatty liver, 
cirrhosis, fibrosis, hepatic tumours, hepatitis, and necrosis. Despite the broad 
spectrum of hepatic injury that can result from drug therapies and drug abuses 
alike, hepatic injury is often ‘silent’, with no overt symptoms of underlying disease 
until more severe injury has occurred. Common ‘late stage’ symptoms are often 
vague and include, malaise, fatigue, abdominal swelling or discomfort, dark 
coloured urine, nausea, confusion, and in some cases, jaundice. While the liver has 
a great capacity for regeneration, if damage extends beyond a certain stage, total 
liver failure can occur. At this stage, liver transplantation is the only treatment 
available.  
 
1.12.1 Diagnosis and Evaluation of Hepatic Injury 
The subtle, and non-specific symptoms of liver damage in the early stages, coupled 
with the impracticalities of performing core liver biopsies to ascertain 
histopathological changes of the earlier stages of hepatotoxicity makes the 
mechanisms of hepatic disease progression difficult to delineate in humans. While 
liver biopsies remain useful in cases of diagnostic uncertainty, coexisting disorders 
can confound diagnosis, and following transplantation of the liver, there are risks of 
complications including bleeding, damage to biliary ducts, and pneumothorax. 
Furthermore, diseased tissue is not always evenly distributed throughout the liver, 
and consequently, biopsies may not detect underlying disease (Carey and Carey 
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2010). Currently, liver function is routinely evaluated using blood tests to analyse 
plasma levels of liver enzymes. These include tests for aminotransferases alanine 
transaminase (ALT) and aspartate transaminase (AST), elevations of which are often 
indicative of hepatocellular injury. AST is present in cytosol and mitochondria in the 
liver, cardiac and skeletal muscle, kidney, brain, pancreas, lung, and several blood 
cell types. ALT is a cytosolic enzyme found in its highest concentrations in the liver 
and resultantly is more specific to the liver. Hepatocellular injury causes the release 
of these transaminases into the circulation where they may be detected in blood 
tests (Limdi and Hyde 2003). 
 
1.13 Pre-Clinical Models of Human Disease 
Therapeutic testing in humans is severely constrained by practical and ethical 
considerations. Similarly so, the use of large mammals and non-human primates in 
medical research incurs high costs and complex ethical concerns. Furthermore, 
while these models have led to great advances in the treatment of human disease, 
they are limited by variations in physiology, metabolism, and genetic background, 
and lack of genetically inbred strains (Macchiarini, Manz et al. 2005).  
The laboratory mouse is the most widely used and genetically amenable rodent 
species in pre-clinical research, offering several advantages over other species. Mice 
are among the smallest laboratory rodents available and may be housed in large 
numbers at a low cage density at comparatively low maintenance and husbandry 
costs when compared to rats, or larger species. Mice have a short gestation period 
of approximately 3 weeks, with females generally producing 5 to 10 pups in a litter. 
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Furthermore, most mouse strains exhibit immediate postpartum oestrus 
(Muruganandan and Sinal 2008).  
1.13.1 Limitations of Mice as Pre-Clinical Models 
While functional counterparts for almost all human genes have been identified in 
the mouse, numerous species differences in the expression, activity and inducibility 
of the cytochrome P450 enzymes have been described between mice and humans. 
The mouse genome contains 102 putatively functional genes, and 88 pseudogenes, 
whereas the human genome contains 57 putatively functional genes and 58 
pseudogenes within 7 main CYP gene clusters. In total, there are 36 orthologous 
pairs of CYP genes in mice and humans, and while these particular genes would be 
suitable to study in mice, with relation to human biology, the vast expansion of the 
Cyp gene clusters in mice means that many genes are not comparable between 
species. For example, the Cyp2d cluster in mice contains 9 full length putatively 
functional genes, whereas the human has only one; CYP2D6. CYP2D6 is of clinical 
importance as it encodes for an enzyme responsible for the metabolism of a broad 
range of over 40 clinically used drugs including a number of antidepressants, 
neuroleptics, beta-blockers and anti-arrhythmics (Ingelman-Sundberg 2005). 
Patients lacking functional CYP2D6 are at risk of toxic drug reactions due to an 
inability to clear CYP2D6 substrates from the body, while conversely, patients 
overexpressing CYP2D6 may fail to maintain therapeutic levels of a drug due to 
overly rapid metabolism. It is likely that the vastly expanded Cyp2d cluster in the 
mouse is responsible for more extensive functions than in the human, rendering the 
mouse as an unsuitable model for studies involving CYP2D6 substrates (Nelson, 
Zeldin et al. 2004).  
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In order to address the disconnect between mouse and human data, powerful 
humanised mouse models have been generated. Humanisation of mice involves the 
replacement of a murine gene or genes with its functional human ortholog in vivo. 
In this way, humanised mice more closely mimic human drug metabolism, improve 
the predictability of drug responses and speed up the drug discovery process 
1.13.2 Humanised Mice 
Humanised mice are set to become the gold standard in pre-clinical modelling. They 
have been shown to better reflect human responses to xenobiotics in several 
different fields of study including research into HIV transmission (Denton, Estes et 
al. 2008), Parkinson’s disease (Yamakado, Moriwaki et al. 2012) and Alzheimer’s 
disease (Hickman, Allison et al. 2008). They are stable models in the sense that many 
generations of mice can be bred and still retain and express the human transgene.  
Genetically modified mice including nude and severe combined immunodeficient 
(SCID) mice have been used for many years to study human tumour growth, and to 
test emerging therapies. The nude mouse carries a mutation in the HNF-3/forkhead 
homolog 11 gene. These mice are athymic, and hairless, hence the name ‘nude’. 
Due to the lack of a functional thymus in these animals, they are unable to produce 
mature T-cells, rendering them immunocompromised (Balciunaite, Keller et al. 
2002). They have proven to be highly useful in immunology research, and are a 
popular model for leukaemia (Potter, Shen et al. 1984), HIV and AIDS (Ensoli, 
Markham et al. 1994), leprosy (Lancaster, McDougall et al. 1984) and tumour 
growth studies (Swami, Krishnan et al. 2011), as they are unable to reject human 
tissue xenografts. Similarly to nude mice, SCID mice are immunodeficient, lacking 
both functional B- and T-lymphocytes, as well as natural killer (NK) cells. SCID mice 
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are homozygous for recessive mutations of the protein kinase, DNA activated, 
catalytic polypeptide (Prkdc) gene, which encodes for a protein kinase involved in 
the repair of double stranded DNA breaks (Maruyama, Suemizu et al. 2002). Their 
attenuated capacity for double stranded DNA break repair makes them particularly 
sensitive to non-genotoxic carcinogens, and a useful model for investigating 
radiation induced DNA damage (Takahashi, Asakawa et al. 2002). SCID mice are 
more severely compromised than nude mice, and there have been several studies 
demonstrating improved invasion of metastatic human tumour xenografts in SCID 
mice than in nudes. This is likely due to T-cell-independent immune responses to 
metastasis in the nude mouse (Xie, Brunner et al. 1992).   
Unlike the nude and SCID models, humanised mice retain a fully functional immune 
system. This is useful when considering tumour models, as the immune response 
may affect tumour progression and development. Moreover, chemotherapeutic 
agents which impair the immune system may be better evaluated in early stages of 
development.  
CYP3A4 is the most highly expressed of the human CYP3A enzymes in the liver. It is 
highly promiscuous and is implicated to some degree in the metabolism of the 
majority of clinically-used drugs (Ekroos and Sjogren 2006). However, mice do not 
possess a CYP3A4 ortholog; of the eight cyp3a genes identified in the mouse, the 
most highly expressed is Cyp3a11, which does not exhibit the same substrate 
specificity as CYP3A4. This led to the generation of several humanised mouse 
models which are able to metabolise drugs using the functional human CYP3A4 
enzyme.  
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A study by van Herwaarden et al. in 2005 described the generation of the 
FVB.129P2-Cyp3a13tm1Ahs Del(5Cyp3a57-Cyp3a59)1Ahs Tg(APOE-CYP3A4)A1Ahs 
mouse line. This is a humanised 3A4 mouse line in which all 8 murine Cyp3a genes 
had been removed or disrupted and replaced with a transgene containing human 
CYP3A4 under the control of a liver specific promoter-human apolipoprotein E 
(APOE) (Taconic, tADMET™ model number 9048). These animals constitutively 
express high levels of human CYP3A4 in the liver alone, and may be used alongside 
the 8-gene knock out line (Taconic, tADMET™ model number 9011) to investigate 
the relative contribution of CYP3A4 in the liver to the overall metabolism of a drug. 
In their study, these mice were administered midazolam and cyclosporine A, both 
of which are CYP3A4 substrates. Their findings showed a greater rate of clearance 
of both drugs in the humanized mice compared to wild-type mice. Such findings 
provide strong evidence that humanised mice provide a more accurate model for 
testing drugs compared to wild-type mice. In particular, drugs such as cyclosporine 
A, which have a narrow therapeutic index may be better understood by using these 
transgenic models, which could improve patient care in the clinic (van Herwaarden, 
Smit et al. 2005).  These models are becoming increasingly complex, with some lines 
possessing multiple transgenes to investigate interactions of various enzymes with 
drug transporters and nuclear receptors.  
In recent years, powerful models with which to study pharmacogenetic variations 
have been developed that are proving to be invaluable tools in determining how 
susceptible a particular drug may be to cytochrome P450 polymorphisms, in 
particular, CYP2D6 and CYP3A4. One such model is the Hepatic Reductase Null 
(HRN) mouse (Pass, Carrie et al. 2005). The rationale for this model was based on 
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the understanding that the P450s are nearly ubiquitously expressed and a global 
knock out is embryonically lethal. There is also significant functional redundancy 
among the P450s, which belong to a large family of enzymes. P450s exhibit 
overlapping substrate specificities and often the loss of one enzyme only, will be 
compensated by the action of another isoform. However, all P450 enzymes receive 
an electron from the electron donor cytochrome P450 oxidoreductase (Por), and so, 
by conditionally deleting this protein in the liver it is possible to inactivate the 
hepatic P450 enzymes only (Henderson, Otto et al. 2003). By administering 
xenobiotics to these mice and measuring the levels of the parent compound and 
metabolites in the plasma over a period of time, it is possible to determine whether 
or not a drug is a P450 substrate, and consequently, whether it will be affected by 
potential polymorphisms in these enzymes (Henderson, Otto et al. 2003). It would 
then be possible to administer the drug to humanized mouse models of cancer 
and/models with modified P450 isoform expression to see if efficacy is lost, or 
enhanced, in different genetic scenarios (van Schaik 2008). 
1.14 Transgenic Technology 
Transgenic animals are animals which have been genetically altered in such a way 
so that they express the functional gene or genes of an animal of another species. 
This differs from knockout technology, whereby the gene of interest is removed 
from the genome of the model organism and not substituted with another gene. By 
using such genetic technology, it is possible to study the effect an absent or non-
functional gene may have on the pharmacology of drugs, or to compare the 
response of wild type and transgenic animals to certain drug regimens. The 
generation of transgenic mice may be achieved by several methods, most common 
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are the embryonic stem cell method, and the pronucleus injection method. The 
pronucleus injection method involves the harvest of freshly fertilized eggs prior to 
the fusing of the male and female pro-nuclei. The male pronucleus is injected with 
the gene of interest and the embryo is implanted into a pseudo-pregnant female at 
the early blastocyst stage (Ittner and Gotz 2007). Alternatively, the embryonic stem 
cell method involves the harvest of embryonic stem cells from the inner cell mass 
(ICM) of mouse blastocysts. These cells are pluripotent, and retain the ability to 
differentiate into any cell line if cultured under the correct conditions. Any 
alterations made to these cells may be transmitted though breeding the embryonic 
stem cell method involves isolating embryonic stem cells and transfecting them 
with the gene or genes of interest before being injected back into the ICM of the 
blastocysts (Gossler, Doetschman et al. 1986). 
 
1.14.1 Cre/LoxP System 
Cre recombinase/loxP system is a site-specific recombination technology which may 
be used to create deletions, insertions, translocations and inversions of DNA and 
genes in cells. Cre recombinase is a 38kD protein derived from the P1 bacteriophage 
and is a member of the integrase family of recombinases. It functions by catalysing 
the recombination between two loxP recognition sites, also derived from the P1 
bacteriophage. This system allows alterations to be made in the genome which are 
inducible, or cell-type specific, which affords many benefits when looking at tissue 
specific gene function in vivo (Nagy 2000). The transgenic animals used in this work 
were developed by Taconic Artemis, Germany, in collaboration with Professor 
Roland Wolf and CXR Biosciences Limited, Dundee, using Cre/LoxP transgenic 
technology. 
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1.15 Limitations of Humanised Mice 
As with all models, humanised mice are not without their limitations. While it is 
useful to be able to model cancers in the species from which they are naturally 
derived, the fact remains that we are still unable to mimic the complexity of the 
human disease progression. Secondly, mouse tumour progression does not offer an 
exact reflection of human tumours. They often respond differently to 
chemotherapy compared to human tumours. It is possible to cure many mouse 
cancers, however this is not reflected in the clinic (Richmond and Su 2008).  
Variation in the genetic background of laboratory mice is of particular importance 
when developing a humanised model. The genetic background may be defined as 
“the genotype of all other related genes that may interact with the gene of interest” 
(Yoshiki and Moriwaki 2006). Laboratory mouse strains used today originated from 
the breeding of domestic varieties of ‘fancy mice’, a once popular pursuit that 
originated in Asia in the 1700s. ‘Fancy mice’ breeding spread to Europe and North 
America, peaking in its popularity in the late 19th to the early 20th Century with the 
rediscovery of Mendel’s laws of inheritance which allowed selective breeding for 
desired qualities such as coat colour and behaviour (Wade and Daly 2005). Because 
of the ‘fancy mouse’ origins of the laboratory mouse, most strains are a variable 
genetic blend of four major subspecies; M. musculus domesticus, Mus musculus 
musculus, Mus musculus castaneus, and Mus musculus molossinus which hail from 
Eastern Europe, Western Europe, South East Asia and Japan respectively (Hedrich 
and Bullock 2004). 
There have been many studies and reports on the effects of genetic background on 
gene expression and regulation. Such impacts may be extreme in nature, as 
described by Carlson et al. in 1997, who showed that over expression of the 
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Alzheimer’s amyloid precursor protein (APP) in outbred mice produced amyloid 
plaques associated with Alzheimer’s disease in the brain, however over-expression 
of APP in inbred FVB/N or C57BL/6J mice is lethal (Carlson, Borchelt et al. 1997). 
Some phenotypes arising from genetic background may be more subtle, with 
differences arising between sub-strains. To avoid confusion over unexpected results 
when using mouse models, it is of paramount importance to select a mouse line on 
a well-defined genetic background, and utilise the correct controls for that strain, 
preferably, a co-isogenic line (Yoshiki and Moriwaki 2006).     
 It is worthy of note that while great advances have been made in the field of mouse 
transgenesis, the rat is the species of choice for a variety of research areas. The 
physiology of the rat more closely mimics that of humans compared to the mouse, 
and so they are often used in research into diabetes, cardiovascular disease and 
age-related disease (Iannaccone and Jacob 2009). Their behaviour is more complex 
and social than the mouse and their ability to learn tasks and skills makes them a 
popular model for learning and behavioural studies. Recent advances in rat ES cell 
technology have led to the generation of new knockout and transgenic rats (Huang, 
Tong et al. 2011), (Li, Tong et al. 2008). While rats may provide good models for 
behavioural and learning studies, they are costly to maintain and require more 
space than mice for high-powered studies. The cost of developing a transgenic rat 
greatly outweighs the cost of developing a transgenic mouse.  
 
1.16 Application of Humanised Mice to Complex Human Disease 
The increasing availability of humanised mice presents a unique opportunity to 
investigate complex human disease, and compare outcomes with those found in 
wild-type mice in the hope that better model systems can be identified. Cancer is a 
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complicated and dynamic disease, especially in later stages of disease progression. 
Cancer is generally more easily treated when identified early, however this is not 
always possible, as some cancers do not present with obvious symptoms until an 
advanced disease state is reached (Smith, Cokkinides et al. 2009).  
Metastatic renal cell carcinoma has typically proven very difficult to treat, with 
patients typically presenting during later stages of disease. This can result in a very 
poor prognosis and high mortality within 5 years. Renal cell carcinoma is largely 
resistant to radiation, hormone therapy and chemotherapy which is a great 
limitation to the armamentarium of traditional treatments (Figlin, Sternberg et al. 
2012). Historically, cytokine therapy with Interferon- α and interleukin-2 was 
considered the most useful treatment option available, with a response seen in 10-
20 % of patients (Motzer, Bacik et al. 2004).  
Recent studies into the development of the underlying mechanisms of the disease 
have identified vascular endothelial growth factor (VEGF), a tumour secreted 
cytokine central to tumour driven angiogenesis, as a key therapeutic target. VEGF is 
a member of the platelet derived growth factor (PDGF) superfamily of growth 
factors, along with VEGF-C, D and E, and placenta growth factor (PlGF) (Rini and 
Small 2005).  
The VEGF proteins are dimeric glycoproteins which are over-expressed in the 
majority of human metastatic tumours as well as many pre-metastatic lesions. They 
bind to 3 transmembrane tyrosine kinase receptors (VEGFR 1-3) which are enriched 
in the vascular endothelium in response to hypoxic conditions (Dvorak 2002).  Upon 
binding to the receptor, VEGF causes autophosphorylation of the tyrosine kinase, 
followed by activation and subsequent phosphorylation of a complex array of 
second messengers and signalling molecules including those of the Raf, MEK, Erk 
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pathway, p38MAPK and the Akt pathway, to promote endothelial cell migration, 
proliferation, survival and vascular permeability (Koch, Tugues et al. 2011) . The 
VEGF signalling cascade is depicted in Figure 1.3.  
 
Figure 1.3. Vascular Endothelial Signalling Cascade. 
 
 
1.16.1 Pazopanib 
Pazopanib (Votrient; GlaxoSmithKline, London, UK) is a novel tyrosine kinase 
inhibitor (TKI), which targets vascular endothelial growth factor receptors (VEGFR) 
1, 2, and 3, platelet derived growth factor receptor (PDGFR) -α and -β and stem cell 
factor receptor (c-kit) tyrosine kinases. The structure of pazopanib is displayed in 
Figure 1.4. Pazopanib exerts its therapeutic effect by inhibiting angiogenesis and 
reducing blood supply to tumours. Pazopanib is currently licensed for treatment of 
advanced renal cell carcinoma (RCC), and is undergoing trials for a number of other 
cancers including glioblastoma (Iwamoto, Lamborn et al. 2010), breast cancer 
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(Taylor, Chia et al. 2010), thyroid cancer (Bible, Suman et al. 2010) and soft tissue 
sarcoma (Sleijfer, Ray-Coquard et al. 2009). A clinical trial carried out by Steinberg 
et al. reported a mean progression free survival of patients receiving pazopanib of 
9.2 months, compared with the control group which had an average progression 
free survival time of 4.2 months (Sternberg, Davis et al. 2010).  
A study in 2007 showed Pazopanib to be orally bioavailable, with a broad anti-
tumour activity in vivo, with tumour growth inhibition being seen at doses as low as 
10 mg/kg. A plasma concentration of 40 µmol/L was required to inhibit VEGFR 
phosphorylation and tumour growth in vivo. These figures correlate well with 
clinical trial outcomes, in which the majority of patients achieve efficacious plasma 
concentrations of 40 µmol/L (approximately 20 µg/ml) at a dose of 800 mg per day 
(Kumar, Knick et al. 2007).  
Pazopanib is known to be a substrate for CYP3A4 and a weak inhibitor of CYP3A4, 
CYP2C8, and CYP2D6. Consequently, drugs with a low therapeutic index that are 
substrates of these P450s should not be given in conjunction with Pazopanib. Strong 
inducers or inhibitors of CYP3A4 should also be avoided. Pazopanib, in addition to 
interaction with various CYP enzymes, is a substrate for p-glycoprotein, and an 
inhibitor of uridine-diphosphoglucuronate glucuronosyltransferase 1A1 (UGT1A1). 
Results from in vitro studies demonstrated that metabolism of pazopanib is 
mediated primarily by CYP3A4, with minor contributions from CYP1A2 and CYP2C8. 
There are three principle pazopanib metabolites; GSK1268992, GSK1268997, and 
GSK1071306 however little is known about their pharmacology. One of the 
metabolites is known to inhibit the proliferation of VEGF-stimulated human 
umbilical vein endothelial cells with a similar potency to that of pazopanib, while 
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the others are 10- to 20-fold less active. Pazopanib itself is considered to be the 
primary active compound (European Medicines Agency).  
 
 
Figure 1.4 Structure of Pazopanib 
 
 
1.16.2 Pazopanib Dosing and Toxicity 
The recommended dose of Pazopanib is 800 mg per day by mouth; however in 
patients who must use a strong inhibitor of CYP3A4, this may be dropped to 400 mg 
per day. Similarly, in patients with moderate liver impairment, a dose of 200 mg per 
day is recommended. Pazopanib carries a black box warning of severe and 
potentially fatal hepatotoxicity and must not be administered to patients with liver 
failure or other hepatic impairment (GSK, 2010). 
According to a study in 2010 by Hawkins et al. Pazopanib hepatotoxicity is fatal in 
approximately 1 % of patients (Sternberg, Davis et al. 2010). GlaxoSmithKline have 
reported fatal hepatic failure in 2 of 977 patients enrolled in clinical trials for renal 
cell carcinoma, and 1 patient in 240 enrolled in a clinical trial with soft tissue 
sarcoma (GSK). 
The mechanisms by which such severe toxicity occurs have not been defined. It is 
not clear if hepatotoxicity in pazopanib patients is idiosyncratic in nature or whether 
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it is attributable to variations in metabolism in individuals. Data from clinical trials 
shows marked variation in plasma concentrations in patients receiving Pazopanib 
(Hurwitz, Dowlati et al. 2009). In a controlled clinical study with pazopanib for the 
treatment of RCC, alanine transaminase (ALT) > 3x upper limit of normal (ULN) was 
reported in 18 % and 3 % of the pazopanib and placebo groups, respectively. ALT > 
10x ULN was reported in 4 % of patients who received pazopanib. Concurrent 
elevation in ALT > 3x ULN and bilirubin > 2x ULN in the absence of significant alkaline 
phosphatase> 3x ULN occurred in 5/290 (2 %) of patients on pazopanib, and 2/145 
(1 %) on placebo (FDA).  
Several animal studies have been carried out with repeated doses of pazopanib up 
to 1000 mg/kg/day in rodents. Liver enzyme elevations were observed in mice at 
doses of 300 - 1000 mg/kg/day and liver function parameters (aspartate 
aminotransferase, AST, and alanine aminotransferase, ALT, and/or bile acids) also 
occurred in individual rats given 300 mg/kg/day for 4 weeks, and alkaline 
phosphatase (ALP) and ALT were elevated after 26 weeks at 3 mg/kg/day. However, 
none of the changes in rats were associated with microscopic findings in the liver.  
No evidence of hepatic toxicity was observed in Cynomolgus monkeys receiving up 
to 500 mg/kg of pazopanib for up to 52 weeks but 2 monkeys given 500 mg/kg had 
moderately increased total bilirubin. The mechanism of liver failure and the risk 
factors pertaining to its development have not been identified and guidelines from 
GSK regarding pazopanib dosing and treatment suggest monitoring patients liver 
function and incremental dose-reductions of 200 mg per day, in a step-wise fashion 
if elevations are noted. There is little information available regarding the effect of 
reduced dosing on the efficacy of the drug (European Medicines Agency).  
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1.17 Project Aims 
It is clear from the literature that there are a number of shortcomings in the current 
system by which new drugs are screened and selected for development. Such 
limitations include rising development costs, and discrepancies between efficacies 
of drugs in animal models which are not reflected in man. Furthermore, currently 
used pre-clinical models of human disease are limited by inter-species variation in 
metabolic pathways, as well as variation in genetic background. These factors are in 
some cases responsible for dramatic and unexpected effects of new therapies in the 
clinic. In order to address these limiting factors, it is necessary to investigate ways 
in which the impact of these variations can be minimised or avoided. Humanised 
mice represent an exciting new technology with which to accomplish this.  
 
This project will focus on the characterisation and uses of several humanised and 
knock out mouse models with regards to the novel chemotherapeutic agent, 
pazopanib. I will investigate whether or not differences in metabolism exist 
between human and murine microsomal metabolism, and whether the human 
metabolism of pazopanib can be mimicked using humanised mouse models. 
Potential differences in pharmacokinetic profiles of pazopanib will also be 
investigated using wild-type and humanised mouse models, and whether or not this 
can alter efficacy and toxicity of pazopanib. 
 
 
 
 
Chapter 2 
Materials and Methods 
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2.1 Statistical Analysis and Graphical Software 
Data was analysed by means of t-tests, or analysis of variance using Instat, (ANOVA) 
(GraphPad Instat version 3.01). Pharmacokinetic parameters were calculated using 
WinNonLin software, version 3.1. A non-compartmental model was used to 
calculate area under the curve (AUC), terminal half-life, maximum plasma 
concentration (Cmax). Enzyme kinetic parameters and Hill coefficients were 
determined using GraFit (Erithacus Software version 5.0.4) software. P values are 
expressed by asterisks, where * = P<0.05, **=P<0.01, and ***=P<0.001.  
 
2.2 Animals 
All animal work undertaken in this thesis was carried out in accordance with the 
British Home Office Animal (Scientific Procedures) Act 1986. All procedures were 
approved following ethical review at Dundee University and Cancer Research UK, 
and conducted under the project licence held by Dr Colin J. Henderson (PIL 
60/3956). Mice were housed in open top cages under standard animal house 
conditions, including a 12 hour light/dark cycle and ad libitum access to water and 
standard RM1 animal diet (SDS, Essex, UK). Breeding mice received RM3 diet (SDS, 
Essex, UK). Transgenic mice were developed by Professor Roland Wolf in 
collaboration with Taconic and CXR Biosciences.  
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2.2.1 C57BL/6NTac-Del(5Cyp3a57-Cyp3a59)1Arte Mouse Line 
This mouse is a knock-out for the murine Cyp3a gene cluster. The line was created 
through the excision of 7 of the 8 mouse Cyp3a genes, including Cyp3a57, -3a16, -
3a41, -3a44, -3a11, -3a25 and -3a59, which are located in close proximity to one 
another within a region of approximately 0.8 Mb, on mouse chromosome 5. The 8th 
Cyp3a gene, Cyp3a13, is located on the same chromosome approximately 7 Mb 
removed from the major Cyp3a cluster, and remains in this model, with negligible 
effect. For the purposes of this thesis, this line will be referred to as “Cyp3ac knock-
out”. 
 
2.2.2 C57BL/6-Del(5Cyp3a57-Cyp3a59)1Artetm1(CYP3A4-CYP3A7)Arte Mouse 
Line 
The C57BL/6-Del(5Cyp3a57-Cyp3a591Artetm1(CYP3A4-CYP3A7)Arte (Taconic, model 
number 8842-M) mouse line is a novel mouse line containing human CYP3A4 and 
CYP3A7. Mice were generated from Cyp3a cluster deleted embryonic stem (ES) cells 
by the insertion of a bacterial artificial chromosome (BAC) containing human 
CYP3A4 and CYP3A7 via Cre-mediated recombination. Selected ES cells were 
injected into BALBc-blastocysts, which were inserted into pseudo-pregnant female 
mice. Resultant progeny were crossed onto a wild type C57BL/6 background. These 
mice were bred with a Flp-deleter mouse strain which harbours Cre-recombinase in 
the germline, and efficiently removes the selection markers from the transgene. 
Further breeding of heterozygous offspring produced homozygous Cyp3a(-/-) and 
huCYP3A4/CYP3A7(+/+) mice (Hasegawa, Kapelyukh et al. 2011). Throughout this 
thesis, this line will be referred to as “hCYP3A4/3A7”. 
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2.2.3 C57BL/6-Nr1i2tm1(NR1I2)ArteNr1i3tm1(NR1I3)Arte Mouse Line 
C57BL/6-Nr1i3tm1(NR1I3)Arte and C57BL/6-Nr1i2tm1(NR1I2)Arte mouse lines containing the 
functional human nuclear receptors CAR and PXR respectively, were generated by 
a knock-in strategy which deleted the murine gene of interest and simultaneously 
inserted the human ortholog. The expression of the human receptors is controlled 
by the corresponding murine promoter.  
In the humanised PXR model, a construct containing exons 2-4, intron 4, exon 5, 
intron 5, and a fusion of exons 6-9 was knocked onto the translational start ATG 
sequence of the mouse Pxr gene. In the humanised CAR mouse, the coding region 
of the mouse Car gene was replaced with the genomic coding region of human CAR, 
including exons 2–9. As was the case with the humanised 3A4/3A7 mouse line, 
these animals were crossed onto a FLP recombinase line to give rise to animals 
expressing human nuclear receptors. These mice were then cross bred to generate 
the C57BL/6-Nr1i2tm1(NR1I2)ArteNr1i3tm1(NR1I3)Arte mouse line, which possesses both 
human CAR and PXR (Taconic, model number 8223-M) (Scheer, Ross et al. 2008). 
For the purposes of this thesis, this line will be referred to as “hCAR/hPXR”.  
 
2.2.4 C57BL/6-Nr1i3tm1(NR1I3)ArteIs(5CYP3A4-CYP3A7;Del5Cyp3a57- 
Cyp3a59)2ArteNr1i2tm1(NR1I2)Arte Mouse Line 
C57BL/6Nr1i3tm1(NR1I3)ArteIs(5CYP3A4CYP3A7;Del5Cyp3a57Cyo3a59)2ArteNr1i2tm1(N
R1I2)Arte mice possess the human CYP3A4/3A7 cluster, as well as human CAR and PXR. 
These mice were generated by crossbreeding of h3A4/3A7 mice with hCAR/hPXR 
mice to create a multiple humanised mouse which may be used in investigations 
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into autoinduction of drug metabolism (Taconic, model number 11585-M). For the 
purposes of this thesis, this line will be referred to as “h3A4/3A7/hCAR/hPXR”. A 
developmental schematic for the generation of this line is displayed in Figure 2.1. 
 
(Hasegawa, Kapelyukh et al. 2011). 
Figure 2.1. Strategy for Generating Humanised 3A4/3A7/hCAR/hPXR mice. 
A) Schematic representation of the chromosomal organization of functional genes within 
the mouse Cyp3a cluster B) exon/intron structure of Cyp3a57 and Cyp3a59. C) vectors used 
for targeting of Cyp3a57 and Cyp3a59 by homologous recombination D) genomic 
organization of the Cyp3a cluster in double-targeted ES cells after homologous 
recombination. E) Deletion of the mouse Cyp3a cluster after Cre-mediated recombination 
at the loxP sites F) modified human BAC containing CYP3A4 and CYP3A7 used for Cre-
mediated insertion into the Cyp3a knockout locus. G) Targeted mouse Cyp3a locus after 
Cre-mediated recombination. H) Humanized Cyp3a locus after deletion of the expression 
cassettes. 
 
 
 2.2.5 Enzyme Induction in Humanised Mouse Lines 
The initial study describing the generation of the hCYP3A4/3A7 mouse line, by 
Hasegawa et al. found that the basal expression of the human enzymes in the livers 
of these models is relatively low, but highly inducible. The levels found in the 
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intestines are constitutively high, and although they are inducible, the magnitude 
of induction is not as great as that seen in the liver. The induction of the 
hCYP3A4/3A7 mouse was achieved by intraperitoneal injection of 10 mg/kg 
pregnenolone-α-carbonitrile (PCN) on two consecutive days. PCN is a potent 
activator of murine PXR, and successfully induces the transgene to a level 
comparable to that found in human tissue. Similarly, the h3A4/3A7/hCAR/hPXR 
model is inducible using an activator of human PXR, in this case, rifampicin. 
Rifampicin was given at a dose of 10 mg/kg for three days by intraperitoneal 
injection to produce an induction equivocal to the induction by PCN in the 
humanised 3A4/3A7 model (Hasegawa, Kapelyukh et al. 2011). 
 
2.2.6 Hepatic Reductase Null Mouse Line 
The hepatic reductase null (HRN™) mouse model is homozygous for a tissue-specific 
disruption of Por, which encodes for P450 oxidoreductase, in the liver. This results 
in a complete ablation of hepatic microsomal P450 activity. The absence of first pass 
metabolism in this model makes it an invaluable tool in assessing the role of the 
P450 system in efficacy, metabolism and toxicology (Henderson 2003). 
 
2.3 Cell Culture 
All cell culture experiments were carried out using aseptic techniques. Cells were 
grown in an incubator at 37°C under 5 % CO2. Syngeneic mouse tumour cell lines 
were purchased from Health Protection Agency Culture Collections (HPACC, 
Salisbury, UK). Cells were cultured in Dulbeccos Modified Eagle Medium, High 
Glucose (DMEM), GlutaMAX™, Pyruvate (Gibco 31966-021), supplemented with 10 
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% Fetal Bovine Serum (FBS) (Gibco 10500064) and 1% penicillin-streptomycin 
(Gibco).  At 80-90 % confluency, cells were washed twice with sterile phosphate-
buffered saline (PBS) before the addition of 2 ml of trypsin (Gibco) to the flask, 
which was then incubated at 37°C for 5 min. Medium (8 ml), containing FBS was 
then added to the flask in order to neutralise the trypsin, and cells were detached 
from the flask by gentle pipetting. The cell suspension was then transferred into a 
15 ml Falcon tube and centrifuged (3 min) at 100 g. The supernatant was aspirated 
from the falcon and the cell pellet was resuspended in fresh medium (5 ml). Cells 
were then grown in flasks containing fresh medium (10 ml) at a dilution of 1:10 for 
2-3 days until 80-90 % confluency was achieved 
2.3.1 Cell Lines 
Syngeneic tumour cells were purchased from the Health Protection Agency Culture 
Collections. 
CMT-93 cells are a murine rectal carcinoma cell line (catalogue number: 89111413) 
B16-F1 cells are a murine derived melanoma cell line (catalogue number: 92101203) 
2.4 Microsomes and in vitro Stability 
Microsomes are vesicular fractions derived from the endoplasmic reticulum during 
tissue homogenisation, and they contain the cell’s P450 enzymes.  
2.4.1 Microsome Preparation from Frozen Tissue 
Microsomes were prepared from 0.2-0.4 g of snap frozen tissue samples as 
previously described by Meehan et al. (Meehan, Forrester et al. 1988). Briefly, tissue 
samples were thawed in 2 ml Eppendorf tubes. 3x volume of microsome buffer (KCL 
phosphate, pH7.4 at 4°C) was added to the tissue samples. Small intestines were 
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harvested using a “squeeze and freeze” technique whereby faecal matter was 
pushed from the intestine prior to snap freezing in liquid nitrogen. During small 
intestine tissue processing, 100 mM phenylmethanesulfonylfluoride (PMSF) and 
protease inhibitor tablets (Roche) were added to the microsome buffer at a 
concentration of 1 tablet per 10 ml of buffer. Tissue was scissor-minced and 
homogenised in short bursts using a PT2500E Polytron homogeniser (Kinematica) 
and kept on ice. Samples were centrifuged at 11,200x g for 20 minutes at 4°C, and 
the supernatant was transferred into a new Eppendorf tube, taking care to avoid 
the fatty upper layer. The supernatant was spun a second time at 11,200x g at 4°C 
to ensure residual debris and fat were removed. The supernatant was placed into 
precooled ultracentrifuge tubes and balanced to within 0.5 mg. Samples were 
centrifuged at 226800x g at 4°C for 80 min. The cytosolic fraction was removed to a 
new tube, and the dried pellet was resuspended in 50-150 µl of microsome storage 
buffer (0.25 M-sucrose buffered with 10 mM KCL phosphate, pH 7.4). All samples 
were stored at -80°C. Protein quantification of microsomal fractions was performed 
by the Bradford technique using the Bio-Rad protein assay reagent (Bradford 1976). 
A typical standard curve using Bovine Serum Albumin (BSA) as a standard, obtained 
for Bradford protein quantification can be seen in Figure 2.1. 
45 
 
 
 
Figure 2.1. Trace depicting a typical linear standard curve of BSA as a 0.1 
mg/ml stock against optical density when performing protein quantification.   
 
2.5 Extraction Method Optimisation 
In order to optimise the protocol for pazopanib extraction from bloods and protein 
samples, it was necessary to perform drug extractions from spiked blood samples 
using various solvents. In order to do so, tubes were set up containing 10 µl of blood 
containing 0.25 µg/ml of pazopanib. To these tubes, 500 µl of ether, diethyl ether, 
hexane, dichloromethane or diethyl ether/ dichloromethane (70 %/30 %) mixture 
was added. Tubes were vortexed for 30 sec, shaken for 20 min and spun down for 
5 min at 23755 g. The clear, organic layer was removed into fresh Eppendorf tubes 
and dried in a speed vac at 30°C. Samples were re-susupended in methanol (80 µl) 
and water (40 µl). Samples were analysed by liquid chromatography mass 
spectrometry (LC/MS-MS) (Section 2.9). 
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2.6 Microsomal Incubations of Pazopanib for Liquid Chromatography-
Tandem Mass Spectrometry  
Incubations and disappearance studies were carried out in triplicate using 0.1 µM 
pazopanib, 1 mM NADPH, and 100 µg of protein, or, 100 pM of human recombinant 
P450, made up to a final volume of 700 µl with buffer (50 mM HEPES 30 mM MgCl2 
pH 7.4). Boiled protein was used as a control and samples were shaken at 35°C for 
the duration of the experiment. Substrate disappearance studies were performed 
by removing 100 µl of the master incubation mixture at 0, 2, 5, 10, 30 and 60 
minutes, and transferring the sample into 500 µl of HPLC grade diethyl ether and 
internal standard solution (60 µl; 6 ng of testosterone). Samples were shaken at 
35°C for 20 min and tubes were centrifuged at 23755 xg. The resultant upper layer 
was removed, spin dried, and resuspended in methanol (80 µl) and water (40 µl) for 
analysis by liquid chromatography tandem mass spectrometry (LC/MS-MS) (Section 
2.9).  
2.7 Midazolam and Pazopanib Incubations in a Panel of Human Liver 
Microsomes 
To validate the accuracy of predictions made using the panel of microsomes, 
incubations were carried out using midazolam; a known substrate for CYP3A4. 
Incubations were performed by preparing 1 master tube for each of the 14 liver 
samples containing 315 µl of Hepes/MgCl2 buffer containing 50 µM midazolam and 
70 µg of protein. Tubes were mixed, and 90 µl of each was added to three reaction 
tubes, which were warmed to 37°C prior to the addition of 10 µl of 10 mM NADPH 
to each. Reaction tubes were incubated at 37°C for 10 minutes before the reaction 
was terminated by the addition of 100 µl of acetonitrile containing 1.4 µM 
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phenacetin as an internal standard. These were extracted using DEE as described 
above, and analysed by LC/MS-MS. The rate of production of 1-OH and 4-OH 
midazolam was calculated using a standard curve for both metabolites and plotted 
in correlation with the activity of each P450. Details of the individual human liver 
microsome samples are included in the Appendix.  
Pazopanib incubations were carried out in the same way as described for 
midazolam, using 14 µM pazopanib, and 350 nM testosterone as an internal 
standard. The peak area of hydroxylated metabolite, as detected by LC-MS/MS was 
plotted in correlation with the activity of each P450. 
2.8 Identification of Pazopanib Metabolite 
Incubations were performed to identify potential pazopanib metabolites in vitro. 
Human recombinant CYP3A4 (100 pmol) was incubated with 100 µM of pazopanib, 
10 mM NADPH or, the equivalent volume of water for control samples, and made 
up to 700 µl with HEPES/MgCl buffer. Tubes were incubated at 37°C under agitation 
for 1 h, and extracted in the same way as described for microsomal incubations. 
Test and control samples were analysed by scanning LC/MS-MS to identify peak 
changes between control and test samples. A peak present in test samples only 
showed a peak representing a mass of 454.14 (Figure 2.2), which in comparison to 
pazopanib at 438.15, is consistent with the expected mass of a hydroxylated 
metabolite.   
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Figure 2.2 Mass spectrometer trace showing pazopanib peaks (438.15) and hydroxyl-
pazopanib peak (454.14). 
 
2.9 Mass Spectrometry Conditions for Pazopanib and Midazolam 
Detection 
Parent compound and microsomal product formation from pazopanib and 
midazolam were analysed by LC/MS-MS (Waters 2795 HPLC and Quattro Micro 
mass spectrometry system). The voltage and collision energy were optimised for 
each drug and product. A dwell time of 0.5s was used between multiple reaction 
monitoring (MRM) transitions.  
4-Hydroxy midazolam, 1’-hydroxy midazolam and the internal standard (IS) 
phenacetin were resolved in 5 min on a Luna C18 (2) (5 µ, 100 Å, 50 x 2.00 mm) 
column (Phenomenex, Torrance, CA). The injection volume was 10 µl. The 
following elution program was used at a temperature of 30°C and a flow rate of 
0.5 ml/min: Eluent A- 0.1 % formic acid; Eluent B- Acetonitrile; (i) a linear gradient 
Pazopanib: 438.15 
 
Metabolite: 454.14 
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from 3 % to 50 % was run in 3 min, (ii) mobile phase was held at 50 % B for 30 sec, 
(iii) linear gradient was run to 60 % B in 30 sec, (iv) solvent composition was 
returned to 3 % B for equilibration.  
Pazopanib, OH-pazopanib and internal standard testosterone, were resolved on a 
Kinetex C18 (2.6 µ, 100 Å, 50 x 2.1 mm) column (Phenomenex, Torrance, CA). The 
injection volume was 10 µl. The following elution program was used at a 
temperature of 30°C and a flow rate of 0.4 ml/min: Eluent A- 0.1 % formic acid; 
Eluent B- Methanol, 0.1 % formic acid; (i) a linear gradient from 63 % to 75 % B 
was run for 1.05 min, (ii) mobile phase was held at 75 % for 56 seconds, (iii) linear 
gradient was reduced to 63 % B for 40 sec, (iv) linear gradient was run from 63 % 
to 75 % B for 5 sec. Mass spectrometer settings are summarised in Table 2.1.  
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Drug Ion 
Mode 
MRM 
Transitions 
Cone 
Voltage 
(V) 
Collision 
Energy 
(kV) 
Pazopanib  +ve 438.1 > 357.19 50 29 
OH-Pazopanib +ve 454.14 > 
436.08 
48 29 
4-Hydroxy 
midazolam 
+ve 342.4 > 234.3 30 23 
1-Hydroxy 
midazolam 
+ve 234.4 > 324.3 30 22 
Testosterone (IS) +ve 289 > 97.07 31 25 
Phenacetin (IS) +ve 180.3 > 110.3 30 30 
 
Table 2.1. Table summarising settings for parent drugs, metabolites and internal 
standards analysed by LC/MS-MS.  
2.10 Enzyme Induction for Pharmacokinetic Studies and Tissue 
Harvesting  
As described in section 2.2.5, transgenic mice were induced with appropriate 
agents prior to the commencement of pharmacokinetic and toxicological 
experiments.  
Following dosing, mice were starved for 2h, and 10 µl of blood was collected from 
each mouse via a venepuncture made in the tail vein. Samples were transferred 
to Eppendorf tubes containing heparin (10 µl, 15 IU/ml). Samples were taken at 
10, 30, 40, 60, 120, 240, 360, 480, 1440 and 1800 min post-dosing. Following the 
final time point, mice were killed by a rising concentration of CO2, livers and small 
intestines were harvested; tissues were snap-frozen in liquid nitrogen and stored 
at -80°C for subsequent preparation of sub-cellular fractions, and/or fixed 
51 
 
 
overnight in Gurr formalin fixative (VWR Prolabo) followed by transfer to 80 % 
ethanol before processing to wax and sectioning for staining (Section 2.13). Blood 
was collected by cardiac puncture into heparinised tubes, spun for serum and 
stored at -80°C for subsequent clinical chemistry analysis (Section 2.11).   
 
2.11 Biochemical Analysis of Serum 
Serum was obtained from terminal blood samples by centrifugation at 23,755 xg 
for 10 min. The serum was removed to a clean Eppendorf tube and stored at -80°C. 
Serum samples were sent on dry ice to the Clinical Pathology Service Laboratory 
at the Mary Lyon Centre (Harwell, Oxfordshire) for biochemical analysis. Serum 
was tested for creatinine, glucose, total bilirubin, lactate dehydrogenase (LDH) and 
alanine transaminase (ALT). 
 
2.12 Drug Extraction from Heparinised Blood Samples 
Internal standard solution (60 µl; 6 ng of testosterone) was added to each tube. 
Pazopanib precipitation was carried out by adding diethyl ether (500 µl). Samples 
were shaken at 30°C for 20 min and spun at 23,755 xg for 10 min. The supernatant 
was transferred to a fresh tube and spin dried at 30°C for 20 min. Precipitate was 
resuspended in methanol (80 µl) and water (40 µl) and analyzed by liquid 
chromatography mass spectrometry as described in Section 2.9. 
For the purposes of quantification of drug in the blood samples, standard curves 
were constructed by spiking blank blood samples with known concentrations of 
pazopanib. Extractions of standard curve samples were carried out in the same 
way as the samples from the pharmacokinetic protocols.  
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2. 13 Histology 
After overnight fixing in Gurr Histological Fixative (Prolab), tissue samples were 
processed overnight in a Shandon Citadel 1000 (Thermo Scientific) before being 
embedded into wax blocks using a Shandon Histocentre 3 embedding centre 
(Thermo Scientific). Tissues were sectioned (10 µM) from wax blocks using a 
Shandon Finess 325 microtome (Thermo), and stained with Haematoxylin and 
Eosin as follows: 
Sections were deparaffinised and stained by the following method: 
 100% Xylene (Sigma) 5 min 
 100% Xylene 5 min 
 100% EtOH 2 min 
 100% EtOH 2 min 
 95% EtOH 2 min 
 95% EtOH 2 min 
 75% EtOH 2 min 
 50% EtOH 2 min 
 ddH2O 2 min 
 Haematoxylin (Sigma) 5 min 
 Running tap water 10 min 
 80% EtOH 2 min 
 Eosin (Sigma) 10-20 sec 
 95% EtOH 2 min 
 95% EtOH 2 min 
 100% EtOH 2 min 
 100% EtOH 2 min 
 100% Xylene 2 min 
 100% Xylene 2 min 
 
Samples were allowed to dry for 5-10 minutes before mounting coverslips with 
DPX (Sigma). Slides were viewed under high power 2-3 days later using an Axio 
Scope A1 microscope (Zeiss). Magnifications are indicated in each figure.  Snap 
frozen tissue was sectioned (5 µm) using an otf 5000 cryostat (Bright Instruments, 
Cambridgeshire, UK). Tissue processing, embedding and sectioning was carried 
53 
 
 
out by Cheryl Wood (Molecular Pharmacology Group, Medical Research Institute, 
Ninewells Hospital and Medical School).  
 
2.14 Periodic Acid Schiff Staining 
A Periodic Acid Schiff (PAS) staining kit was purchased from Sigma and carried 
out according to the manufacturers instructions. 
 
2.15 Oil Red O Staining 
Oil Red O staining was carried out on snap-frozen tissue sections courtesy of Dr 
Shaun Walsh of the Pathology department, Ninewells Hospital and Medical 
School.  
 
2.16 In Vivo Tumour Growth Studies 
Wild-type and humanised 3A4/3A7/hCAR/hPXR animals were divided into groups 
and induced with Aroclor 1254 or corn oil as control animals. CMT 93 and B16 cells 
were cultured as described in section 2.3. When cells reached approximately 70 % 
confluency, cells were harvested and resuspended in PBS at a concentration of 
6x106 cells/ml. Mice were anaesthetised using isoflurane and anaesthesia was 
maintained during injection of the cells using a face mask. 150 µl of the cell 
suspension was injected subcutaneously (s.c.) into the left and right flank of each 
mouse. Mice were monitored daily until the development of palpable tumours, at 
which stage, animals were administered with either 100 mg/kg pazopanib (p.o) or 
the equivalent volume of vehicle (cremaphore 8 %, ethanol 15 %, water), and the 
dosing regimen was continued daily until tumours reached a maximum geometric 
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mean diameter (GMD (√𝑙𝑥𝑏𝑥ℎ
3
)) of 12.5 mm, tumours became ulcerated, or mice 
showed signs of morbidity or diminished movement. Tumours were measured 
daily for the duration of the tumour growth protocol. Once the tumours reached 
the maximum acceptable tumour GMD, tumours were excised from both flanks, 
and livers were harvested. All excised tissues were halved for snap-freezing or 
fixing.   
 
2.17 Generation of Recombinant Enzymes 
Human recombinant enzymes were generated in E.coli as follows: 
Commercially available competent E.coli (Promega) were thawed on ice. Plasmid 
DNA (300 ng) containing the gene of interest was added to competent bacteria 
(100 µl) and chilled on ice for 10 min. The cells were placed in a water bath at 42°C 
for 90 sec and then chilled on ice for a further 20 min. The cells were plated on 
agar plates containing 50 µg/ml ampicillin and incubated overnight at 37°C.  
The following day, colonies were scraped from the agar plate and placed into liquid 
broth (LB) medium (150 ml) containing antibiotic. The culture was incubated in a 
2L flask under agitation at 30°C overnight. The following day the culture was 
divided into flasks containing of Terrific Broth (200 ml, Sigma) and 50 µg of 
appropriate antibiotic. The cultures were left to grow at 30°C under agitation. 
Samples were tested periodically throughout the day using an Ultrospec 2100 pro, 
(Amersham Biosciences) using unmodified Terrific Broth as a blank sample, until 
an optical density of 1 was reached at 600 nM. Once this was achieved, protein 
expression was induced by the addition of 1 mM aminolevulinic acid (ALA) and 1 
mM Isopropyl β-D-1 thiogalactopyranoside (IPTG) overnight.  
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2.17.1 Harvest Culture and Generation of Spheroplasts 
Cultures were transferred into 1 litre centrifuge bottles and centrifuged at 2800 
xg at 4°C for 20 min in a Sorvall RC 3C Plus centrifuge and the supernatant was 
discarded. Pellets were resuspended in 50 ml of 2x TSE (100 mM Tris-acetate pH 
7.6, 500 mM sucrose, 0.5 mM EDTA) and 50 ml of ddH20, using a 10 ml pipette to 
aid homogenisation. All resuspended pellets were pooled and 0.26 mg/ml 
Lysozyme (Sigma) was added, and samples were rocked at 4°C for 1 hour. Bottles 
were balanced and centrifuged as previously described. The supernatant was 
discarded and the pellet resuspended in a total volume of 100 ml of spheroplast 
re-suspension buffer (100 mM Potassium phosphate pH7.6, 6 mM magnesium 
acetate, 20 % (v/v) glycerol) and stored in aliquots of 25 ml at -70°C until further 
processing.  
Frozen aliquots were thawed in lukewarm water and 100mM (2 ml) PMSF was 
added to each tube, along with one complete cocktail protease inhibitor tablet 
(Roche) dissolved in 1 ml of H2O. Samples were sonicated for 4 rounds of 4x10 
second bursts with placement on ice for 10 sec in between. The sonicated samples 
were decanted into 250 ml plastic centrifuge bottles and spun at 12,000 xg for 20 
min at 4°C and the supernatant was retained. Supernatant was decanted into 
ultracentrifuge tubes and balanced. Samples were spun at 180,000 xg for 1 h and 
the resultant supernatant was discarded. The pellet was resuspended in 1x TSE 
buffer (50 mM Tris-acetate pH 7.6, 250 mM sucrose, 0.25 mM EDTA) and hand 
homogenised using a Dounce homogeniser (Wheaton, USA). Aliquots were stored 
at -80°C.  
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2.17.2 Cytochrome P450 Quantification 
CYP content in bacterial cells and membranes was assayed as described by Omura 
and Sato (Omura and Sato 1964) using a Varian Cary 4000 spectrophotometer. 2x 
P450 Spectrum Buffer (1 ml; 200 mM Tris-HCL pH7.4, 20 mM CHAPS, 40 % (v/v) 
glycerol, 2 mM EDTA) was added to 10 µl of microsomal sample and diluted with 
1 ml of dH20. The sample was reduced by the addition of a few grains of sodium 
hydrosulfite (dithionite), and the sample divided between a reference and a 
sample cuvette. Samples were measured in a Spectrophotometer at wavelength 
between 400 and 500 nM, with scale set at -0.02- 0.02 to acquire a baseline 
measurement. The sample cuvette was removed and bubbled with carbon 
monoxide for 40 sec, and the sample was rescanned. A peak was seen at 420 nm 
and 450 nm and the P450 concentration was measured using the following 
equations: 
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𝑥
0.091
= 𝑛𝑚𝑜𝑙 𝑝450 𝑖𝑛 1 𝑐𝑢𝑣𝑒𝑡𝑡𝑒 
 
𝑛𝑚𝑜𝑙 𝑝450 𝑝𝑒𝑟 𝜇𝑙 =
𝑛𝑚𝑜𝑙 𝑖𝑛 𝑐𝑢𝑣𝑒𝑡𝑡𝑒
0.5 × 𝑣𝑜𝑙𝑢𝑚𝑒 𝑚𝑖𝑐𝑠 𝑖𝑛 𝑎𝑠𝑠𝑎𝑦 
 × 1000 = 𝑝𝑚𝑜𝑙/𝜇𝑙 
 
Where ‘𝑥′denotes the amplitude of P450, and 0.091 is the extinction coefficient 
for P450. 
 
A typical reduced carbon monoixide spectrum can be seen in Figure 2.3.   
a)                                                                                     b) 
                                  
 
 Figure 2.3.Cytochrome P450 Spectrum Traces 
Representative traces obtained from a) whole bacterial cell preparations 
expressing human CYP3A4. b) processed bacterial membranes expressing human 
CYP3A4 where ‘X’ denotes the amplitude of P450.  
 
X 
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Final P450 concentrations of recombinant enzymes derived from E. Coli are detailed 
in Table 2.2.  
 
Enzyme  P450 Concentration 
(pmol/µl) 
Enzyme  P450 Concentration 
(pmol/µl) 
CYP 1A1 7.2 pmol/µl CYP 2C19 8.2 pmol/µl  
* CYP 1B1 3.1 pmol/µl CYP 2C9 14 pmol/µl 
CYP 1A2 20.3 pmol/µl CYP 2D6 19.7 pmol/µl 
CYP 2A6 3 pmol/µl  CYP 2E1 10.4 pmol/µl 
* CYP 2B6 7.6 pmol/µl * CYP 3A4 18.2 pmol/µl 
CYP 2C8 22.5 pmol/µl Cyp 3a11 (murine) 37 pmol/µl 
  
Table 2.2. P450 concentrations of recombinant enzymes expressed in E.coli. Starred items 
were generated from constructs kindly donated by Lesley McLaughlin (Molecular 
Pharmacology Group, Medical Research Institute, Ninewells Hospital and Medical School). All 
other items were taken from stocks previously generated by Lesley McLaughlin.  
 
2.18 In Vitro PXR Assay 
A 96-well format human PXR nuclear receptor activation assay kit was purchased 
from Puracyp (Carlsbad, CA). This assay system utilizes DPX2™ human hepatoma 
cells. These cells harbor the human PXR gene, as well as a luciferase reporter gene 
linked to two promoters of human CYP3A4. The assay was carried out in 
accordance to the manufacturer’s instructions by Dr A. K. McLeod (Molecular 
Pharmacology Group, Medical Research Institute, Ninewells Hospital and Medical 
School).   
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2.19 Western Blotting 
2.19.1 Sodium Dodecyl Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate polyacrylamide Gel electrophoresis allows proteins to be 
separated according to their molecular mass. Protein ladders containing proteins 
of known sizes were run adjacent to test samples so that the molecular weights of 
proteins of interest could be identified. Protein samples (10 μg) were separated by 
SDS-PAGE using BioRad Protean equipment. 
 
2.19.2 SDS-PAGE Gels 
SDS-PAGE gels were poured to make a 10 % running gel and 4 % stacking gel, as 
detailed in Table 2.4. Electrophoresis was carried out using a Tris/Glycine/SDS 
running buffer (Table 2.5) at a constant voltage of 100 V for 1 h.                                                                                                                                                                                     
 
2.19.3 Transfer of Proteins to Nitrocellulose Membrane 
Following electrophoresis through the gel, the proteins were transferred 
electrophoretically to Protran® nitrocellulose membrane (Whatman®, Dassel, 
Germany). Sandwiched gels were then placed into a cassette holder and placed into 
a transfer tank containing ice cold transfer buffer (Table 2.5) and an ice block. 
Proteins were transferred at 100 V at room temperature for 90 mins.  
Upon completion of the transfer stage, membranes were stained with Ponceau S (0.1 
% w/v, 5 % acetic acid; Sigma) to verify equal protein loading. A typical Ponceau S 
stained membrane is shown in Figure 2.4. Ponceau S is a sodium salt of a diazo 
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dye that is designed for rapid (5 min) staining of protein bands on nitrocellulose or 
polyvinylidene difluoride (PVDF) membranes, both of which may be used for Western 
blotting. Ponceau S staining on nitrocellulose and PVDF is reversible by washing the 
stained membrane with Tris-buffered saline (Table 2.5). Proteins bound to the 
stained and destained membrane can then be immunologically detected using 
appropriate antibodies.  
 
2.19.4 Immunoblotting 
In order to minimize non-specific binding of antibody to the nitrocellulose 
membrane, the membranes were blocked using a 10 % w/v solution of non-fat milk 
powder (Marvel ™) in TBS-T for 1h at room temperature with gentle agitation. 
Membranes were subsequently washed in TBS-T before being incubated in the 
relevant primary antibody overnight at 4°C on a Stuart roller mixer (Fisher Scientific, 
UK) to allow antibody binding. The following morning, the membranes were washed 
3 times for 5 minutes each time. The relevant horseradish peroxidase-conjugated 
mouse or rabbit secondary antibody was then incubated with the membrane at a 
dilution of 1:10000 in TBS-T, 5 % w/v Marvel™. A summary of antibodies can be found 
in Table 2.3.  
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Antibody Dilution        Supplier Raised in Reference/Cat. Number 
CH32 
(CYP3A/CYP3a) 
1:1000 In House Rabbit (Forrester, Henderson 
et al. 1992)  
CYP1A1 1:10,000 In House Mouse 
CYP2B 1:2000 In House Rabbit 
CYP2C9 1:2000 In House Rabbit 
POR 1:2000 In House Rabbit (Smith, Tew et al. 1994) 
CYP2D6 1:1000 Sigma 
Aldrich 
Rabbit Cat. Num. AV41675 
 
Table 2.3. Summary of antibodies, their dilution, and supplier. 
 
2.19.5 Development 
The bound protein-antibody complex was detected using the Immobilon Western 
enhanced chemiluminescence (ECL) system (Millipore). This is based on a 
horseradish peroxidase (HRP) chemiluminescent reaction whereby luminol reagent 
is oxidized by peroxidase. The oxidized luminol emits visible light as it decays to a 
basal state. Freshly made ECL solution (1 ml, as per manufacturer’s instructions) was 
applied to each membrane for 40 sec prior to developing. The membranes were 
then visualized using a LAS-3000 luminescent image analyzer (Fujifilm). 
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Ingredient 10% Resolution Gel (10ml) Stacking Gel (4ml) 
H2O 5.3 ml 2.7 ml 
30% acryl-bisacrylamide mix 2 ml 0.67 ml 
1.5M Tris (pH8.8) 2.5 ml 0.5 ml (pH 6.8) 
10% SDS 0.1 ml 0.04 ml 
10% ammonium persulfate 0.1 ml 0.04 ml 
TEMED 0.008 ml 0.004 ml 
Table 2.4. Recipes for 10 % resolution gel (10 ml) and stacking gel (4 ml) sufficient for 
two blots. 
 
Buffer Composition (10X Concentrated Stock) 
Electrophoresis Buffer 520 mM Tris Base, 533 mM Glycine, 
34.7 mM SDS 
Transfer Buffer 250 mM Tris Base, 1.87 M Glycine 
TBS 1.5 M NaCl, 500 mM Tris Base (p.H to 
7.9) 
Table 2.5. Recipes for buffers and solutions for Western blotting. 
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Figure 2.4. Typical Ponceau S - stained membrane. 
Following transfer of proteins to nitrocellulose membranes, membranes were stained in 
Ponceau S (5 min), then rinsed in distilled H2O. Proteins stained red, and even loading could 
be confirmed. 
. 
 
 
 
Chapter 3 
Enzyme Kinetics and Microsomal Stability
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3.1. Enzyme Kinetics 
 
Predictions of the pharmacokinetics of drugs in man, volume of distribution and 
clearance, are often extrapolated from animal data and traditionally were based on 
body weight or surface area. This technique is known as ‘allometric scaling’. 
Allometric scaling is a mathematical, empirical approach for inferring physiological 
data from one species to another, using factors such as organ, or body weight to 
‘scale’ values (Obach, Baxter et al. 1997).  
A general function for the scaling of pharmacokinetic parameters can be written as 
shown below: 
𝑌 = 𝑎𝑊𝑏 
Where Y is the parameter in question, W is the body or organ weight, and a and b are 
the coefficient and exponent of the allometric equation respectively. This may be log 
transformed and expressed as shown below: 
log 𝑌 = log 𝑎 + 𝑏 log𝑊 
 
Where log a is the y-intercept, and b is the slope.  
These are the basic principles of allometric scaling and such a method is not always 
applicable for all drugs. Many studies have utilised modified versions of these 
principles to attempt to normalise and correct for a particular experimental set up, 
however there is no real consensus within the scientific community on these 
equations (Mahmood 1999). While allometric scaling and dose selection based on 
body weight have proven popular methods to carry out dose extrapolations, it does 
not allow for the consideration of species differences in biological metabolic 
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pathways, oxygen consumption, basal metabolic rates and other physiological 
parameters. 
Understanding of in vitro enzyme kinetics and drug metabolism, is of fundamental 
importance if the drug in question is to be accurately adapted to the in vivo situation. 
Understanding the time-course, or kinetics, of an enzymatic reaction facilitates 
understanding of the underlying metabolic mechanism taking place. In order to 
evaluate enzyme kinetics, it is necessary to fit the enzymatic data to mathematical 
models which describe the hypothesized mechanisms. The solutions of these 
equations, based upon the “goodness of fit” of the data, allow the hypotheses to be 
accepted or excluded (Marangoni 2002). The equations used to fit enzymatic kinetics 
depend on the nature of the enzyme in question.  
 
3.1.1 Michaelis-Menten Kinetics 
 
For the majority of enzymes, the rate of catalysis, defined as the number of moles of 
product formed per second, rises with substrate concentration until a saturation 
point is reached.  In 1913, Leonor Michaelis and Maud Menten proposed a basic 
model to account for these kinetic characteristics. The important feature of this 
model is that a specific enzyme-substrate (ES) complex is a necessary intermediate in 
catalysis. The model proposed, which is the simplest one that accounts for the kinetic 
properties of many enzymes, is: 
 
𝐸 + 𝑆   
𝐾1
↔     𝐸𝑆 
𝑘2
→    𝐸 + 𝑃 
 
In which the enzyme ‘E’, reacts with its substrate ‘S’ at a rate constant of k1 to form 
an enzyme-substrate complex ‘ES’. From here, the ES complex undergoes a reaction 
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and dissociates into enzyme and product ‘P’, at a rate constant of k2. When reactions 
which obey Michaelis-Menten kinetics are plotted, traces such as described in Figure 
3.1 are produced.  
 
 
 
Figure 3.1 Michaelis- Menten Enzyme Kinetics 
The reaction velocity (V0) is a function of the substrate concentration (S). Vmax is the 
maximum rate of reaction for an enzyme, and it occurs when all active sites of the 
enzyme are occupied with substrate. At this point, the enzyme is considered to be 
saturated. The Michaelis-Menten constant for the reaction refers to the substrate 
concentration required to achieve Vmax /2  (Berg 2002).  
 
3.1.2. Allosteric Enzyme Kinetics 
 
The Michaelis-Menten model for enzyme kinetics is suitable for most enzymes in the 
presence of a single substrate. However, enzymes which are subject to allosteric 
modulation require a model which can accommodate their more complex kinetics. 
Allosterism refers to the modulation of an enzymes catalytic activity by a second 
substrate which binds to a different active site than the isosteric site, iso meaning 
‘same’, and ‘allo’ meaning ‘other’. Enzymes may possess more than one allosteric 
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site, with different ligand specificities. Allosteric modulation may be agonistic or 
antagonistic in nature. An agonistic allosteric modulator will elicit an enhancement in 
the catalytic activity of an enzyme by causing a conformational change in the active 
sites of the enzyme to enhance affinity for the substrate. An antagonistic modulator 
has the inverse effect, and reduces the rate of catalysis of the enzyme (Debajyoti 
1978).  
 
3.1.3 Hill Equation  
One such model which may be used in describing allosteric enzyme activity is the Hill 
equation. The Hill equation was first defined in 1913 by A. V. Hill to describe the 
binding of oxygen to haemoglobin (Hill 1913). The Hill equation, similarly to 
Michaelis-Menten, provides a measure of the affinity of the ligand to its receptor or 
enzyme, while additionally offering a measure of co-operativity of allosteric binding 
(Weiss 1997). The measure of co-operativity is indicated by the Hill coefficient. The 
equation may be represented by the following: 
 
v =
𝑉𝑚 𝑆
ℎ
𝐾𝑑+𝑆ℎ
 
 
Where Kd is the dissociation constant, h is the Hill coefficient and Vm is the maximal 
velocity. The nature of the binding is described by the Hill coefficient. A Hill coefficient 
is greater than 1 describes positive cooperative binding, while a value less than 1 
describes negative cooperative binding. A value equal to 1 denotes non-cooperative 
binding (Sauro 2011). 
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3.1.4 Metabolism of Pazopanib 
In vitro studies suggest that oxidative metabolism of pazopanib in human liver 
microsomes is mediated primarily by CYP3A4 with minor contributions by CYP1A2 
and CYP2C8. Consequently, co-administration of strong inhibitors of CYP3A4, such as 
ketoconazole is contraindicated in patients being treated with pazopanib (Vasudev 
and Larkin 2011). Four metabolites of pazopanib have been described, although not 
as yet in detail. However, pazopanib is considered to be pharmacologically active in 
its parent form, with only a very minor contribution from one of its metabolites 
(European Medicines Agency). CYP3A4 is the most abundant P450 enzyme in the 
liver, constituting approximately 30 % of total P450 present, and is involved in the 
metabolism of up to 50 % of all clinical drugs (Bozina, Bradamante et al. 2009). 
CYP3A4 exhibits broad substrate specificity and is highly polymorphic amongst the 
human population. This has important implications when considering drug 
metabolising capacities and dosing regimens for individual patients. As yet, no data 
are available pertaining to CYP3A4 expression and the rate of metabolism of 
pazopanib.  
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3.2. Results 
 
3.2.1 Microsomal Stability of Pazopanib In Vitro 
To broadly assess the rate of pazopanib metabolism in vitro, microsomal fractions 
from wild-type (C57 BL/6) mouse liver, and human liver (Invitrogen) were incubated 
with pazopanib (0.1 µM) and NADPH (10 µM) in a final volume of 700 µl with 
HEPES/MgCl2 buffer. Alternatively, human recombinant CYP3A4 was used (100 
pmols) in place of the microsomal sample. Samples were kept on a shaker at 37°C 
and 100 µl of the reaction mixture was removed into 100 µl of methanol at time 
points of 0, 2, 5, 10, 30 and 60 min. Samples were extracted using DEE as described 
in the Methods section.  The percentage disappearance of pazopanib over 60 min in 
mouse and human microsomes does not differ significantly (12.7 % and 23.6 % 
respectively), however, incubations containing human recombinant CYP3A4 shows a 
89 % disappearance (Figure 3.2.1) which is consistent with the literature showing 
human CYP3A4 is the major enzyme implicated in pazopanib clearance (Vasudev and 
Larkin 2011).  
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a) 
 
b) 
 
c 
 
Figure 3.2.1 Pazopanib Metabolism in Mouse microsomes, Human microsomes 
and Recombinant CYP3A4 
Time-courses showing disappearance of pazopanib (0.1 µM) in a) pooled wild-type mouse, 
or b) human liver microsomes (100 µg) over 60 min, compared to boiled protein control, c) 
time-course showing pazopanib disappearance in incubation with human recombinant 
CYP3A4 (100 pM). n=3 extractions per master incubation. Red squares denote boiled protein 
controls, blue diamonds denote live protein. Values expressed ± standard deviation (SD).  
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3.2.2 Optimisation of Protein Concentration in Enzyme Incubations 
Modelling of enzyme kinetics is a more definitive method of predicting the extent of 
drug metabolism in vivo. To determine optimum incubation conditions to allow 
accurate comparisons between the kinetics of mouse and human microsomes to be 
drawn, protein concentration experiments were initially performed. Here, 
incubations were set up in triplicate, containing 0.1 µM pazopanib with 15 µg, 30 µg 
or 40 µg of mouse, or human liver microsomes. Samples were taken from incubation 
tubes at 0, 5, 10, 20, 30 and 40 min, to be extracted and analysed by LC-MS/MS. 
Figure 3.3 depicts graphed data from the time courses using human liver microsomes. 
The coefficient of determination (R2) values are included as an indication of the 
correlation between OH-pazopanib formation and time in each data set. In 
accordance with Pearson’s correlation, as the R2 value approached 1, the correlation 
between metabolite formation and P450 activity was increasingly linear and positive. 
Conversely, as the R2 value approached -1 the correlation is considered increasingly 
linear and negative.  Figure 3.3 shows the time course containing 15 µg of microsomal 
protein and demonstrates the highest R2 value of 0.92, indicating the strongest 
correlation of the three protein quantities. As the protein concentration in the 
incubations increases, the R2 value approaches ‘0’ indicating a decrease in the linear 
correlation between metabolite formation and time. As these conditions were to be 
used to calculate the kinetic parameters of pazopanib metabolism, the conditions 
yielding the highest R2 value were adopted for subsequent experimental use.  
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Identical incubations were performed using mouse liver microsomes, the results of 
which are presented in Figure 3.4 Similarly to the human liver microsomes, the 
correlation between metabolite production and time was highest at the lowest 
protein concentration (15 µg). Interestingly, despite having the highest R2 value of all 
of the mouse protein incubations, it is still poorly correlated when compared with the 
15 µg incubations using human microsomal protein (0.79 vs. 0.92 respectively). This 
would suggest that, in general, pazopanib is better metabolised by human liver 
microsomes than by mouse liver microsomes, as evidenced in Figure 3.5, 3.6 and 3.7.  
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a) 
 
b) 
    
c) 
 
 
Figure 3.3. Correlation of OH-pazopanib formation with protein concentration 
Graphs showing linear correlation between the formation of OH-pazopanib in pooled 
human liver microsome incubations over 40 min with a) 15 µg, b) 30 µg, c) 40 µg of protein. 
R2 values were calculated in Microsoft Excel as a representation of the linearity of the data 
points. n=3 incubations per protein concentration. Values expressed ± SD. 
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a) 
 
b)  
 
c) 
 
 
Figure 3.4 Correlation of OH-pazopanib formation with protein concentration 
Graphs showing linear correlation between the formation of OH-pazopanib in mouse liver 
microsome incubations over 40 min with a) 15 µg, b) 30 µg and c) 40 µg of protein. R2 values 
were calculated in Microsoft Excel as a representation of the linearity of the data points; 
n=3 incubations per protein concentration. Values expressed ± SD. 
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3.2.3. Optimisation of Duration of Enzyme Incubations 
 
Similarly to the protein optimisation method, the optimal duration of incubations was 
determined by plotting OH-pazopanib formation against protein concentration at 
each of the five time points. As with the protein concentration optimisation, the time 
point displaying the strongest correlation between metabolite formation and protein 
concentration would be adopted for use. Data from incubations with human liver 
microsomes or mouse liver microsomes are shown in Figure 3.5 and 3.6 respectively, 
graphed separately to show correlations at 5, 10, 20, 30 and 40 min. The strongest 
correlation between metabolite formation and time in both human and mouse 
microsome preparations was observed at 20 min (0.99 vs 0.96 respectively). 
 
3.2.4 Enzyme Kinetics 
 
In order to establish Vmax and Km values for human and mouse liver microsomes, 
incubations were set up in triplicate, containing 20 µg of human or mouse liver 
microsomes over a range of pazopanib concentrations between 0.5 and 40 µM. 
Incubations were terminated by the addition of 100 µl of methanol and extracted as 
described in the Methods. Data were plotted and analysed in GraFit 5 (Erithacus 
Software), using the Hill allosteric enzyme model (Figure 3.7).  The Vmax value 
calculated from human microsome incubations was found to be approximately 3.5x 
higher than the mouse incubations (1805 vs 512 peak area/min/mg respectively), 
suggesting that the maximum rate of pazopanib metabolism is much higher in 
humans than in the mouse. The Km value of 8.9 µM in human microsomes compared 
to 5.2 µM in the mouse microsomes is not dissimilar, suggesting that pazopanib has 
a similar affinity for both human and mouse microsomes. 
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a)                                                                                b) 
      
c)                                                                             d) 
       
      e) 
 
 
Figure 3.5 Correlation of OH-pazopanib with protein concentration at various 
time points 
Graphs showing linear correlation between the formation of OH-pazopanib in pooled 
human liver microsome incubations at a) 5 min, b) 10 min, c) 20 min , d) 30 min, e) 40 min. 
R2  values were calculated in Microsoft Excel as a representation of the linearity of the data 
points; n=3 incubations per time point.  Values expressed ± SD. 
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a)                                                                               b) 
  
c)                                                                                 d) 
       
                                          e)                      
 
 
 
Figure 3.6 Correlation of OH-pazopanib with protein concentration at various 
time points 
Graphs showing linear correlation between the formation of OH-pazopanib in pooled 
mouse liver microsome incubations at a) 5 min, b) 10 min, c) 20 min, d) 30 min, e) 40 min. 
R2  values were calculated in Microsoft Excel as a representation of the linearity of the data 
points; n=3 incubations per time point. Values expressed ± SD. 
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a)                                                                                         b) 
                             
 
Figure 3.7. Enzyme kinetics for pazopanib metabolism differs in human and 
mouse liver microsomes. 
Various concentrations of pazopanib were incubated with a) commercially available pooled 
human liver microsomes (20 µg) or b) wild-type mouse liver microsomes (20 µg) for 20 min. 
Incubations were carried out in triplicate. Samples were extracted and analysed by MS-MS 
to measure peak area of OH-pazopanib metabolite. Data was analysed using GraFit 5. 
Values expressed ± SD. 
  
 
From the Vmax and Km values, the intrinsic clearance (CLint) of drug may be calculated 
as follows:  
 
𝐼𝑛𝑡𝑟𝑖𝑛𝑠𝑖𝑐 𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =
𝑉𝑚𝑎𝑥
𝐾𝑚
 
(Kumar, Samuel et al. 2002) 
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From the Vmax and Km values show in Figure 3.7 the intrinsic clearance based upon 
the equation above in human and mouse microsomes is 202.6 µmols/min/mg and 
96.9 µmols/min/mg respectively.  
3.2.5 Human Liver Microsome Panel Validation 
 
A panel of 14 human liver microsomes from individual donors were purchased from 
BD Gentest (Woburn, MA) in order to carry out correlation studies between P450 
enzyme activity, and pazopanib metabolism (see Appendix 1 for details of individual 
human microsome samples). The level of detection of OH-pazopanib metabolite 
was used as an indication of metabolic turn over. Initially, the panel of microsomes 
were validated using, midazolam, a known and established CYP3A4 substrate 
(Wandel, Bocker et al. 1994). Midazolam is metabolised almost exclusively by 
CYP3A4 (Kronbach, Mathys et al. 1989) and two major hydroxylated metabolites are 
produced; 1-OH midazolam, and 4-OH midazolam. The production of these 
metabolites was plotted against the activity of each of the cytochrome P450 
enzymes in each liver sample. Microsomes (20 µg) were incubated with midazolam 
(50 µM) for 10 min (Figure 3.8), and correlations are listed in Table 3.1. In keeping 
with the literature, CYP3A4 showed the highest correlation with both 1-OH and 4-
OH metabolite production (0.92, 0.97 respectively). Correlations were also seen 
with other cytochrome P450 enzymes including CYP2A6 (1-OH; 0.91, 4-OH; 0.92), 
CYP2C8 (1-OH; 0.83, 4-OH; 0.75) and CYP2B6 (1-OH; 0.65, 4-OH; 0.64), however, as 
these enzymes are not implicated in midazolam metabolism, this was considered to 
be a due to the activity of this particular panel of microsomes.  
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3.2.6 Pazopanib Metabolite Correlations in Human Liver Microsome Panel 
Having validated the panel of human liver microsomes using midazolam as a test 
substrate, it was accepted that the panel would be useful in identifying enzymes 
implicated in the metabolism of pazopanib. Similarly to midazolam, pazopanib (14 
µM) was incubated with individual liver microsome samples (20 µg) for 30 min. OH-
pazopanib formation was plotted again cytochrome P450 activities in Figure 3.9. 
Strongest correlation was noted with CYP3A4 (0.98), as was expected. As was the 
case in the midazolam incubations, correlations were also seen with a number of 
other cytochrome P450s, including CYP2A6 (0.84), and considerably weaker 
correlations with CYP2B6 (0.37) and CYP2C8 (0.27). These correlations are common 
in the midazolam experimental set, as well as the pazopanib set. Correlations are 
summarised in Table 3.2. 
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Figure 3.8. Correlation of 1-OH Midazolam and 4-OH Midazolam with P450 
enzyme activity  
Graphs showing linear correlation between the formation of 1-OH Midazolam and 4-OH 
Midazolam and CYP450 enzyme activity in a panel of human liver microsomes. Midazolam 
(50 µM) was incubated with individual human liver microsomes (20 µg), for 30 min in a total 
volume of 100 µl. Incubations were halted by the addition of acetonitrile (100 µl) and 
extracted. 1-OH midazolam and 4-OH-midazolam formation was measured by LC-MS/MS. 
R2 values were calculated in Microsoft Excel as a representation of the linearity of the data 
points; n=3 incubations per liver sample. Values expressed ± SD. 
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Table 3.1. Table of R2  values and correlation between 1-OH midazolam and 4-OH 
midazolam formation in relation to P450 activity.  
Enzyme contribution to metabolite formation ranked in descending order. R2 values and 
correlation were calculated in Microsoft Excel; n=3 incubations per liver sample.  
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3.2.7 Pazopanib Metabolism in a Panel of Human Recombinant P450s 
To verify that unexpected correlations between enzyme activity and pazopanib 
metabolism were a function of the microsome panel, and not necessarily 
applicable in vivo, pazopanib was incubated with a panel of recombinant human 
cytochrome P450s.  Recombinant human P450s were generated in E.coli as 
described in the Methods. Pazopanib (14 µM), was incubated with 100 pM of 
each recombinant enzyme, in triplicate. The results displayed in Figure 3.9.1. 
show that CYP3A4 is predominantly responsible for the metabolism of 
pazopanib with non-significant contributions from CYP1A1, CYP1A2 and 
CYP2C8. This is generally in keeping with the literature, which states that 
pazopanib is predominantly metabolised by CYP3A4, with minor contributions 
from CYP1A2 and CYP2C8. The predominant murine Cyp3a isoform, Cyp3a11, 
appears to metabolise pazopanib with a similar capacity to the lesser 
contributing human enzymes.  
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Figure 3.9. Graphs showing linear correlation between the formation of OH-
Pazopanib and enzyme activity in a panel of human liver microsomes  
Pazopanib (14 µM) was incubated with individual human liver microsomes (20 µg), for 20 
min in a total volume of 100 µl. Incubations were halted by the addition of methanol (100 
µl) and extracted. OH-Pazopanib formation was measured by LC-MS/MS. R2 values were 
calculated in Microsoft Excel as a representation of the linearity of the data points; n=3 
incubations per liver sample. Values expressed ± SD. 
 
Table 3.2. Table showing the R2 figures and corresponding correlation of 
metabolite formation versus P450 in human liver microsomes.   
R² = 0.0949
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Figure 3.9.1. OH-Pazopanib formation in a panel of recombinant P450s 
Human CYP3A4 is the predominant enzyme responsible for the metabolism of pazopanib. 
Pazopanib (14 µM) was incubated in triplicate with a panel of human recombinant CYPs 
(100 pM), and the predominant murine Cyp3a isoform; Cyp3a11. OH-pazopanib formation 
was measured by LC-MS/MS. *** P>0.001. Values expressed ± SD. 
  
3.2.8. In Vitro Metabolism of Pazopanib in Transgenic Mouse Microsomes  
Transgenic mice expressing human CYP3A4 are better models for modelling drug 
metabolism of CYP3A4 substrates in vivo, compared with wild-type mice. In order to 
validate the use of humanised CYP 3A4/3A7 mice for in vivo studies, microsomal 
stability experiments were carried out using microsomes derived from wild-type, un-
induced hCYP3A4/3A7, induced hCYP3A4/3A7 mice, and commercially available 
human liver microsomes, purchased as a pool, from Invitrogen. Induced mice were 
treated with pregnenolone-α-carbonitrile (PCN) dissolved in corn oil for three days, 
at a dose of 10 mg/kg by oral gavage, while un-induced animals received corn oil prior 
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to being sacrificed on day 4. Livers were harvested and snap-frozen and stocks of 
microsomes were prepared as described in Section 2.4.2. Figure 3.9.2 shows the level 
of expression of CYP3A/Cyp3a in these liver microsomes. The expression of CYP3A in 
human liver and induced hCYP3A4/3A7 mouse liver microsomes are comparable with 
one another, whereas the band in the wild-type mice is likely to be Cyp3a11, the most 
abundant mouse Cyp3a isoform in the liver. As expected, the un-induced animals 
express no CYP3A as the use of an inducing agent is required to drive expression of 
the transgene, and these animals lack endogenous Cyp3a11 as a result of the genetic 
manipulations, which involves the excision of the major murine Cyp3a cluster in the 
genome. This shows that induced hCYP3A4/7 mice express the human P450 protein 
at a level which approximates that found in human liver.  
Pazopanib (14 µM) was incubated with protein (20 µg) and 10 µl of 10 µM NADPH at 
37°C for 30 min and OH-pazopanib was measured using LC-MS/MS (Figure 3.9.2 b). 
OH-Pazopanib formation in wild-type and un-induced hCYP3A4/3A7 mouse liver 
microsomes does not differ; however, when hCYP3A4/3A7 mice are induced with 
PCN, the formation of OH-pazopanib is significantly increased compared to the un-
induced hCYP3A4/3A7, and wild-type mice, to levels which are comparable to the 
human microsomes (P <0.001). These data show that the capacity of the 
hCYP3A4/3A7 mouse microsomes to metabolise pazopanib, can be elevated to levels 
comparable with human microsomes when animals are pre-treated with an inducing 
agent.  
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a) 
 
                      Human            h3A4/7 +           h3A4/7 -        wild-type 
 
b) 
 
Figure 3.9.2. OH-pazopanib formation in humanised mouse, and human 
liver microsomes. 
Metabolic capacity of induced humanised CYP3A4/3A7 mouse microsomes is more similar 
to metabolism in human liver microsomes than wild-type mouse. a) Western blots showing 
Cyp3a/CYP3A levels in liver microsomes of human, induced humanised CYP3A4/3A7 mice, 
un-induced humanised CYP3A4/3A7 mice, and wild-type mice. CH32 antibody can detect 
both human and mouse CYP3a/Cyp3a respectively b) OH-pazopanib formation in 
microsome incubations with pazopanib (14 µM) using human, induced humanised 
CYP3A4/3A7 mice, un-induced humanised 3A4/3A7 mice, and wild-type mouse microsomes 
(20 µg) for 30 min. All mouse microsomes are pools of 3 animals, pooled human 
microsomes were from Invitrogen. Incubations were extracted in triplicate. Values 
expressed ± SD. 
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3.3 Discussion  
3.3.1 Summary 
This chapter describes a species difference in the microsomal stability of pazopanib 
in human and mouse liver microsomes. The higher rate of metabolism seen in human 
microsomes compared to the mouse may have significant implications on the 
relevance of pre-clinical trials in animals, for extrapolation to the human situation. 
Furthermore, transgenic mice expressing human CYP3A4/3A7 better mimic human 
microsome metabolism of pazopanib in vitro, compared to wild-type mice.  
 
3.3.2 Microsomal Stability of Pazopanib in Mouse and Human 
Microsomes.  
Little difference was noted between total disappearance of pazopanib in mouse and 
human microsomes, which may be attributable to the sensitivity of the LC-MS/MS 
assay, or constraints of the experimental set-up, such as the availability of NADPH, 
oxygen, duration of incubation and so forth. However, varying these parameters had 
a negligible effect on the outcome of these incubations. An alternative method of 
assessing drug metabolism in vitro, is the measurement of metabolite formation. 
Metabolite analysis is an important consideration when an animal model is being 
tested for later extrapolation to humans. It is rare that a metabolite would be formed 
in humans but not test animals, however the metabolite may be present at 
significantly higher levels in humans compared to animal models. Furthermore, the 
rate at which it is produced may be much more rapid. This is of particular importance 
as often drugs may form toxic intermediate compounds and metabolites. Possibly 
one of the most well described examples of drug metabolism resulting in a toxic 
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product is N-acetyl-p-benzoquinoneimine (NAPQI), formed by CYP-mediated 
metabolism of acetaminophen in the liver (Bender, Lindsey et al. 2004). Given that 
pazopanib is known to cause hepatotoxicity in a small number of patients, but not 
mice, it was of interest to compare the production of OH-pazopanib formation in 
mouse and human microsomes. 
 
3.3.3 Michaelis-Menten Enzyme Kinetics in Mouse and Human 
Microsomes 
The traditional method for determining Vmax and Km for a metabolic reaction is the 
initial formation rate of metabolite method (IFRMM), where the Michaelis-Menten 
equation is fitted to the initial rates of formation of metabolite under linear 
conditions of substrate concentration, protein and time. This method is suitable 
when the metabolite of the parent compound has been identified and is measurable. 
Being based upon initial formation rates allows for relatively short incubation lengths 
compared to other methods of kinetic modelling (Sjogren, Lennernas et al. 2009). 
IFRMM is not generally appropriate for high throughput screens of new compounds 
however, as many compounds will undergo extensive metabolism to several 
metabolites, which are often unknown. An alternative approach often utilised in drug 
discovery and development is the substrate depletion method, which is based on the 
disappearance of the parent compound in question without requiring the 
metabolite(s) to be characterised. Linearity optimisation experiments are not usually 
carried out when performing substrate depletion methodologies and arbitrary values 
are used for time and protein are used (Jones and Houston 2004). Linearity is 
necessary for scaling intrinsic clearance from microsomal incubations to the whole 
liver, making substrate depletion an inappropriate method for such extrapolation.  
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Additionally, the substrate depletion method tends to require approximately 20 % 
substrate disappearance in order to distinguish any depletion from baseline 
variability. This creates the requirement for longer incubation times and high protein 
content which in turn may create limitations in this approach, including oxygen 
availability and end product inhibition. Owing to the almost negligible depletion 
observed in early disappearance studies, IFRMM was employed to construct kinetic 
curves for both mouse and human liver microsomes, from incubations carried out 
under the same optimal, linear conditions. The minimal disappearance of pazopanib 
in early experiments may be due to the limits of detection of the analysis, as well as 
the limitations of the assay itself. It would appear from the IFRMM method and 
resultant kinetic curves, that while the Km for both the mouse and human liver 
microsomes are very similar, the Vmax is substantially greater in the human liver 
microsomes, and consequently, the intrinsic clearance is considerably greater than in 
the mouse liver microsomes.  
 
3.3.4 Human Recombinant Enzymes 
This chapter makes use of a panel of human recombinant enzymes to compare the 
relative capacity of human enzymes to metabolise pazopanib. Human recombinant 
enzymes are used routinely in high throughput assays during the development of new 
chemical entities (NCEs), to predict clearance, and the potential for drug-drug 
interactions. This method offers the advantage of allowing enzymes to be studied 
individually (Baranczewski, Stanczak et al. 2006).  
Pazopanib is described in FDA reports as being metabolised primarily by CYP3A4, with 
minor contributions from CYP1A1 and CYP2C8. Pazopanib is thought to be broken 
down into three main metabolites. These metabolites are not well described in the 
99 
 
 
literature however; one is reported to inhibit the proliferation of VEGF-stimulated 
umbilical vein endothelial cells with potency similar to pazopanib. The remaining 
metabolites are reported to be 10- to 20- fold less active (European Medicines 
Agency). Data described in this chapter confirm that pazopanib is a good substrate 
for human CYP3A4, and while mouse microsomes are capable of metabolising 
pazopanib, the major Cyp3a isoform in the mouse, Cyp3a11, does not contribute 
significantly.  
 
3.3.5 Humanised Mouse Microsomes  
One aim of this research is to investigate the utility of humanised mice as models to 
address the disparity between mouse models and human data. Having established a 
species difference in microsomal metabolism of pazopanib in vitro, between mouse 
and human liver microsome preparations, it was of interest to assess whether or not 
liver microsomes from humanised CYP3A4/3A7 mice better reflected the metabolism 
of pazopanib by human liver microsomes compared to the wild-type microsomes. 
This was addressed using liver microsomes pooled from humanised CYP3A4/3A7 
mice, with and without induction, alongside human and wild-type mouse liver 
microsomes. These data show that following induction, the expression of CYP3A4 in 
the transgenic mouse microsomes is on par with that seen in the human liver 
microsome pool. The band in the wild-type lane is likely to be representative of 
Cyp3a11, the predominant murine Cyp3a isoform. Interestingly, despite Cyp3a11 
being expressed at a level approximating the level of CYP3A4 in the human liver 
microsomes and the humanised mouse microsomes, metabolite formation in these 
incubations does not differ significantly from the un-induced humanised mouse liver 
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microsomes, which lack any CYP3A.  These data show, that in in vitro microsome 
stability assays, murine Cyp3a does not contribute to the metabolism of pazopanib, 
whereas human CYP3A4 does.  
 
  
 
 
 
 
Chapter 4 
In Vivo Pharmacokinetic and Toxicological Studies
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4.1 Introduction 
Understanding the behavior of clinically used drugs in terms of their absorption, 
distribution, metabolism and excretion (ADME), is of paramount importance to 
pharmacological research and development. Understanding the pharmacokinetic 
and pharmacodynamic properties of a drug forms the basis of safety testing, efficacy 
predictions and importantly, the extrapolation of animal studies to the human 
situation. Each of the four components of ADME affects the overall pharmacology of 
a drug and must be considered individually in order to obtain a comprehensive 
understanding of the mechanism by which the drug works, and to allow for optimum 
dosing strategies (Caldwell, Gardner et al. 1995). 
 
4.2 Absorption 
The absorption of a drug is the process by which the drug enters the body’s systemic 
circulation. The rapidity at which this occurs depends largely on the route of 
administration of the drug, for example, a drug which is administered by intravenous 
injection is incorporated into the circulation immediately, and with 100% 
bioavailability, whereas a drug which is administered orally must pass through the 
stomach in order to reach the gastrointestinal tract and liver, often resulting in a 
lower dose of the drug reaching its site of action. While the gastrointestinal tract is 
the main site of drug absorption, absorption through the skin and via the lung may 
also occur. Regardless of the site of absorption, all drugs must pass across cell mem-
branes to reach the systemic circulation. The way in which this occurs depends on 
the chemical properties of the drug. For example, small lipophilic compounds may 
cross cell membranes by passive diffusion, such is the case for drugs such as 
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nifedipine and amitriptyline which have low solubility in water, but readily diffuse 
across the gastrointestinal (GI) tract. Upon absorption from the GI tract, drugs may 
be subjected to metabolism in the gut wall itself, before being transported to the liver 
via the hepatic portal vein. The liver is the main site for detoxification and metabolism 
in the body, and all nutrients, toxins, and drugs absorbed by the intestine are 
transported to the liver to undergo metabolism and detoxification prior to entering 
the systemic circulation. This is known as “first-pass elimination”. The extent to which 
a drug is subjected to first-pass elimination is a major determinant of how much of 
the given dose of drug will enter the circulation and reach its target, and 
consequently, the amount of active drug remaining in the body may be considerably 
lower than the initial dose (Pond and Tozer 1984). Many drugs are either weak acids, 
or bases, and therefore are present in solution in both an ionized and non-ionized 
form. Non-ionized molecules are lipid soluble, and will readily diffuse through the 
intestinal wall. Ionized molecules however are poorly lipid soluble and will be 
retained in the lumen of the intestine.  
                                      AH                                                      A + H+ 
                               Non-ionized                                             Ionized         
The equilibrium of non-ionized and ionized forms of a drug is dependent on the 
intrinsic ionization constant (pKa) of the drug, and on the pH gradient across the 
membrane (Ellis and Blake 1993). The relationship between pKa, pH, and ionization 
can be described by the Henderson-Hasselbach equations for acids and bases: 
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𝑝𝐻 = 𝑝𝐾𝑎 + log
[𝑅]
[𝑅𝐻]
 (𝑎𝑐𝑖𝑑) 
 
𝑝𝐻 = 𝑝𝐾𝑎 + log
[𝐵]
[𝐵𝐻]
 (𝑏𝑎𝑠𝑒) 
(Craig 2004) 
 
4.3 Distribution 
Understanding the distribution of a drug is an important factor when estimating the 
efficacy of a given dose. If a drug is to be efficacious, it must be able to reach its site 
of action, or, target tissue in the body. Upon entry into the systemic circulation, the 
distribution of a drug throughout the body is dependent on a number of factors, 
including tissue haemodynamics, lipophilicity, plasma protein binding, diffusion into 
lipid membranes and the function of active drug transporters. Drug distribution 
describes the relationship between measurable systemic concentrations of drug, and 
the amount of drug in the body. It is an indication of the extent of drug distribution 
and is therefore a theoretical parameter, rather than a physiological volume (Grover 
and Benet 2009).  
When considering drug distribution, it is important to take into account the potential 
for a given drug to diffuse out of the plasma and into surrounding tissues, creating a 
“drug reservoir”. Drug reservoirs have the potential to prolong the duration of action 
of a drug. If the drug reservoir is in equilibrium with the plasma concentration of the 
drug, the stored drug may be released from its storage tissue to maintain this 
equilibrium as the plasma concentration falls, thus maintaining the initial plasma 
concentration for longer. This is well described with regards to the anaesthetic agent 
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thiopental. Thiopental is a highly lipophilic anaesthetic, given prior to surgery via an 
intravenous bolus injection. Due to the high blood flow to the brain, thiopental has a 
very short onset of action, leading to rapid induction of anaesthesia. However, 
thiopental binds poorly to brain lipids and as the plasma concentrations falls as 
thiopental diffuses into tissues, the concentration in the brain falls in order to 
maintain concentration equilibrium with the plasma. This leads to loss of anaesthesia 
by redistribution rather than by metabolism. If thiopental is administered repeatedly, 
it will diffuse into poorly perfused tissues such as adipose tissue, creating a reservoir. 
If this occurs, the action of thiopental may be greatly prolonged as the drug is 
released slowly from the adipose stores upon termination of administration, and the 
recovery period is significantly prolonged (Hemmings and Hopkins 2006).  
4.4 Metabolism 
The majority of drugs which enter the body will undergo some form of metabolism 
prior to excretion. The routes by which metabolism may occur are vast and varied 
and are influenced by innumerable external and endogenous factors making the term 
“drug metabolism”, one of the most complex aspects of ADME to define. The primary 
site of xenobiotic metabolism is the liver however, extra-hepatic tissues, often the 
site of absorption or secretion of a drug (e.g. lungs, kidneys and intestine) are also 
involved in drug metabolism.  Typically, xenobiotic metabolism is a biphasic process, 
whereby a drug undergoes a primary metabolic process which in turn creates a 
substrate for secondary metabolism, as discussed previously in Chapter 1.  
While metabolism may be an integral step in the ultimate excretion of a drug, it may 
also serve as an activation step in the conversion of an inactive “pro-drug”, to a 
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pharmacologically active metabolite. This is true for the oestrogen receptor 
antagonist, tamoxifen, which is used in the treatment of oestrogen-positive breast 
cancer. Tamoxifen undergoes extensive oxidative metabolism by the cytochrome 
P450 enzymes, resulting in the formation of several pharmacologically active 
metabolites, some of which have been found to exert a greater anti-oestrogen effect 
than the parent compound. The plasma concentrations of tamoxifen and its 
metabolites vary considerably among patients. This is considered to be a result of 
variations in P450 activity which lead to altered rates of metabolism, and ultimately 
altered systemic exposure to tamoxifen and its metabolites (Desta, Ward et al. 2004). 
Variation in metabolic capacity and routes may have significant effects on the efficacy 
of a drug.   
4.4.1 Species Differences in Metabolism 
Variation in drug metabolism by both Phase 1 and Phase 2 enzymes between species 
has been recognized for many years and has become an area of increasing interest 
with the advent of simpler assay systems, such as isolated liver cells and hepatocytes, 
which allow for closer interrogation of drug metabolism mechanisms. Variation in 
drug metabolism between species may be described as quantitative, wherein the 
same metabolic pathways are active as in the human but at a different rate, or, 
qualitative, wherein different metabolic routes than the human are instigated 
(Gibson).  
Species differences in metabolism may be attributable to variations in transcription 
factors. For example, species differences in CAR and PXR activators are well 
recognized, and they are attributable to structural variances in the ligand binding 
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domains of these receptors in different species.  These are important considerations 
when extrapolating data obtained from rodent safety studies to human trials 
(Graham and Lake 2008). One example of such species variation is seen in the 
metabolism of the tranquilizer, diazepam. Diazepam metabolism in humans and in 
canines is primarily by N-demethylation and C-3 hydroxylation, however in rats, C-3 
and 5-phenyl hydroxylation are the main pathways (Hucker 1970). It is also known 
that the anticonvulsant activity of diazepam is more persistent in mice than in rats. 
In the brain, diazepam levels are similar in both species, however the concentrations 
of N-demethyl diazepam and oxazepam appear to accumulate in mouse brain, and 
not in the rat. This metabolite accumulation is considered to be responsible for the 
prolonged effect of diazepam in mice compared to rats (Marcucci, Fanelli et al. 1970).  
4.4.2 Sex Differences in Drug Metabolism 
Disparity in drug metabolism between the sexes is another confounding factor when 
attempting to establish a paradigm for the metabolism of new drugs. Male and 
female animals, including humans display differences in drug metabolizing enzyme 
expression and regulation.  
One of the first reports of gender differences in the response to xenobiotics was 
described by Nicholas and Barron in 1932. Their work reported different responses 
to various doses of sodium amytal in male and female rats. Their study showed that 
the dose of sodium amytal required to achieve anesthesia in female rats was half of 
that required to elicit the same effect in the male (Nicholas and Barron 1932).  
As well as physical factors such as body weight and composition, the hormonal and 
genetic control of drug metabolism is a major determinant to drug responses. Early 
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studies concerning hormonal control of drug metabolizing enzymes found that 
differences between P450 activities in male and female rats could be abolished by 
castration. Furthermore, the higher P450 activity of the male animals could be 
restored in castrated animals with testosterone administration (Kato and Onoda 
1970). Initially it was thought that gonadal hormones elicited their effect on hepatic 
drug metabolizing enzymes by acting directly on the liver itself. This was challenged 
by several studies which found that the gonadal hormones only exerted effects on 
hepatic enzymes in the presence of an intact pituitary gland. A study by Eden in 1979, 
described differences in growth hormone secretion patterns in adult male and female 
rats. In the male, growth hormone (GH) is secreted in a pulsatile manner, with ‘bursts’ 
of hormone secretion occurring approximately every three hours. The female 
however releases growth hormone at a tonic, low level, resulting in a constant level 
of GH in the blood at a lower level than the peak concentrations seen in males (Eden 
1979). A later study by Mode et al. showed that by administering a constant low dose 
of growth hormone to hypophysectomised female rats, that a feminisation of liver 
enzyme expression occurred. Similarly, oestrogen treatment of male rats also 
produced a shift toward female liver enzyme expression (Mode, Gustafsson et al. 
1982).   
More recently, human studies have found that drug metabolizing enzymes are 
expressed at different levels between males and females. In a study by Wolbold et al. 
surgically acquired liver samples obtained from male and female patients were tested 
for CYP3A4 expression. CYP3A4 levels were found to be two-fold higher in females 
compared with males. This was reflected in a 50 % increase in the rate of N-
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dealkylation of verapamil (a CYP3A4 substrate) in microsomal incubations (Wolbold, 
Klein et al. 2003).  
4.4.3 Age-Related Variations in Drug Metabolism 
There are several factors which contribute to variation in drug metabolism capacity 
with age, including liver size, hepatic blood flow, protein binding, and the amount of 
drug metabolizing enzymes present. Both Phase 1 and Phase 2 drug metabolizing 
enzymes, including the cytochromes P450s are differentially expressed throughout 
all stages of life, from gestation to adult life. In foetal liver, the total P450 content is 
approximately 30-60 % of that found in adult liver. For this reason, neonates are 
generally at greater risk of drug toxicity than infants and adults due to their impaired 
ability to metabolize drugs. The hepatic P450 content and drug metabolizing capacity 
of newborn infants approaches adult levels at the age of around ten years old 
(Choonara 2005). Age-related variation in drug metabolizing capacity can have 
significant toxicological consequences, as was demonstrated by the so called ‘grey 
baby syndrome’, following chloramphenicol treatment in newborns. ‘Grey baby 
syndrome’ was identified in infants whose mothers had received chloramphenacol in 
the late stages of pregnancy, and in neonates receiving the drug after birth. The 
resultant condition is characterized by vomiting, anorexia, respiratory distress, 
hypotension, grey discolouration of the skin, and death. This syndrome was found to 
occur due to neonatal immaturity of the hepatic glucuronide pathway by which 
chloramphenacol is metabolized, meaning the drug accumulates in the infant at toxic 
levels (Hughes et al. 2001).  
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Advancing age is not generally associated with any significant alterations in the level 
of phase 1 or 2 enzymes in the liver, however hepatic metabolism is affected by a 
decrease in hepatic blood flow by approximately 40 %, compared with the average 
adult. Drug metabolism in the elderly is also highly impacted by polypharmacy, with 
elderly individuals consuming on average four times the quantity of prescribed drugs 
compared to younger individuals (McLean and Le Couteur 2004).  
4.5 Excretion  
Excretion of a drug from the body is via two major routes; biliary and renal, and is 
heavily influenced by drug transporters. Small contributions towards excretion of 
drugs may occur in saliva, sweat, breast milk and the lungs, however, these are most 
often negligible, with the exception of exhalation of volatile anesthetics (Preckel and 
Bolten 2005). With the primary function of metabolism being the transformation of 
a drug to a more polar, water-soluble form, the primary route for the excretion of 
most drugs is by renal filtration. The kidneys receive approximately 25 % of the total 
systemic circulation in humans, and so are constantly exposed to drugs and 
xenobiotics which are present in the blood. Filtration of blood through the 
glomerulus and the movement of glomerular filtrate through the nephron is the 
process during which reabsorption of non-toxic substances such as water, glucose 
and amino acids occur, while waste material is carried to the collecting ducts for 
excretion in urine. Large molecules such as albumin, to which many drugs bind with 
some degree of affinity are not filtered at a glomerular level, and therefore only 
unbound drug is able to be removed from the circulation by glomerular filtration 
(Verbeeck and Musuamba 2009). In addition to passive filtration, the nephron is able 
to selectively transport molecules in and out of the tubular lumen via a myriad of 
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drug transporters. These transporters include organic anion transporters (OAT) 1-4, 
P-glycoprotein (Pgp) of which there are two subclasses; multidrug resistance protein 
(MDR) 1 and 2, peptide transporter 1 and 2, and organic cation transporters 1 and 2. 
These transporters exhibit broad substrate specificity, with many xenobiotics serving 
as substrates for one or more type of transporter. This means that the process of 
active transport of molecules in the kidney is subject to competition and inhibition, 
which can lead to drug-drug interactions with multiple substrates  (Shitara, Sato et al. 
2005).  
Biliary excretion is the second major route of elimination, however, research into the 
mechanisms by which it occurs in humans has been somewhat confounded by 
difficulties in obtaining bile from healthy patients. Bile sampling is an invasive 
procedure and so is usually limited to post-operative patients who have undergone 
surgery for existing hepatobiliary dysfunction. Consequently, faecal elimination is 
used as a measure of non-urinary drug elimination (Ghibellini, Leslie et al. 2006). Bile 
is secreted from hepatocytes in an osmotic process and is released into canaliculi 
running between adjacent cells. Canalicular bile is drained into bile ductules and 
ducts before being further concentrated in the gall bladder, where it is stored in the 
fasting state prior to release into the small intestine in the fed state. Organic solutes 
including bile salts, phospholipids and cholesterol are secreted by hepatocytes into 
the bile, where they form micelles which may be reabsorbed in the intestine (Trauner 
and Boyer 2003). In addition to organic solutes drugs and their metabolites may also 
be excreted into the bile. Similarly to the kidney, the liver contains a vast array of 
uptake and efflux transporters which are localized to the apical and the basolateral 
membranes of both hepatcoytes and cholangiocytes. As the liver is both a major site 
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of drug metabolism, as well as excretion of xenobiotics, it is therefore at high risk of 
prolonged exposure to toxic compounds and metabolites and consequential tissue 
damage. Similarly to bile salts and cholesterol, xenobiotics which enter the bile may 
be reabsorbed in the intestine and undergo enterohepatic cycling, which re-
introduces the compound back into the liver (Roberts, Magnusson et al. 2002). 
Furthermore, xenobiotics may cause disruption to the bile formation process and 
result in drug-induced cholestasis, where bile cannot flow from the hepatic ducts to 
the gallbladder or intestine. This may also result in liver injury as drugs and 
metabolites can linger for extended periods of time, during which they may be re-up 
taken into hepatocytes, causing further injury (Padda, Sanchez et al. 2011).  
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4.6 Results 
4.6.1. Establishing the Role of Cyp3a in the Metabolism of Pazopanib In 
Vivo. 
In order to acquire a general understanding of the contribution of Cyp3a in the mouse 
to pazopanib metabolism in vivo, adult male wild-type (n=4) and Cyp3ac knock-out 
mice (n=4) were administered pazopanib at a dose of 20 mg/kg pazopanib per os. 
(p.o.). A pharmacokinetic experiment was carried out as described in Chapter 2 and 
the data are shown in Figure 4.1. Interestingly, despite pazopanib being a known 
CYP3A4 substrate, the deletion of the murine Cyp3a cluster has no significant effect 
on the pharmacokinetic profile of pazopanib in vivo, suggesting that murine Cyp3a is 
not implicated in pazopanib metabolism in the mouse.  
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b) 
Genotype 
Half Life 
(Mins) 
Cmax  
(µg/ml) 
AUClast 
(min*µg/ml) 
AUCinfin 
(min*µg/ml) 
Clearance  
(ml/min/kg) 
WT 1037 ± 136.6 24.5 ± 6 24642 ± 4298 39321 ± 29692 0.7 ± 0.3 
Cyp3a KO 478 ± 127.8 22 ± 7.6 18084 ± 3861 19488 ± 3665 1.1 ±  1.8 
Figure 4.1. The deletion of the murine Cyp3a cluster has no effect on the 
pharmacokinetic profile of pazopanib compared to wild-type mice. a) 
Pharmacokinetic profile of pazopanib in wild-type, indicated by open circles (n=4) and Cyp3a 
cluster knock-out mice, indicated by black boxes (n=4). Pazopanib (20 mg/kg) administered 
by oral gavage b) raw data summarizing pharmacokinetic parameters calculated in Winonlin. 
No significant differences in pharmacokinetic parameters were noted between the groups. 
Values expressed ± SEM. 
 114    
  
 
4.6.2. Investigation into Hepatic P450 Contribution to Pazopanib 
Metabolism in the Mouse 
The apparent non-involvement of Cyp3a in the metabolism of pazopanib in the 
mouse raised the question; which, if any cytochrome P450s are implicated in the 
hepatic metabolism of pazopanib in the mouse? The HRN mouse was utilized in an 
attempt to address this question. Adult male wild-type (n=4) and HRN mice (n=5) 
were dosed with pazopanib at a dose of 20 mg/kg (p.o.) and the pharmacokinetic 
profiles of pazopanib were analyzed. The data are displayed in Figure 4.2. If a drug 
undergoes extensive hepatic metabolism, it would be expected that the exposure to 
the drug in HRN mice, which lack functional P450 enzymes in the liver, would be 
greatly increased due to the inability of these mice to metabolize the drug. However, 
it can be seen in Figure 4.2. that once again there is no significant difference between 
the pharmacokinetic profile of pazopanib in wild-type and HRN mice. Taken together 
with data from Cyp3ac knock-out mice, this implies that in the mouse, hepatic P450s 
play a negligible role in the metabolism of pazopanib.  
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b) 
Genotype 
Half Life 
(Mins) 
Cmax  
(µg/ml) 
AUClast 
(min*µg/ml) 
AUCinfin 
(min*µg/ml) 
Clearance  
(ml/min/kg) 
WT 772 ± 270.3* 11.5 ± 5.5 12274 ± 6316 15276 ± 7645 1.5 ± 0.6 
HRN 385 ± 114.8* 14.8 ± 3.9 10451 ± 2218 10933 ± 2193 1.9 ± 0.4 
 
Figure 4.2. Inactivation of hepatic P450 enzyme activity has a marginal effect on 
the pharmacokinetic profile of pazopanib compared to wild-type mice.  a) 
Pharmacokinetic profile of pazopanib in wild type (n=5) and HRN (n=5) mice. Pazopanib (20 
mg/kg) administered by oral gavage. b) raw data summarizing pharmacokinetic parameters 
calculated in WinNonLin.  Half-life was found to differ between groups (t-test, P<0.05). Values 
expressed ± SEM. 
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4.6.3 Pharmacokinetic Profiling of Pazopanib in Induced Wild-Type Mice 
In Chapter 2, Figure 3.7 describes differences in the rate of pazopanib metabolism 
between mouse and human microsomes in vitro, which suggests a species variation 
in the metabolism of pazopanib exists between mice and humans. In order to assess 
the potential significance of human CYP3A4 in the clearance of pazopanib, 
pharmacokinetic experiments were carried out using wild type, h3A4/3A7 and 
h3A4/3A7/hCAR/hPXR mice. The mice were induced prior to the pharmacokinetic 
dosing using the drugs and dosing schedule carried out by Hasegawa et al. 
(Hasegawa, Kapelyukh et al. 2011). Each inducing agent had a corresponding wild 
type control. A western blot showing the levels of induction in wild-type, humanised 
CYP3A4/3A7 and humanised CYP3A4/3A7/hCAR/hPXR animals using PCN and 
rifampicin can be seen in Figure 4.6. Little differences were observed in OH-
pazopanib pharmacokinetics among the treatment groups, however the pattern of 
OH-pazopanib formation in wild-type and h3A4/3A7/hCAR/hPXR animals when 
induced, is consistent with an increase in metabolism of pazopanib. It is relatively 
complex to interpret these OH-pazopanib profiles in vivo, as there is no information 
available on Phase 2 reactions involved in the metabolism of pazopanib. 
Wild-type mice were dosed with vehicle (corn oil), or rifampicin at 10 mg/kg for 3 
days or, PCN at 10 mg/kg (i.p) for 2 days prior to the commencement of the PK study 
(n=4 all groups). Mice were then dosed with 20 mg/kg pazopanib (p.o.) the resultant 
pharmacokinetic profiles are displayed in Figure 4.3. Both the human-specific inducer 
rifampicin, and mouse-specific inducer PCN cause a non-significant reduction in 
maximum plasma concentration, compared with the corn oil treated vehicle control 
group (Table 4.1). Furthermore, both inducing agents cause a non-significant 
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decrease in the bioavailability of pazopanib, as represented by the area under the 
curve (AUC), compared to the vehicle control group. PCN is a potent activator of 
murine PXR, and this is reflected in the Cyp3a induction seen in Western blots 
displayed in Figure 4.7.  
4.6.4 Pharmacokinetics of Pazopanib in Humanised CYP3A4/3A7 mice 
Having established that induction of wild-type mice had a small, albeit non-significant 
effect on the metabolism of pazopanib, as outlined in Table 4.1, the pharmacokinetic 
study was repeated in hCYP3A4/3A7 mice, induced with the murine PXR agonist PCN 
at 10 mg/kg (i.p) for 2 days, as was the case in the wild-type animals. Two groups of 
hCYP3A4/3A7 mice were used; one group received vehicle (corn oil) and one received 
PCN. The pharmacokinetic profiles obtained in these animals are displayed in Figure 
4.4.  
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Figure 4.3. The pharmacokinetic profile of pazopanib does not change with 
induction with PCN or Rifampicin in wild-type mice. Pharmacokinetic data from wild 
type mice induced with either 10 mg/kg PCN 10 mg/kg (i.p.) for 2 days or 10 mg/kg 
rifampicin (i.p.) for 3 days. Pazopanib (20 mg/kg) administered by oral gavage, n=4. 
Statistical analysis of pharmacokinetic parameters (t-test) showed no significant difference 
between groups b) OH-pazopanib formation in wild-type mice differs slightly between 
inducing treatments over PK time course. CMax -* Corn Oil vs PCN. P<0.05, N=2. Values 
expressed mean ± SEM 
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Figure 4.4. Induction of hCYP3A4/3A7 mice with PCN does not significantly alter 
pazoapnib pharmacokinetic parameters. Pharmacokinetic data from h3A4/3A7 mice 
induced with 10 mg/kg PCN (i.p.) for 2 days, vs corn oil. Pazopanib (20 mg/kg) administered 
by oral gavage, n=6. Pharmacokinetic parameters are not statistically different between 
treatments (t-test) b) OH-pazopanib detection does not differ between hCYP3A4/3A7 animals 
treated with corn oil or PCN and dosed with pazopanib. Values expressed mean ± SEM 
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4.6.5. Pharmacokinetics of Pazopanib in h3A4/3A7/hCAR/hPXR Mice.  
The pharmacokinetics of pazopanib was non-significantly altered in un-induced and 
induced hCYP3A4/3A7 mice. The pharmacokinetic study was performed in 
h3A4/3A7/hCAR/hPXR mice induced with the human PXR ligand, rifampicin. Mice 
were administered rifampicin at a dose of 10 mg/kg for 3 days (i.p.) On day 4, mice 
were dosed with pazopanib at a dose of 20 mg/kg (p.o.) and a PK experiment was 
carried out previously described. Un-induced animals received corn oil as a control 
for rifampicin. The pharmacokinetic profiles of pazopanib and OH-metabolite in these 
mice are displayed in Figure 4.5.  Statistical analysis (t test) showed clearance, half- 
life and area under the curve to differ significantly between induced and un-induced 
groups as displayed in Table 4.1 (P < 0.001). 
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Figure 4.5. Induction of humanised CYP3A4/3A7/hCAR/hPXR mice with 
rifampicin significantly alters the pharmacokinetic profile of pazopanib.  
Pharmacokinetic data from h3A4/3A7/hCAR/hPXR mice induced with 10 mg/kg rifampicin 
(i.p.) for 3 days vs corn oil. Pazopanib (20 mg/kg) administered by oral gavage, n=6. Clearance, 
half-life and AUC differd significantly between treatments (t-test, P < 0.001) b) OH-pazopanib 
formation does not differ between h3A4/3A7/hCAR/hPXR animals treated with corn oil or 
rifampicin and dosed with pazopanib.  Values expressed ± SEM.
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Figure 4.6.  Western blots from pharmacokinetic study showing induction of 
murine Cyp3a, or the CYP3A4/7 transgene. Pools of 4 (wild-type), and 6 (humanized) 
microsomes derived from mouse livers were blotted to confirm induction of Cyp3a with PCN 
and CYP3A with rifampicin.   
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Mouse 
Treatment 
Half Life 
(Mins) 
Cmax  
(µg/ml) 
AUClast 
(min*µg/ml) 
AUCinfin 
(min*µg/ml) 
Clearance  
(ml/min/kg) 
WT CO 314 ± 42.3 13.7  ± 1.4 7140 ± 639 7268 ± 757 2.8 ± 0.3 
WT PCN 280 .9 ± 
32.6 
13.7  ± 4.6 5759 ± 2344 5878  ± 2390 3.4 ± 1.6 
WT Rif 300 .4 ± 
69.4 
13.4  ± 3.7 5770 ± 2654 5841 ± 2739 3.9 ± 1.3 
h3A4/3A7 
CO 
366 .3 ± 
81.9 
21.7 ± 10.1 14221 ± 6852 14961  ± 
7337 
1.6 ± 0.7 
h3A4/3A7 
PCN 
349 .3 ± 
99  
16.9 ± 4.6 8808 ± 2834 9203 ± 2843 2.4  ± 0.8 
h3A4/3A7/ 
hCAR/hPXR 
CO 
366 .3 
±49.8 
21.2 ± 5.0 11704 ± 3149 12150  ± 
3353 
1.7  ± 0.6 
h3A4/3A7/ 
hCAR/hPXR 
Rif 
241 .8 ± 
34.6 
  
15.7 ± 7.7 4484 ± 1213 4508 ± 1214 4.7   ± 1.2 
 
Table 4.1. Pharmacokinetic parameters from in vivo experiments 
Mean pharmacokinetic data calculated using WinNonLin software. Values expressed mean ± 
SD.  Statistics as calculated using Graphpad Instat, are described in Tables 4.2-4.4.  
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Mouse 
Treatment 
W
T 
CO 
WT 
PC
N 
W
T 
RIF 
h3A4/3A
7 CO 
h3A4/3A
7 PCN 
h3A4/3A7/ 
hCAR/hPX
R CO 
h3A4/3A7/hCAR
/ 
hPXR Rif 
WT CO  ns ns ns ns ns Ns 
WT PCN ns  ns ns ns ns Ns 
WT Rif ns ns  ns ns ns Ns 
h3A4/3A7 
CO 
ns 
 
ns ns  ns ns * 
h3A4/3A7 
PCN 
ns ns ns ns  ns Ns 
h3A4/3A7/ 
hCAR/hPX
R CO 
ns ns ns ns ns  * 
h3A4/3A7/ 
hCAR/hPX
R Rif 
ns ns ns ns ns ns  
 
Table 4.2. Statistically significant differences between half-life in in vivo 
pharmacokinetic experiments   ns= non-significant, * P< 0.05.  
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Mouse 
Treatmen
t 
WT 
CO 
WT 
PCN 
WT 
RIF 
H3A4/
3A7 
CO 
h3A4/3A7 
PCN 
h3A4/3A7/ 
hCAR/hPXR 
CO 
h3A4/3A7/hCA
R/ 
hPXR Rif 
WT CO  ns ns ns ns Ns Ns 
WT PCN ns  ns * ns Ns Ns 
WT Rif ns ns  * ns Ns Ns 
h3A4/3A7 
CO 
ns 
 
ns ns  ns Ns *** 
h3A4/3A7 
PCN 
ns ns ns ns  Ns Ns 
h3A4/3A7
/ 
hCAR/hPX
R CO 
ns ns ns ns ns  * 
h3A4/3A7
/ 
hCAR/hPX
R Rif 
ns ns ns ns ns Ns  
 
Table 4.3. Statistically significant differences between the area under the curve in in 
vivo pharmacokinetic experiments ns= non-significant, * P< 0.05, ***P< 0.001 
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Mouse 
Treatment 
W
T 
CO 
WT 
PC
N 
W
T 
RIF 
h3A4/3A
7 CO 
h3A4/3A
7 PCN 
h3A4/3A7/ 
hCAR/hPX
R CO 
h3A4/3A7/hCAR
/ 
hPXR Rif 
WT CO  ns ns ns ns Ns ns 
WT PCN ns  ns ns ns Ns ns 
WT Rif ns ns  * ns * ns 
h3A4/3A7 
CO 
ns ns ns  ns ns *** 
h3A4/3A7 
PCN 
ns ns ns ns  ns ** 
h3A4/3A7/ 
hCAR/hPX
R CO 
ns ns ns ns 
 
ns  *** 
h3A4/3A7/ 
hCAR/hPX
R Rif 
ns ns ns ns ns ns  
 
Table 4.4. Statistically significant differences between clearance of pazopanib in in 
vivo pharmacokinetic experiments ns= non-significant, * P< 0.05, ** P< 0.01, *** P< 
0.001 
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4.6.6 Pazopanib and PXR Activation 
GlaxoSmithKline has reported that pazopanib has shown potential to induce CYP3A4 
in an in vitro human PXR assay (Shukla, Sakamuru et al. 2011); however, drug 
concentrations at which this was seen and the degree of induction achieved are not 
described. In an in vitro human PXR assay in human liver hepatocellular carcinoma 
derived cells (DPX2 cells) (Figure 4.7 a), performed by Dr A.K. McLeod (Molecular 
Pharmacology Group, Medical Research Institute, Ninewells Hospital and Medical 
School) it can be seen that indeed, pazopanib elicits a dose-dependent activation of 
PXR in vitro, with maximum induction (approximately 8-fold compared to DMSO 
control) at a concentration of approximately 1 µM. This suggested that pazopanib has 
the potential to activate PXR in vivo, and therefore may have the potential to induce 
its own metabolism through the up-regulation of CYP3A4. 
To investigate PXR activation in vivo, wild-type and humanised PXR mice were dosed 
with pazopanib or 4 days at 200 mg/kg by oral gavage. Untreated mice received an 
equivalent of vehicle based upon body weight. On day 4, mice were sacrificed and 
livers harvested for Western blot. Drugs that are strong PXR activators will cause an 
induction of hepatic CYP3A4/Cyp3a, however, western blots shown in Figure 4.7 b, 
show only a marginal increase in Cyp3a levels in wild-type mice, which is not reflected 
in the humanised PXR animals.    
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a) 
 
b) 
  
 
 
Figure 4.7. In vitro and in vivo investigations into the effect of pazopanib on 
PXR.  
a) Graph obtained from in vitro DPX2 Assay and b) Western blots of pooled wild type and 
humanised PXR mouse liver microsomes (10 µg pooled protein per lane) showing induction 
of Cyp3a in wild-type mice which is not reflected in the humanised PXR mice, n=3 untreated, 
n=4 pazopanib treated. 
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4.6.7 Treatment of wild-type and humanised mice with high dose 
pazopanib 
Having observed differences in the pharmacokinetic parameters of pazopanib in wild-
type and h3A4/3A7/hCAR/hPXR mice (Figure 4.5), as well as a species difference in 
the kinetics of metabolism of pazopanib in mice and human microsomes (Figure 3.7), 
it was of interest to establish whether or not susceptibility to hepatic injury differed 
between the two models. Groups of hCYP3A4/3A7/hCAR/hPXR and wild-type mice 
were induced for three days using rifampicin, at a dose of 60 mg/kg. On the fourth 
day, all animals received a high dose of pazopanib (200 mg/kg) by oral gavage while 
control animals received an equivalent volume of vehicle (cremaphore 15 %, ethanol 
8 % and water) based on body weight. Mice were monitored for 30 h post pazopanib 
dosing. Animals appeared healthy, and at 30 h post dosing, animals were killed and 
blood was taken for biochemical analysis as described in section 2.11. Upon 
harvesting the livers from these mice, it was noted that h3A4/3A7/hCAR/hPXR mice 
exhibited large, pale livers which were mottled in appearance. Liver to body weight 
ratio was used as an indication of hepatic hypertrophy, and are represented in Figure 
4.8. h3A4/3A7/hCAR/hPXR animals treated with vehicle had slightly larger livers than 
wild-type animals, although this difference was not statistically significant. However, 
h3A4/3A7/hCAR/hPXR animals induced with rifampicin and treated with pazopanib 
have significantly larger livers compared to h3A4/3A7/hCAR/hPXR animals treated 
with vehicle (P <0.05, n=3), as well as wild-type animals treated with either vehicle or 
rifampicin and pazopanib (P <0.001, n=3). Figure 4.9 shows no significant elevations 
in ALT levels in wild-type mice following high dosing with pazopanib compared with 
controls  (75.4 ± 6.8 U/I rifampicin and pazopanib, 37.8 ± 14.3 U/I pazopanib, 30.5 ± 
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13.6 U/I vehicle). This is largely consistent with findings outlined by the FDA and 
GlaxoSmithKline, which describe repeated high dosing of pazopanib in wild-type mice 
as having negligible effects on blood biochemistry in these animals (GlaxoSmithKline 
2013). h3A4/3A7/hCAR/hPXR animals treated with rifampicin and pazopanib and 
which exhibited enlarged, pale livers however also displayed elevated levels of ALT 
compared to wild-type animals which received the same dosing regimen (117.8 ± 34 
U/I h3A4/3A7/hCAR/hPXR rifampicin and pazopanib, 41.2 ± 1.9 U/I pazopanib, 43.6 
± 4.0 U/I vehicle, P <0.01, n=3), as well as wild-type and h3A4/3A7/hCAR/hPXR 
animals which received pazopanib alone, or vehicle (P <0.001, n=3 all groups). No 
changes were seen in total bilirubin levels in any group. 
 
                 
 
Figure 4.8. Liver to body weight ratios of wild-type and 
h3A4/3A7/hCAR/hPXR mice treated with either vehicle, or rifampicin 
and pazopanib. Humanised mice (hhh) treated with rifampicin and pazopanib have 
significantly enlarged livers compared to wild-type animals. *= P< 0.05 hhh Rif + Paz 
vs hhh Veh, **= P< 0.01 hhh Rif + Paz vs WT Veh. n=3 all groups. Values expressed ± 
SD. 
 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
Wt Veh Wt Rif + Paz hhh Veh hhh Rif + Paz
Li
ve
r 
to
 B
o
d
y 
W
e
ig
h
 t
 R
at
io
* 
 
** 
 131    
  
 
 
 
 
 
Figure 4.9. Plasma ALT levels in high dose pazopanib mice.  
ALT levels were determined in blood obtained from cardiac punctures 
performed 30h post-pazopanib dosing. H3A4/3A7/hCAR/hPXR (hhh) mice 
showed significantly elevated ALT compared to animals treated with vehicle or 
pazopanib alone and wild-type animals. n=3 all groups. ***= hhh R+P vs Wt Veh, 
hhh Veh, WT Paz, hhh Paz. **= hhh R+P vs Wt R+P. Values expressed ± SD. 
 
 
4.6.8 Liver Pathology 
Pale, mottled and enlarged livers are often the result of excessive lipid accumulation 
in the hepatocytes. Initial haemotoxylin and eosin (H&E) staining appeared to show 
lipid-like droplets such as would be expected in fatty liver disease. Figure 4.10 shows 
H&E staining on snap-frozen liver sections of vehicle treated and rifampicin and 
pazopanib treated wild- type h3A4/3A7/hCAR/hPXR mice. It is apparent that animals 
which exhibited an enlarged, pale liver phenotype, coupled with elevated ALT also 
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showed distinct lipid-like vacuoles in the liver. This vacuolation and ALT elevation is 
absent in wild-type animals (Figure 4.11). Furthermore, this phenotype was absent 
in h3A4/3A7/hCAR/hPXR animals which received vehicle and pazopanib, or 
rifampicin and vehicle, suggesting that induction and expression of the human 
CYP3A4 transgene as well as dosing with pazopanib is required to elicit the 
phenotype.  
Having established that the phenotype is exclusive to Rif-induced and pazopanib-
treated h3A4/3A7/hCAR/hPXR mice, several sections from vehicle treated and 
affected livers were stained in an attempt to identify the nature of the vacuolation 
seen in them. Oil Red O staining was carried out with the help of Dr Shaun Walsh, 
Ninewells Hospital and Medical School, and sections are displayed in Figure 4.12. 
Interestingly, these sections are negative for lipids, which are normally detected by 
red staining in affected tissue. Subsequently, Periodic Acid Schiff staining was 
performed on sections from the same livers, using a commercially available staining 
kit from Sigma (section 2.14) to stain for polysaccharides such as glycogen. Sections 
were also negative for glycogen, which stains pink to red, in colour. These sections 
are represented in Figure 4.13.  
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a)                                                                     
                 
 
 
b)     
   
 
Figure 4.10: Haemotoxylin and Eosin stained liver sections from wild-
type and humanised mice 
Haematoxylin and Eosin staining performed on sections from snap-frozen liver 
of h3A4/3A7/hCAR/hPXR mice treated with a) corn oil and vehicle or b) 
rifampicin induced (60mg/kg, 3 days i.p.) and 200mg/kg pazopanib p.o. H&E was 
carried out as described in the methods. Arrows indicate lipid like vacuolation in 
the pazopanib-treated animals, which are absent in the control animals. 
Photomicrographs are representative of n ≥ 2, magnification x 20. 
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Figure 4.11. Degenerative vacuolation in livers of humanised animals.  
Wild-type and h3A4/3A7/hCAR/hPXR  animals treated with corn oil show no 
signs of liver abnormality (Dr Zoe Riches, Molecular Pharmacology Group, 
Ninewells Hospital and Medical School), “Rif” (60 mg/kg, i.p) treated wild-type 
animals show a normal liver phenotype while h3A4/3A7/hCAR/hPXR animals 
show evidence of liver abnormality. “Rif + Paz” wild-type animals treated with 
60 mg/kg rifampicin (i.p) and 200 mg/kg pazopanib (p.o) appear to show little 
sign of liver abnormality, h3A4/3A7/hCAR/hPXR animals treated with 60 mg/kg 
rifampicin (i.p) and 200 mg/kg pazopanib (p.o) show extensive degeneration 
coupled with hepatomegaly and a mild elevation in ALT. Pictomicrographs 
representative n≥2.  
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    a) 
   
    b)               
   
 
         Figure 4.12. Lipid staining in vehicle treated and pazopanib treated mice. 
Oil Red O staining for lipids on a) vehicle treated h3A4/3A7/hCAR/hPXR mice, and b) 
Oil Red O staining on h3A4/3A7/hCAR/hPXR mice induced for 3 days with 60 mg/kg 
rifampicin (i.p) and treated on day 4 with 200 mg/kg pazopanib (p.o.). Neither vehicle 
nor treated livers stained positively for lipids, Photomicrographs representative of n 
≥ 2.Magnification x 40.  
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a)                                                                            
 
     
          b) 
                                  
 
Figure 4.13. Periodic Acid Schiff (PAS) staining in vehicle treated and 
phenotypic mice. 
PAS staining for glycogen on a) vehicle-treated h3A4/3A7/hCAR/hPXR mice and b) 
h3A4/3A7/hCAR/hPXR mice induced for 3 days with 60 mg/kg rifampicin (i.p.) and 
treated on day 4 with 200 mg/kg pazopanib (p.o.). Neither vehicle-treated or Rif-
induced livers stained positively for glycogen. Photomicrographs are representative 
of n ≥ 2, magnification x 40.  
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4.6.9 Mechanism of Liver Phenotype 
The pale and enlarged liver phenotype observed in h3A4/3A7/hCAR/hPXR mice when 
induced with rifampicin for 3 days at 60 mg/kg (i.p.) and dosed with 200 mg/kg 
pazopanib (p.o.) was not observed in wild type mice treated with the same drug 
regimen. It was then of interest to attempt to define which aspect of the 
humanisation of the h3A4/3A7/hCAR/hPXR mouse was the causative gene in the 
observed phenotype. The h3A4/3A7/hCAR/hPXR mouse is generated by crossing 
h3A4/3A7 mice, with hCAR/hPXR mice, as described in Section 1.14.4, and therefore 
the phenotype observed in these livers may be the product of CYP3A4/3A7 activity, 
or of the human nuclear receptors CAR and PXR.  
Initial attempts to address this were made by dosing 3 groups of mice; 
h3A4/3A7/hCAR/hPXR, h3A4/3A7 and hCAR/hPXR, with 60 mg/kg rifampicin (i.p), for 
3 days prior to the administration of 200 mg/kg pazopanib (p.o.). At 60 mg/kg, 
rifampicin induces Cyp3a in wild-type mice, and therefore it was expected to induce 
in all genotypes in this study. Western Blots in Figure 4.14 however, show no 
induction in the h3A4/3A7 animals, for reasons that are yet to be elucidated. The 
groups which displayed the mottled liver phenotype are highlighted by boxes. The 
h3A4/3A7 mouse possesses murine CAR and PXR, and therefore PCN, the murine 
PXR-specific inducing agent is the drug of choice for use with this line, as opposed to 
rifampicin. To avoid introducing further inducing agents and controls for these 
experiments, a pharmacological approach was adopted to circumvent the 
requirement for entire new data sets using PCN. Ketoconazole is a clinically used 
antifungal agent, and a potent inhibitor of CYP3A4 in vivo. At high doses, 
ketoconazole has the capacity to inhibit the activity of most cytochrome P450 
 138    
  
 
enzymes. The rationale behind this investigation was to inhibit the activity of CYP3A4, 
which is required for the production of OH-pazopanib, to ascertain whether or not 
the phenotype persists in the absence of the metabolite. h3A4/3A7/hCAR/hPXR mice 
were induced for 3 days using 60 mg/kg rifampicin (i.p.) on day 4, 100 mg/kg 
ketoconazole (p.o. in corn oil) or corn oil alone was administered to mice 30 min prior 
to the administration of 200 mg/kg pazopanib (p.o.). Mice then underwent a 
pharmacokinetic experiment as previously described and killed at 30 hr post 
pazopanib dosing. The traces illustrated in Figure 4.15 shows that co-administration 
of ketoconazole at 100 mg/kg is sufficient to significantly alter the PK parameters of 
pazopanib in rifampicin-induced h3A4/3A7/hCAR/hPXR mice. Furthermore, liver to 
body weight ratios and ALT levels were unchanged between ketoconazole treated 
and control animals.  
The mottled liver phenotype persists in ketoconazole treated mice (Figure 4.16), 
suggesting that this is a cytochrome P450-independent effect.  
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Figure 4.14. Western Blots showing levels of various cytochrome P450 enzymes 
in mice treated with various inducers, followed by a high dose of pazopanib.  
From left to right: Human liver microsomes (HLM), h3A4/3A7/hCAR/hPXR 60 mg/kg 
rifampicin for 3 days (i.p), h3A4/3A7/hCAR/hPXR 60 mg/kg rifampicin for 3 days (i.p) plus 200 
mg/kg pazopanib (p.o.) on day 4, hCAR/hPXR 60 mg/kg rifampicin (i.p.) for 3 days, hCAR/hPXR 
60 mg/kg rifampicin (i.p.) for 3 days plus 200 mg/kg pazopanib (p.o.) on day 4, h3A4/3A7 60 
mg/kg rifampicin (i.p) 3 days, h3A4/3A7 60/mg/kg rifampicin (i.p.) for 3 days plus 200 mg/kg 
pazopanib (i.p) on day 4. Animals not receiving pazopanib on day 4, received an equivalent 
dose of vehicle, based on body weight. Western blotting was carried out on a pool of human 
liver microsomes, or a pool of mouse liver microsomes (n=3 mice per lane).  
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Treatment 
Half Life 
(Mins) 
Cmax  
(µg/ml) 
AUClast 
(min*µg/ml) 
AUCinfin 
(min*µg/ml) 
Clearance  
(ml/min/kg) 
Corn Oil 452.1 ± 
97.6 
41.6 ± 20.1 29607.8 ± 
12960.3 
29978.3 ± 
14087.4 
8.5 ± 5.3 
Ketoconazole 504.8 ± 122 124.7 ± 
36.3 (***) 
84109.9 ± 
16083.5 
94813 ± 21732.4 2.2 ± 0.6 (*) 
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c)                                                                         
 
d) 
 
 
Figure 4.15. Ketoconazole significantly alters the pharmacokinetics of pazopanib 
in h3A4/3A7/hCAR/hPXR mice but has no effect on ALT levels or liver size. 
a) Pharmacokinetic profile from h3A4/3A7/hCAR/hPXR mice induced with 60 mg/kg rifampicin 
(i.p) for 3 days and administered with 200 mg/kg pazopanib (p.o.). One set of mice were pre-
treated with 100 mg/kg ketoconazole (p.o.) 30 min prior to pazopanib dosing, control mice 
received corn oil, n=6. Values expressed mean ± SEM b) Pharmacokinetic parameters from a) 
*** Cmax, AUC, and AUC infin. * Clearance. Corn oil half-life, AUC infin, and clearance n=4, due 
to ill-fitting parameters from two animals, which could not be calculated. All other values n=6 
c) No significant differences exist between liver to body weight ratios of ketoconazole treated 
and control mice, n=6 d) No significant differences exist between plasma ALT in ketoconazole 
treated and control mice, n=3. Values expressed ± SD. 
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a)                                                                               
      
 b) 
                 
 
Figure 4.16. Vacuolaton persists in liver sections from ketoconazole and 
pazopanib treated h3A4/3A7/hCAR/hPXR mice. 
a) h3A4/3A7/hCAR/hPXR mice treated with rifampicin at 60 mg/kg (i.p.) for 3 days 
followed by 200 mg/kg pazopanib (p.o.) exhibited the mottled phenotype b) mice 
induced with rifampicin and received ketoconazole at 200 mg/kg (p.o.) 30 min prior to 
the administration of pazopanib at 200 mg/kg (p.o.) also exhibited this phenotype 30 hr 
after pazopanib dosing. Arrows indicate vacoulation. Photomicrographs representative 
of n=2, magnification x20.  
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Given that this phenotype was reproducible, and its cause remained undefined, new 
sections were cut and stained with H&E for microscopy at a magnification of x100 in 
an effort to identify the structure of these lipid-like vacuoles. Interestingly, under high 
magnification it can be seen that these ‘vacuoles’ appear to be holes in the tissue as 
seen in Figure 4.11. Upon examination, the cells appear to be undergoing a 
degenerative process which includes the swelling and eventual collapse of the 
nucleus along with destruction of the cytoplasm. Interestingly, this phenotype was 
not as pronounced in h3A4/3A7/hCAR/hPXR mice which received pazopanib alone as 
it is in h3A4/3A7/hCAR/hPXR mice which were induced with rifampicin and also 
treated with pazopanib. The phenotype was never found in wild-type animals with 
any treatment combination. This suggests that rifampicin has a role in the 
development of this phenotype, but only in the humanised model. As the phenotype 
persists in humanised mice co-treated with ketoconazole, and therefore the effect is 
unlikely to be due to the humanisation of CYP3A4/3A7, rifampicin may be acting 
through human PXR on a non-CYP target to elicit this response.  
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4.7 Discussion 
4.7.1 Summary 
The data in this chapter describe a species difference in the pharmacokinetic profiles 
of pazopanib in vivo in wild-type and humanised mice. Furthermore, a difference in 
sensitivity to the toxic effects of pazopanib in the presence and absence of enzyme 
induction in these animals is explored.  
 
4.7.2 Species Variation in the Pharmacokinetics of Pazopanib 
In vitro data obtained from microsomal and recombinant CYP450 incubations 
described in Chapter 3 shows that murine enzymes are less efficient at metabolising 
pazopanib compared to human P450 enzymes. A dose of 20 mg/kg pazopanib was 
selected for pharmacokinetic studies based on the efficacy this dosed elicited in 
human xenografts of a variety of cancers as reported by Kumar et al. This study 
reported an efficacious plasma concentration of pazopanib in tumour bearing mice 
of 40 µM. The maximum plasma concentrations observed in the pharmacokinetic 
experiments detailed in this chapter range between 27 and 45 µM (Kumar, Knick et 
al. 2007).  
It is apparent from pharmacokinetic studies in Cyp3a cluster knockout animals that 
Cyp3a has a negligible role in pazopanib metabolism in vivo, with no significant 
differences in pharmacokinetic parameters observed between the wild-type and 
Cyp3a cluster knockout animals. Further investigations using the HRN model indicate 
that the murine hepatic P450 system is not implicated in pazopanib metabolism, with 
a negligible shift occurring between the wild-type and HRN animals. Given the in vitro 
evidence suggesting that the human enzymes are more efficient at metabolising 
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pazopanib than the mouse, the humanised 3A4/3A7 and humanised 
3A4/3A7/hCAR/hPXR animals were employed in order to assess whether this 
observation was reflected in vivo. These animals were induced as described in the 
Methods prior to administration of pazopanib. All inductions included a 
corresponding wild-type control. In keeping with the hypothesis that wild-type 
animals do not significantly metabolise pazopanib, neither PCN or rifampicin 
induction altered the pharmacokinetic parameters of pazopanib in the wild-type 
control group, despite induction of Cyp3a in the PCN treated animals, as shown by 
Western Blot. The humanised 3A4/3A7 mice show a non-significant decrease in the 
maximum plasma concentration and area under the curve, as well as a non-significant 
elevation in the rate of clearance. Despite being statistically insignificant, the trend 
seen in these mice suggests that the presence of human CYP3A4, induced with PCN, 
may play a minor role in the metabolism of pazopanib in these animals. It would be 
of interest to repeat this study and extend the induction protocol from two to three 
days to ascertain whether or not the induction of the transgene can be increased and 
significant changes in the pharmacokinetic parameters elicited.  This experiment was 
repeated in the h3A4/3A7/hCAR/hPXR mouse line. Humanisation of animals for 
CYP3A4, and the nuclear receptors CAR and PXR, elicited a profound shift in the 
pharmacokinetic profile of pazopanib with a statistically significant decrease in half-
life and area under the curve, and an increase in the rate of clearance, suggesting 
that the human CYP3A4 enzyme is significantly better at metabolising pazopanib than 
the mouse Cyp3a isoform, in the presence of the humanised nuclear receptors. Taken 
together these data suggest that while CYP3A4 is likely to contribute towards 
pazopanib metabolism when maximally induced in these mice, the nuclear receptors 
CAR and PXR may also be implicated.  
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4.7.3 Pazopanib and Pharmacogenomics  
Pazopanib monotherapy outcome varies significantly between patients and little is 
known about mechanisms by which pazopanib therapy fails in certain individuals. In 
2011, a study by Xu et al. presented evidence for genetic biomarkers which were 
predictive of positive pazopanib outcome. The study analysed 27 functional 
polymorphisms in 13 genes associated with angiogenesis or exposure and 
metabolism of pazopanib in 397 renal cell carcinoma patients (Xu, Bing et al. 2011) 
The genotypes were correlated with progression-free survival (PFS) and objective 
response rate (RR) in patients receiving either 800 mg/day pazopanib, or placebo. 
The study identified 3 polymorphisms in genes coding for interleukin 8 (IL-8) and 
hypoxia inducible factor 1 alpha (HIF1α) which were significantly correlated with 
progression-free survival, as well as 5 polymorphisms in HIF1α, PXR (nuclear receptor 
1/ 2) and vascular endothelial growth factor A (VEGFA) which were significantly 
associated with positive RR (Xu, Bing et al. 2011). Given that our model is humanised 
for PXR, it was of interest to assess whether or not our mouse model reflected in vitro 
pazopanib-induced PXR activation described by the FDA. The data shown in this 
chapter demonstrate that pazopanib is able to activate PXR in an in vitro human 
hepatoma cell assay, which is in keeping with the literature. Chronic dosing of wild-
type animals with 200 mg/kg pazopanib (p.o.) for 4 days, leads to a modest induction 
of hepatic Cyp3a in these animals. This would be expected as pazopanib is a PXR 
substrate, and the activation of PXR leads to an up-regulation of its target genes, 
including Cyp3a. Interestingly, these results are not reflected in the humanised PXR 
animals given the same treatment. It is worthy of note however, that these animals 
show higher basal levels of Cyp3a in the liver than the wild-type animals, and this may 
limit the inducibility of P450s in these animals.  
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4.7.4 Pazopanib-Induced Hepatic Failure in Humans 
Pazopanib-induced liver failure occurs in approximately 0.2 % of patients receiving 
the drug. Fatal hepatotoxicity is associated with elevations of ALT and total bilirubin 
levels; however, overall elevations in ALT and total bilirubin have been observed in 
53 % and 36 % of patients enrolled in clinical trials, respectively.  Specific risk factors 
pertaining to fatal hepatotoxicity have not been identified (Keisner and Shah 2011). 
A recent report by Klempner et al. presented two case studies of patients who had 
succumbed to pazopanib-induced liver failure with accompanying biopsy 
information. Neither patient exhibited any underlying chronic liver pathology prior 
commencing pazopanib treatment. Both patients experienced grade 3 elevations in 
ALT levels by 6 weeks of pazopanib treatment, and underwent a core-biopsy at weeks 
7-8. Both patients were described as exhibiting mild cholestatic hepatitis with 
inflammation surrounding portal tracts (Klempner, Choueiri et al. 2012).   
 
A further aim of this research was to investigate potential differences in hepatic 
toxicity of pazopanib in wild-type and humanised mouse models. This was of 
particular interest as there is no published evidence of hepatic toxicity in pre-clinical 
studies using mice. The selection of the humanised 3A4/3A7/hCAR/hPXR model for 
these studies was made as these mice showed a significant shift in pharmacokinetic 
parameters when induced, and it is yet unknown whether the toxicity associated with 
pazopanib therapy is due to the parent compound, or a metabolite.  
Livers from humanised 3A4/3A7/hCAR/hPXR animals induced with rifampicin and 
dosed with a high dose of pazopanib as described in Section 4.6.9, exhibited an 
enlarged, mottled liver phenotype at the time of harvest, which was not present in 
the wild-type animals. Sections taken from these livers showed extensive lipid-like 
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vacuolation when stained with haemotoxylin and eosin; however, histological stains 
for lipids and glycogen were negative, and confirmed by a pathologist. At a higher 
magnification (x 100), an unusual apoptosis-like phenotype was identified in which 
the nuclei in the phenotypic liver sections appear to become enlarged and collapse. 
This appears to be accompanied by the destruction of the surrounding cytoplasm. It 
can be concluded from these sections that the vacuole-like structures seen at lower 
magnifications are in fact ‘vacant’ areas in the section where cells have died. Mouse 
studies using rifampicin at doses of 100 mg/kg have been described and no liver 
damage has been reported when given as a monotherapy. However, in a study by 
Chowdhury et al. a combination therapy of isoniazid and rifampicin elicited a 
hepatotoxic effect through apoptosis in wild-type BALB/c mice, however neither drug 
was toxic when given alone. This suggests that there may be a cumulative effect of 
combinational therapy on liver toxicity using rifampicin (Chowdhury, Santra et al. 
2006). Interestingly, the high dosing studies detailed in this chapter do not describe 
any liver abnormalities in wild-type mice given any treatment combination, although 
the humanised 3A4/3A7/hCAR/hPXR mice, when treated with rifampicin and 
pazopanib together, do show an abnormal liver phenotype.  
 
4.7.5 CYP3A4 Activity and Pazopanib-Induced Liver Injury 
Given that the humanised 3A4/3A7/hCAR/hPXR mouse is a multiple-humanised line, 
there are several aspects of this model that could be responsible for the development 
of this phenotype, be it the humanisation of CYP3A4/CYP3A7, or one or both of the 
nuclear receptors. In order to assess the role of CYP3A4 in the development of this 
phenotype, a pharmacological approach was adopted in which ketoconazole was co-
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administered alongside rifampicin and pazopanib. Ketoconazole is a potent inhibitor 
of CYP3A, and exerts this inhibition by antagonising the nuclear receptors CAR and 
PXR, as well as the farnesol X receptor (Huang, Wang et al. 2007).  
The dose of 100 mg/kg ketoconazole has been shown to abolish acetaminophen-
induced hepatotoxicity in mice; however the mechanisms by with this occurs have 
only been speculated (Culo, Renic et al. 1995). The experiments presented in Chapter 
4, however show a persistent liver phenotype in mice co-dosed with ketoconazole, 
suggesting that CYP3A4 is not the causative factor of this liver phenotype.  
 
4.7.6 PXR and CAR in Liver Injury 
The apparent lack of involvement of CYP3A4 suggests that the phenotype observed 
may be a result of the humanisation of PXR or CAR in this model, however, there is 
extensive evidence in the literature supporting the hypothesis that PXR is 
hepatoprotective against drug induced liver injury and inflammatory liver disease.  
A study by Daly et. al. in 2010 presented evidence that patients possessing a SNP 
variant of PXR and as a consequence, lower levels of expression may be more 
susceptible to liver injury caused by flucloxacillin treatment. Patients expressing the 
PXR variant ‘rs3814055; C-25385T’ accumulated higher levels of drug in the liver, 
leading the formation of flucloxacillin, which in turn can result in an immune response 
leading to liver damage (Andrews, Armstrong et al. 2010).  
There is little information in the literature regarding the role of CAR in human 
hepatoprotection, however several mouse studies suggest a role for CAR in the 
protection against bile acid toxicity. A study by Guo et al. showed that mice knocked 
out for both PXR and FXR (both bile acid sensing nuclear receptors), showed high 
levels of liver damage when fed a diet containing 1 % cholic acid. This toxicity was 
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shown to be ablated by pre-treatment of the mice with CAR activators phenobarbital 
(PB) or TCPOBOP. Pre-treatment of the animals with CAR activators caused a marked 
reduction in bile acid and bilirubin in the PXR/FXR knock-out mice, suggesting a 
protective roll for CAR in bile acid toxicity (Guo, Lambert et al. 2003). 
 
    
 
 
Chapter 5 
Syngeneic Tumour Cell Lines and Xenograft Studies
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5.1 Introduction  
In many xenograft studies, cell lines are selected based on a particular genotype, 
tumour type, or mutation. In this way it is possible to generate mouse models of 
specific human cancers in immunocompromised mice with which to test tailored 
chemotherapeutic regimens. Immunocompromised mice remain a useful model for 
investigating the growth patterns of human- derived tumours, as well as the efficacy 
of new drugs against such tumours in mice. As discussed in Section 1.12.2 
immunocompromised mice have several limitations in terms of accurately reflecting 
human disease, including the lack of a functional immune system, and differences in 
the expression and activity of cytochrome P450 enzymes, among others.  
 
 5.1.1 Discrepancies between Murine and Human Responses to 
Chemotherapy 
It is not uncommon for anti-cancer therapies to elicit highly effective anti-cancer 
results in transplanted human xenografts in nude and scid mice; however these 
promising pre-clinical results are often followed by failure of the drug in question in 
clinical trials (Kerbel 2003). A study in 1989 by Giovanella et al. demonstrated the 
impressive, curative potential of the synthetic camptothecin analog, 9-AC in nude 
mice bearing human colon cancer xenografts (Giovanella, Stehlin et al. 1989). Later 
studies demonstrated its effectiveness against human melanoma xenografts 
(Pantazis, Hinz et al. 1992), and human ovarian carcinoma xenografts (Pantazis, 
Kozielski et al. 1993).  Despite the extensive efficacy of 9-AC in nude mice against 
several human tumour types, its limited efficacy in humans led to the development 
of 9-AC to be halted in 1999 (Takimoto 2001). In 2001, Kirstein et al. analysed the 
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pharmacokinetics of 9-AC in paediatric solid tumour xenografts under several dosing 
schedules, and found that exposure of 9-AC required for maximal anti-cancer activity 
in the mice exceeded the maximum tolerated exposure in patients (Kirstein, 
Houghton et al. 2001). While xenografts in immunocompromised mice remain an 
essential tool for drug development, it is understandable that variations in outcome 
between xenograft models and human trials have led to scepticism among some 
researchers. This has led to the development of genetically engineered and 
humanised mouse models, which may better reflect the human outcome of future 
pre-clinical trials. Several mouse models may be employed in a study to allow a more 
detailed insight into the effects of the immune system, microenvironment 
interactions and genetics on drug pharmacokinetics and efficacy (Richmond and Su 
2008).  
 
5.1.2 Allosteric and Xenograft Tumour Growth Studies 
A study by Wood et al. in 2000 described the pharmacological properties of an 
emerging tyrosine kinase inhibitor PTK787/ZK 222584 (vatalanib) in nude and wild-
type mice. The study showed vatalanib caused a significant growth inhibition of 
human tumours; A-431 epidermoid carcinoma, Ls174T and HT-29 colon carcinomas 
and PC-3, DU145 and CWR-22 prostate carcinomas grown subcutaneously in nude 
mice. The study also utilised a syngeneic orthotopic renal cell carcinoma cell line 
(RENCA) in immune competent mice. Vatalanib was found to significantly reduce the 
rate of growth of primary tumours, as well as the incidences of metastases into the 
lymph nodes and lung. Furthermore, histolological analysis revealed a significant 
reduction in microvessel formation in primary and secondary tumours in mice treated 
with valatanib (Wood, Bold et al. 2000). Given the similar modes of action of valatanib 
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and pazopanib, it is reasonable to assume that pazopanib would be efficacious 
against syngeneic tumour growth in vivo.   
5.1.3 Efficacy of Pazopanib in Tumour Growth Studies 
A later study by Kumar et al. in 2007 described the efficacy of pazopanib against a 
range of human xenografts in scid mice. The study showed pazopanib to be 
efficacious against HT29 colon, A375P melanoma, PC3 prostate, Caki-2 renal, BT474 
breast and H322 lung tumour xenografts, at doses as low as 20 mg/day (p.o). While 
Pazopanib is licensed for the treatment for the treatment of renal cell carcinoma, 
data presented in this study suggest that it has a broad anti-cancer effect in vivo 
against a variety of tumour types (Kumar, Knick et al. 2007).  
The work described in this chapter attempts to assess, for the first time, whether or 
not pazopanib is efficacious against syngeneic, mouse- derived tumours in humanised 
mice, and whether or not the presence of the human transgene affected the efficacy 
of pazopanib compared to wild-type mice. While a renal cell carcinoma cell line would 
have been the primary choice for such studies, a murine renal cell carcinoma cell line 
was not available for use. The cells chosen were based upon successful pilot studies 
performed by Lesley McLaughlin (Molecular Pharmacology Group, Medical Research 
Institute, Ninewells Hospital and Medical School). CMT 93 cells are a mouse- derived 
colorectal tumour cell line, while B16 cells are a murine melanoma cell line.  
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5.2 Results 
5.2.1 Validation of Syngeneic Cell Lines CMT 93 and B16 
One aim of this research is to investigate variations in efficacy of pazopanib against 
tumours in vivo, in h3A4/3A7/hCAR/hPXR and wild-type mice. Pazopanib is an anti-
angiogenic compound, and therefore elicits little cell death in vitro. Cytotoxicity data 
are displayed in Figure 5.1.  
 
One further consideration when performing xenograft studies in humanised mice is 
the duration of transgene induction. For short term induction in pharmacokinetic 
studies as described earlier, rifampicin and PCN are effective inducing agents. These 
treatments are, however, short acting and the level of induction declines over 
approximately 72 h. Western blots carried out by Dr Zoe Riches (Molecular 
Pharmacology Group, Medical Research Institute, Ninewells Hospital and Medical 
School) are displayed in Figure 5.2.a. These Western blots show that the induction of 
Cyp3a/CYP3A4 in wild-type and humanised 3A4/3A7/hCAR/hPXR mice induced with 
either 10 mg/kg, or 60 mg/kg rifampicin (i.p.) for 3 days declines after 48 h after the 
last dose. Establishing an effective dosing regimen to maintain the expression of the 
transgene would require complex investigation and a great number of animals. It was 
therefore of interest to identify an inducing agent which would maintain a suitable 
level of induction of Cyp3a/CYP3A4 for a long-term protocol. Aroclor 1254 is a 
polychlorinated biphenyl mixture that was originally developed for industrial uses, 
including the manufacturing of plastics and inks, for use in capacitors, and the 
production of heat exchange and hydraulic fluids  (Mayes, McConnell et al. 1998). 
Additionally, Aroclor 1254 has been shown to be a potent inducer of hepatic 
cytochrome P450s in mammals (Matthews, Fries et al. 1978). Its high lipophillicity 
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means that Aroclor 1254 is an extremely long-acting drug, and maintains CYP 
induction for extended time periods (Chen, Chen et al. 2003). Blots performed by Dr 
Zoe Riches (Molecular Pharmacology Group, Medical Research Institute, Ninewells 
Hospital and Medical School) confirmed that Aroclor 1254 at a dose of 500 mg/kg was 
sufficient to induce hepatic Cyp3a in wild type mice after 7 days (Figure 5.2-b). With 
evidence showing that it is possible to induce Cyp3a in wild-type animals using 500 
mg/kg Aroclor 1254 i.p. an induction study was performed in h3A4/h3A7/hCAR/hPXR 
mice. H3A4/3A7/hCAR/hPXR mice were treated with Aroclor 1254 at 500 mg/kg i.p. 
or corn oil as a control, and culled at a series of timepoints over a period of 4 weeks. 
The livers were harvested and microsomes prepared as previously described. The 
data are displayed in Figure 5.2-c. and show a robust induction that persists over the 
4 week period.  
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a) 
 
b) 
     
c) 
 
 
Figure 5.1. In Vitro Experiments to determine pazopanib efficacy against CMT 
93 and B16 cells.  
a) Pazopanib does not cause cytotoxic cell death in CMT 93 cells, or in B16 Melanoma cells 
(b), while bortezomib (c), a proteasome inhibitor and cytotoxic agent, kills efficiently in 
vitro in CMT 93 cells. Values expressed ± SD. 
 
 
 
0
50
100
150
200
%
 C
e
ll 
Su
rv
iv
al
[Pazopanib] (µM)
0
50
100
150
%
 C
e
ll 
Su
rv
iv
al
[Pazopanib] (µM)
0
50
100
150
%
 C
e
ll 
Su
rv
iv
al
[Bortezomib] (µM)
 157    
 
 
 
a)  
 
 
b) 
 
c) 
 
 
Figure 5.2. Western blots showing induction of Cyp3a/CYP3A using rifampicin 
and Aroclor 1254 
a) Rifampicin induction of CYP3A/Cyp3a is diminished after 48 hours b) Aroclor 1254 induces 
Cyp3a in wild-type mice (7 days following injection) ‘-‘ indicates control treated animals, ‘+’ 
indicates Aroclor 1254-treated animals. Calreticulin as a loading control c) Aroclor 1254 
induced CYP3A in h3A4/3A7/hCAR/hPXR mice over a 4 week time course. Animals received 
a single dose of Aroclor (500 mg/kg, i.p), and livers were harvested weekly thereafter. n ≥ 2 
animals per lane.  
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5.2.2 CMT 93 Pilot Study 
Despite previous success in growing these cells in vivo, only 2 of 38 mice included in 
the study showed any signs of tumour development on one flank, for reasons that 
remain unclear. Possible explanations to account for the lack of growth include the 
passage number of the cells (17), or the length of time they had been in storage since 
their first use. Another potential contributory factor was the age of the mice used, 
which differed between groups and genotypes from approximately 10 weeks, to 3 
months old.  
5.2.3 Investigation into the Utility of the B16 Melanoma Cell Line; Growth 
Curves 
B16 Cells are a mouse-derived melanoma cell line. These cells were injected 
subcutaneously in the same fashion as the CMT93 cells as previously described. Wild-
type and h3A4/3A7/hCAR/hPXR mice were divided into Aroclor 1254-induced, and 
un-induced cohorts.  The tumours developed in all mice included in the study, with 
38 out of 39 mice developing tumours in both flanks. Given the aggressive nature of 
these cells, and the rapidity at which the tumours developed, mice were weighed and 
dosed, and tumours were measured daily to monitor changes. The data are displayed 
in Figure 5.3. Tumour growth was reasonably consistent among all the cohorts of 
mice. Average survival post inoculum differed between groups however, and data are 
displayed in Figure 5.3. It can be seen that in both wild-type and 
h3A4/3A7/hCAR/hPXR animals pre-treated with corn oil, pazopanib significantly 
improves survival compared to vehicle-treated animals. Interestingly, pre-treatment 
of wild-type mice with Aroclor 1254 causes a significant reduction in overall survival 
time compared to uninduced animals. Pre-treatment of h3A4/3A7/hCAR/hPXR 
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animals with Aroclor 1254 also reduces overall survival compared to corn oil treated 
animals; however this is not statistically significant. It would have been expected that 
pre-treatment of h3A4/3A7/hCAR/hPXR mice with Aroclor 1254 would have 
significantly increased the rate of growth of tumours, and decreased the overall 
survival rate of these animals due to the increased metabolism of pazopanib by the 
induced CYP3A4, and subsequent decrease in exposure to the parent drug. It is 
possible that while inducing CYP3A4 using Aroclor 1254, the induction may not be 
great enough to alter the pharmacokinetics of pazopanib to the degree to which 
efficacy would be affected. Data presented in Chapter 4, Figure 4.5 and Table 4.1, 
show a significant decrease in exposure of h3A4/3A7/hCAR/hPXR animals to 
pazopanib when induced with rifampicin compared to control animals pre-treated 
with corn oil (4484 ± 1213 vs 11704 ± 3149 min*µg/ml respectively). It may be that 
while Aroclor 1254 does induce CYP3A4 to a similar extent as rifampicin, the 
induction may not be sufficient to affect the efficacy of pazopanib in vivo. It would be 
necessary to carry out a pazopanib pharmacokinetic study using both inducing agents 
in two cohorts of mice in order to compare the exposure seen using both agents.   
a) 
 
Wild-type animals treated with corn oil and vehicle (blue), or corn oil and pazopanib 
(red).  
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b) 
  
Wild-type animals treated with Aroclor 1254 and vehicle (blue), or Aroclor 1254 
and pazopanib (red).  
c) 
                 
h3A4/3A7/hCAR/hPXR animals treated with corn oil and vehicle (blue), or corn oil 
and pazopanib (red).  
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d)  
 
h3A4/3A7/hCAR/hPXR animals treated with Aroclor 1254 and vehicle (blue), or 
Aroclor 1254 and pazopanib (red).  
 
e) 
 
h3A4/3A7/hCAR/hPXR animals treated with corn oil and pazopanib (blue), or Aroclor 
1254 and pazopanib.  
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f) 
 
h3A4/3A7/hCAR/hPXR animals treated with Aroclor 1254 and pazopanib (blue), or, 
wild-type animals treated with Aroclor 1254 and pazopanib (red).  
 
Figure 5.3. Tumour growth curves showing the growth of B16 melanoma 
tumours in wild-type and h3A4/3A7/hCAR/hPXR mice 
Mice were pre-treated with either corn oil or Aroclor 1254, and dosed with vehicle or 
pazopanib. Data points show the mean tumour burden of both flanks across the entire cohort 
of mice. N=5 mice in all groups except h3A4/3A7/hCAR/hPXR pre-treated with corn oil and 
dosed with vehicle in which one mouse died prior to commencement of the experiment, 
giving a group n=4. Values expressed ± SD. 
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Mouse Genotype and Treatment Maximum Survival Post-
Injection (days) 
Wild-type corn oil and vehicle 12.4         ±     2.5 
Wild-type corn oil and pazopanib 20.2         ±     3 
Wild-type Aroclor 1254 and vehicle 10.2         ±     5.7 
Wild-type Aroclor 1254 and pazopanib 15            ±     3 
h3A4/3A7/hCAR/hPXR corn oil and vehicle 13.3         ±     2.5 
h3A4/3A7/hCAR/hPXR corn oil and pazopanib 20            ±     3 
h3A4/3A7/hCAR/hPXR Aroclor 1254 and vehicle 15.8         ±     3.3 
h3A4/3A7/hCAR/hPXR Aroclor 1254 and pazopanib 16.2         ±     2.4 
Figure 5.4 Graph and table showing the average survival of mouse groups 
following the appearance of tumours in one or both flanks, and the 
commencement of treatment  
WT corn oil and pazopanib vs WT corn oil and vehicle = * P<0.05, hhh corn oil and pazopanib 
vs WT corn oil and vehicle= * P<0.05, WT corn oil pazopanib vs WT Aroclor 1254 and vehicle= 
** P< 0.01, hhh corn oil and pazopanib vs WT Aroclor 1254 and vehicle= ** P < 0.01. Values 
expressed ± SD. 
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5.2.4. Rate of B16 Tumour Growth from Normalised Data 
Data obtained from the tumour growth curves were normalised by subtracting the 
initial GMD measurement from subsequent GMD measurements, i.e. the first 
measurable tumour GMD is considered the first measurement, and all subsequent 
measurements on following days have the first measurement subtracted from them. 
This provides a more linear plot in the early stages of growth until the growth rate 
increases or tumours become static. The linear sections of the normalised graphs are 
displayed in Figure 5.5. By normalising the data and obtaining the linear section of 
the growth curve, it is possible to calculate the initial rate of tumour growth per day 
by selecting a linear section of the plot and dividing the latest measurement by the 
earliest measurement, divided by the number of days elapsed. The mean initial 
growth rates of the tumours are detailed in Table 5.1. Statistical analysis was 
performed by means of a paired t-test.  
 
a) 
 
Wild-type animals treated with corn oil and vehicle (blue), or, corn oil and pazopanib 
(red). *, P< 0.05.  
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b) 
 
Wild-type animals treated with Aroclor 1254 and vehicle (blue), or, Aroclor 1254 and 
pazopanib (red).  **, P<0.01 
 
c) 
 
h3A4/3A7/hCAR/hPXR animals treated with corn oil and vehicle (blue), or, corn oil and 
pazopanib (red). No statistically significant difference was observed.  
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d) 
 
h3A4/3A7/hCAR/hPXR animals treated with Aroclor 1254 and vehicle (blue), or, 
Aroclor 1254 and pazopanib (red). No statistically significant difference was observed. 
 
e) 
 
h3A4/3A7/hCAR/hPXR animals treated with Aroclor 1254 and pazopanib (blue), or, 
corn oil and pazopanib (red). No statistically significant difference was observed.  
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f) 
 
Wild-type animals treated with Aroclor 1254 and pazopanib (blue), or, 
h3A4/3A7/hCAR/hPXR animals treated with Aroclor 1254 and pazopanib (red).     **, 
P < 0.01. 
  
Figure 5.5. Graphs showing normalised linear growth rate curves of B16 
melanoma tumour in wild-type and h3A4/3A7/hCAR/hPXR mice pre-treated 
with either corn oil or Aroclor 1254, and dosed with vehicle or pazopanib.  
Data points show the mean tumour burden of both flanks across the entire cohort of mice. 
Data was normalised by subtracting the first GMD measurement from subsequent 
measurements. N=5 mice in all groups except h3A4/3A7/hCAR/hPXR pre-treated with corn 
oil and dosed with vehicle in which one mouse died prior to commencement of the 
experiment, giving a group n=4. Values expressed ± SD. 
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Mouse Genotype and Treatment Rate of Initial Growth 
(mm2) / day 
Wild-type corn oil and vehicle 7.8 
Wild-type corn oil and pazopanib 3.35 
Wild-type Aroclor 1254 and vehicle 1.9 
Wild-type Aroclor 1254 and pazopanib 0.6 
h3A4/3A7/hCAR/hPXR corn oil and vehicle 1.2 
h3A4/3A7/hCAR/hPXR corn oil and pazopanib 0.3 
h3A4/3A7/hCAR/hPXR Aroclor 1254 and vehicle 0.8 
h3A4/3A7/hCAR/hPXR Aroclor 1254 and pazopanib 1.49 
 
Table 5.1. Mean initial tumour growth rates in mouse treatment groups 
 
Figure 5.6. Liver to body weight ratios of wild-type and h3A4/3A7/hCAR/hPXR 
mice treated with corn oil or Aroclor 1254 and vehicle  
Aroclor 1254-induced wild-type mice show enlarged livers compared to un-induced mice of 
the same genotype. **, P<0.01. Values expressed ± SD. 
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5.3 Discussion 
5. 3.1 Summary 
Data in this chapter describe the use of the polychlorinated biphenyl mixture, Aroclor 
1254 as an effective long term enzyme inducing agent in mice compared to a single 
dose of rifampicin. A single dose of Aroclor 1254 in humanised 3A4/3A7/hCAR/hPXR 
mice lasts a minimum of 4 weeks, compared to rifampicin, which lasts approximately 
48 hours. Furthermore, this chapter investigates the efficacy of pazopanib against 
syngeneic B16 melanoma tumours in vivo, in wild-type and humanised 
3A4/3A7/hCAR/hPXR. Pazopanib significantly improved the survival of both 
genotypes following tumour implantation compared to vehicle treated animals. 
Interestingly, induction of cytochrome P450s by Aroclor 1254 did not have a radical 
effect on initial tumour growth rate, or survival.  
 
5.3.2 Induction of Hepatic P450s by Aroclor 1254 
Data described in this chapter show that a single dose of Aroclor 1254 (500 mg/kg, 
i.p) is sufficient to induce hepatic P450s in mice for a minimum of 4 weeks. This is 
consistent with several published studies in rodents, which have shown significant 
induction of cytochromes P450 in rodent liver following exposure to Aroclor 1254 
(Easterbrook, Fackett et al. 2001). It is clear that Aroclor 1254 is a useful compound 
for studies requiring long term induction of the cytochromes P450; however, Aroclor 
1254 is harmful and has been shown to have hepatotoxic effects. A study by Mayes 
e al. described a 24 month study, in which male and female Sprague-Dawley rats were 
exposed daily to various doses of Aroclor 1254 in the rat chow. Upon completion of 
the study, animals were killed and tissues harvested for analysis. Key findings outlined 
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in this study were elevated serum enzyme levels (AST and ALT), enlargement of the 
liver, hepatocellular hypertrophy, general discolouration of the liver, and an 
increased incidence of hepatocellular lesions and neoplasms. The frequency and 
severity of these abnormalities were dose-dependent and generally more common 
in females than in males (Mayes, McConnell et al. 1998).  
While mice treated with Aroclor 1254 in the tumorigenesis study detailed in this 
chapter did not exhibit the mottled phenotype that was observed following 
rifampicin treatment described in Chapter 4, the livers were generally larger than 
corn oil treated animals at the time of harvest as can be seen in Figure 5.5. It would 
be of interest to stain liver sections of Aroclor 1254- and rifampicin-treated animals 
to identify any differences in liver morphology. Aroclor 1254 is a ‘dirty’ compound, 
and impacts on many different enzymes and pathways. Microarrays have been 
shown to be a highly sensitive technique for assessing chemical toxicity of drugs. They 
can be used to generate and characterise unique gene expression profiles for various 
drugs and models between which comparisons may be made between transcriptional 
expression of proteins associated with a particular toxic response. It would therefore 
be useful to perform microarray analysis on the livers and tumours of these induced 
and un-induced mice, to assess differences in gene expression. This is particularly 
important when considering an inducing agent such as Aroclor 1254 which has itself 
been shown to cause toxicity in both animals and humans, in combination with 
pazopanib, which also has the potential to elicit hepatotoxicity in man (Waring, 
Ciurlionis et al. 2001).  
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5.3.3 Pazopanib and B16 Melanoma Tumours 
B16 melanoma cells were selected from a collection of syngeneic tumour cell lines 
for these tumour growth studies, based on their successful growth during a small 
pilot study with several syngeneic cell lines.  
B16 melanoma tumours grow rapidly in vivo and must be monitored closely. These 
tumours are palpable typically between 5 and 10 days post implantation, and they 
have a propensity to develop ulcers which may bleed, and require the animal to be 
sacrificed (Overwijk and Restifo 2001). Angiogenesis is a hallmark of all solid cancers 
and is essential for primary tumour growth, metastasis and the growth of secondary 
tumours, and therefore it is reasonable to conclude that a drug capable of inhibiting 
angiogenesis may be useful in decreasing the rate of growth and metastasis of 
tumours (Ciardiello, Caputo et al. 2001).  
A study by Manning et al. investigated the effect of sunitinib, a tyrosine kinase 
inhibitor developed by Pfizer which exerts its anti-cancer effect in a similar manner 
to pazopanib, on the growth and vascularisation of B16 melanoma tumours in vivo. 
The study began administering sunitinib to mice between 11 and 15 days following 
implantation of the cells. Their results showed vessel density of B16 melanoma was 
significantly decreased after treatment with 40 mg/kg sunitinib for 4–5 days, and 
melanoma growth was significantly slower (Manning 2013). This result reflects well 
the findings presented in this Chapter, which show that pazopanib significantly slows 
the rate of growth of B16 melanoma tumours in wild-type mice, as well as 
significantly improving their overall survival time. While data described in Chapter 5 
does show tumour growth to slowing and beginning to plateau in mice receiving 
pazopanib, no tumour regression was observed. It is possible that tumour regression 
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may occur at higher daily doses of pazopanib, however, it is likely that toxicity issues 
would be encountered. Interestingly, the study by Manning et al, described the 
vascular heterogeneity of B16 melanoma tumours as being phenotypically zonal, with 
the peripheral tortuous zone vasculature proving sensitive to sunitinib 
chemotherapy, while the immediate sprouting vascular zone was refractory to 
sunitinib (Manning 2013). This may suggest that pazopanib, similarly to sunitinib is 
effective against one zone, and combination therapy of pazopanib and an adjuvant 
drug may elicit tumour regression in mice. Such a result may lead to better patient 
outcomes.  
A study by Podar et al, in 2006 demonstrated that combined treatment regimens of 
pazopanib, bortezomib, and melphalan induce synergistic cytotoxicity in a multiple 
myeloma cell- endothelial cell co-culture. Such in vitro multiple myeloma co-culture 
experiments have typically proven to be highly predictive of patient responses, and 
the data presented in this study strongly suggest a role of low-dose pazopanib in a 
combination therapy with other chemotherapeutic agents as a method of improving 
tolerability and efficacy of chemotherapy, as well as overcoming dose-limiting toxicity 
as drugs may be given at lower doses when combined with another 
chemotherapeutic agent (Podar, Tonon et al. 2006). Combination therapy has also 
been used effectively in vivo, with promising results for the treatment of ovarian 
cancer. Ovarian cancer is typically very difficult to treat as patients often present with 
late stage disease. Furthermore, the development of chemoresistance to initially 
successful chemotherapy is common. A study by Faratian et al. described the use of 
trastuzumab in combination with pertuzumab as a combination therapy in an SKOV3 
ovarian cancer xenograft model. While trastuzumab and pertuzumab slowed the 
growth of tumours when administered as a monotherapy, when given as a combined 
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therapy, complete regression of all tumours was observed. Not only was the 
combined therapy seen to be significantly more effective than either monotherapy, 
trastuzumab therapy was found to increase the sensitivity of these tumours to 
letrozole therapy. These findings have significant consequences for the design of 
personalised therapy for ovarian cancer patients, while also providing strong 
evidence for further investigations into combination therapies for a range of cancers  
(Faratian, Zweemer et al. 2011).  
 
5.3.4 Effects of Induction on Pazopanib Efficacy 
If human CYP3A4 was more heavily implicated in the metabolism of pazopanib 
compared with murine cyp3a, it would be expected that humanised 
3A4/3A7/hCAR/hPXR mice, induced with Aroclor 1254 and treated with pazopanib, 
would show more rapid tumour growth and decreased survival compared to un-
induced animals. It was hypothesised that the induction of the human CYP3A4 would 
cause pazopanib to be more rapidly metabolised than in un-induced animals, 
resulting in lower plasma concentrations of pazopanib. It can be seen in Figure 5.4 
that while overall survival of Aroclor 1254-induced humanised 3A4/3A7/hCAR/hPXR 
animals is shorter than un-induced animals, the difference is not quite significant. It 
may be the case that an additional dose of Aroclor 1254 may be required to maximise 
the induction of the CYP3A4 enzyme. Western Blots must be performed to assess the 
level of induction in these animals at the time of sacrifice. Furthermore, it can be seen 
in Figure 5.5 e. that Aroclor 1254 does not affect the initial rate of B16 melanoma 
tumour growth in humanised 3A4/3A7/hCAR/hPXR animals treated with pazopanib. 
The overall survival of wild-type mice was not expected to be altered by Aroclor 1254 
induction, as it was shown in Chapter 4 Figure 4.2, that hepatic P450s were not 
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implicated in the metabolism of pazopanib in wild-type mice. Aroclor 1254 induction 
did reduce the overall survival of wild-type mice (Figure 5.4), however this was not 
significant. These data taken together raise the question of the contribution of 
intestinal metabolism of pazopanib. Thus far, this research has focussed on hepatic 
metabolism of pazopanib, as the liver is the major site of pazopanib metabolism and 
toxicity in humans. It is however likely that metabolism may also take place in the 
intestine of the mouse. It would be useful to perform further pharmacokinetic studies 
with pazopanib in a gut P450 knock out model such as the IE-Cpr-null model described 
by Zhang et al. (Zhang, Fang et al. 2009) in order to compare the pharmacokinetic 
profile to that seen in the HRN mouse. 
 
     
 
 
Chapter 6 
Final Conclusions 
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6.1 Final Conclusions and Further Work 
This thesis attempted to investigate the activity of the novel tyrosine kinase inhibitor, 
pazopanib in vitro and in vivo in a panel of powerful humanised mice. Furthermore, 
the efficacy of pazopanib against syngeneic tumour cell lines in vivo was investigated.  
The research detailed in Chapter 3 is concerned with the in vitro metabolism of 
pazopanib in human liver microsomes, mouse liver microsomes and recombinant 
cytochrome P450 enzymes. Metabolism of pazopanib in a panel of human and mouse 
recombinant cytochrome P450 enzymes is in-keeping with the information presented 
by GSK, with CYP3A4 being the major contributor to pazopanib metabolism, with 
minor contributions from CYP2C8 and CYP1A2 (Agency 2013).  One enzyme that 
showed pazopanib metabolising capacity which is not identified as being implicated 
in vivo by GSK, was CYP-1A1. This seemingly anomalous result may be attributed to 
the artificial nature of the experimental conditions. Furthermore, Chapter 3 
demonstrated that humanised CYP3A4/3A7 mouse liver microsomes better reflect 
the metabolic capacity of human liver microsomes in vitro, suggesting that 
humanised mice may present a better model system for in vitro metabolic stability 
testing of emerging drugs compared to wild-type mice.  
The data described in Chapter 4 is concerned with the pharmacokinetics of pazopanib 
in humanised 3A4/3A7, h3A4/3A7/hCAR/hPXR, Cyp3a knock-out and hepatic 
reductase null mouse models. Interestingly, results show that Cyp3a, and indeed any 
murine hepatic Cyps are not significantly implicated in the metabolism of pazopanib 
in vivo. The pharmacokinetics of pazopanib is altered in humanised mice in which the 
human CYP3A4 and CYP3A7 enzymes are present and induced. This suggests that a 
species difference exists between wild-type and humanised mice with regards to 
pazopanib metabolism. These data are in agreement with the in vitro data in Chapter 
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3 which illustrated faster metabolism of pazopanib by human liver microsomes 
compared to wild-type mouse liver microsomes. Additionally, differences in liver 
phenotypes following treatment with rifampicin and administration of high dose 
pazopanib were observed between wild-type and h3A4/3A7/hCAR/hPXR animals, 
with wild-type mice showing no changes in liver morphology and humanised mice 
showing a mottled, enlarged liver phenotype. This phenotype persists in 
h3A4/3A7/hCAR/hPXR mice pre-treated with ketoconazole, suggesting that CYP3A4 
is not the causative factor. It would therefore be of interest to perform a microarray 
analysis on these livers to identify possible pathways involved in the development of 
this phenotype, and the mechanisms by which it arises.  
Chapter 5 outlined preliminary studies into the growth of syngeneic B16 melanoma 
tumours in wild type and humanised 3A4/3A7/hCAR/hPXR mice, and their response 
to pazopanib with and without induction of the cytochrome P450s by Aroclor 1254. 
This is the first time pazopanib has been utilised in humanised mice bearing syngeneic 
B16 melanoma tumours. The data show that both wild-type and humanised 
3A4/3A7/hCAR/hPXR show retarded tumour development when treated with 
pazopanib compared to control treated animals. It would be of interest to measure 
the plasma levels of pazopanib in tumour bearing animals to correlate any differences 
in steady state drug concentration with tumour response. Furthermore, high doses 
of pazopanib, administered over an extended period of time may have an effect on 
blood chemistry in these mice, which would be of interest to assess. Western blots 
on the liver microsomes and tumours harvested from these animals should be carried 
out to identify any differences in P450 expression between the treatment groups 
which again may be correlated with the efficacy of pazopanib between the wild-type 
and h3A4/3A7/hCAR/hPXR genotypes and treatments. This study involved repeated 
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high dosing of pazopanib or vehicle to induced and uninduced wild-type and 
h3A4/3A7/hCAR/hPXR animals. Sectioning of livers taken from these animals, 
coupled with micro-array analysis, may offer further insight into the origin of the 
abnormal liver phenotype described in Chapter 4.  Given that pazopanib is an 
angiogenesis inhibitor, it would be of great interest to section excised melanoma 
tumours to carry out CD31 staining for vasculature in order to ascertain the effect of 
pazopanib in the development of these tumours. 
This thesis is the first example of the utility of the humanised 3A4/3A7/hCAR/hPXR 
mouse as a pre-clinical model of human disease and drug metabolism. When 
compared to wild-type mice, the humanised 3A4/3A7/hCAR/hPXR mouse offers a 
better model of human metabolism of pazopanib in vitro and in vivo. The data 
described in this thesis provide compelling evidence which supports the use of 
humanised animal models in pre-clinical research, and may have significant 
implications in the fields of drug discovery, as well as personalised medicine and 
cancer modelling.  
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Appendix 1 
 
Enzyme Measured Assay 
Total P450 Omura and Sato 
OR Cytochrome c Reductase 
Cytochrome b5 Spectrophotometric 
CYP1A2 Phenacetin O-deethylase 
CYP2A6 Coumarin 7-hydroxylase 
CYP2B6 (S)-Mephynytoin N-Demethylase 
CYP2C8 Paclitaxel 6α-hydroxylase 
CYP2C9 Diclofenac 4’-hydroxylase 
CYP2C19 (S)-Mephenytoin 4’-hydroxylase 
CYP2D6 Bufuralol 1’-hydroxylase (the amount of 
activity inhibited by 1µM quinidine) 
CYP2E1 Chlorzoxazone 6-hydroxylase 
CYP3A4 Testosterone 6β-hydroxylase 
CYP4A11 Lauric acid 12-hydroxylase 
 
Table 6.1: P450 enzymes in human liver microsomes and the assays by which they are 
measured 
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Enzyme 
Measured 
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Total P450 400 
pmol/mg 
450 
pmol/mg 
210 
pmol/mg 
380 
pmol/mg 
96 
pmol/mg 
620 
pmol/mg 
OR 290 320 220 340 200 320 
Cytochrome 
b5 
260 
pmol/mg 
1100 
pmol/mg 
270 
pmol/mg 
700 
pmol/mg 
450 
pmol/mg 
690 
pmol/mg 
CYP1A2 880 640 150 340 570 430 
CYP2A6 1900 680 730 730 400 2100 
CYP2B6 110 67 60 50 15 60 
CYP2C8 310 240 97 110 100 230 
CYP2C9 3900 3300 3600 560 3600 3000 
CYP2C19 100 0 29 3 34 29 
CYP2D6 91 63 160 70 86 30 
CYP2E1 1700 3000 2700 3000 1700 940 
CYP3A4 13700 970 2100 6900 4100 16000 
CYP4A11 2100 980 2000 2100 2700 1300 
 
 
 
 
 
 
 
180 
 
 
Enzyme 
Measured 
Donor 7 Donor 8 Donor 9 Donor 10 Donor 
11 
Donor 12 
Total P450 360 
pmol/mg 
400 
pmol/mg 
440 
pmol/mg 
250 
pmol/mg 
170 
pmol/mg 
1200 
pmol/mg 
OR 280 130 290 270 96 260 
Cytochrome 
b5 
350 
pmol/mg 
740 
pmol/mg 
690 
pmol/mg 
430 
pmol/mg 
500 
pmol/mg 
1000 
pmol/mg 
CYP1A2 240 110 700 570 84 260 
CYP2A6 1500 1200 930 460 430 2100 
CYP2B6 58 69 59 21 ND 98 
CYP2C8 140 280 190 26 160 960 
CYP2C9 5500 2100 5400 1200 2900 5400 
CYP2C19 18 13 19 450 12 89 
CYP2D6 73 81 250 7.3 46 180 
CYP2E1 2900 1600 4100 960 860 1100 
CYP3A4 7400 5700 6200 4800 2600 15000 
CYP4A11 1800 450 2600 2500 1500 5300 
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Enzyme 
Measured 
Donor 13 Donor 14 
Total P450 250 
pmol/mg 
770 
pmol/mg 
OR 260 250 
Cytochrome 
b5 
370 
pmol/mg 
550 
pmol/mg 
CYP1A2 780 2100 
CYP2A6 250 810 
CYP2B6 39 33 
CYP2C8 160 100 
CYP2C9 3300 4100 
CYP2C19 41 59 
CYP2D6 130 18 
CYP2E1 1800 2000 
CYP3A4 1950 5400 
CYP4A11 2000 3100 
 
Table 6.2 : Enzyme activity in human liver microsomes from 14 individual donors 
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Donor Gender Age 
(yrs) 
Race Cause of 
Death 
Medical History Medication Given 
During 
Hospitalisation 
1 F 52 A CVA Hypertension, 
Acid Reflux, 
Constipation 
Nipride, Naloxone, 
Mannitol, Cerebrex, 
Propofol, Morphine, 
Crystalloids, 
Neosynephrine, 
Heparin 
2 M 55 A Aneurysm Hypertension, 
Arthritis 
Heparin, Mannitol, 
Furosemide, 
Solumedrol, T4, 
Insulin, Dopamine 
3 M 63 C CVT Warfarin Morphine, 
Midazolam 
4 M 70 C Brain Stem 
Infarct 
Type 2 
Diabetes, 
nsulin, 
Parkinsons, 
Appendectomy 
Dopamine, 
Glucernia, 
Cimetidine, 
Phenytoin, 
Nifedipine, 
Ceftriaxone, 
Humulin, 
Nitroglycerine, 
Atropin sulphate, 
Maalox, 
Acetaminophen, 
ACLS protocol, 
Furosemide  
5 M 46 C Anoxia Hypertension, 
Brain Tumour 
Dopamine, Cefazolin 
6 F 47 C CVA Mitral Valve 
Prolapse, 
Hypertension, 
Intestinal 
Ulcers, Maxide, 
Metoprolol 
Labetolol, 
Hydralazine, 
Mannitol, 
Magnesium, 
Cefazolin 
7 M 68 C Head Trauma N/A N/A 
8 F 62 H Brain 
Infarction 
Verapamil, 
Diltiazem, 
Methyldopa 
Heparin, Mannitol, 
Dopamine, 
Vasopressin, 
Methylprednisolone, 
Normodyne, 
Phenobarbitol, 
Vancomycin, 
Thrombin, Propofol, 
Crystalloids 
9 M 54 C Anoxia Malaria, 
Darvocet 
Epinephrine, 
Atropine 
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10 F 23 C Head Trauma N/A Dexamethasone, 
Furosemide, 
Mannitol, Cefazolin, 
Naloxone, 
Pancuronium, 
Vasopressin, 
Phenytoin 
11 F 42 H Intracranial 
Haemorrhage 
Gestational 
Diabetes, 
Fexofenadine 
Dopamine, Thyroxin 
12 F 60 C Head Trauma Hypertension, 
Gall Bladder 
Removed, Ex-
smoker 
Opranolol, 
Dicyclomine, 
Verapamil, 
Alendronate, 
Norepinephrine 
13 M 41 C Traffic 
Accident 
N/A N/A 
14 M 58 C Subarachnoid 
Haemorrhage 
COPD, 
Emphysema, 
Hypertension, 
Peptic Ulcer, 
Myocardial 
Infarction 
Esmalol, 
Nitroprusside, Blood 
Products 
 
Table 6.3: Human Liver microsome donor information. 
Abbreviations; ‘M’ Male, ‘F’ Female, ‘A’ Asian, ‘C’ Caucasian, ‘H’ Hispanic, ‘CVT’ 
Cerebrovascular Trauma, ‘CVA’ Cerebrovascular Accident, ‘COPD’ Chronic Obstructive nary  
Disease’.  
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